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Abstract 
Susanthi Jayasinghe Mudiyanselage 
Department of Chemistry, April 2013 
The University of Kansas 
 The focus of this dissertation is the utilization of phosphate tether mediated 
approaches to synthesize bioactive natural products and their analogs in !n efficient 
and effective manner.  The several salient features, which are inherent to phosphate 
triesters, include: (i) orthogonal stability under acid conditions, (ii) leaving group 
ability, (iii) multivalent activation of carbinol centers, (iv) protecting group attributes, 
and serving as a (v) temporary tether that can be removed under various conditions.  
Taken collectively various transformations, including chemoselective reductions as 
well as oxidations of the exocyclic olefin, a diastereoselective cuprate addition and 
successful cross-metathesis of type I and type II olefins with the exocyclic double 
bond, all mediated by phosphate tether, have provided the facile synthetic routes 
towards the synthesis of several natural products.  Application of this protocol toward 
the total synthesis of fostriecin and 8-epi-fostriecin are reported.  Fostriecin, an 
antitumor antibiotic isolated from Streptomyces pulveraceus, is the most selective and 
potent inhibitor of protein phosphatases 2A and 4, known to-date (IC50s 3.2 nM and 3 
nM, respectively).  It has been shown to be active against L1210 and P388 leukemia 
cells in vivo and in vitro against leukemia, lung, breast, and ovarian cancer cells.  
Synthetic studies related to diastereoselective ring-closing metathesis reaction, 
regioselective oxidation, diastereoselective Grignard addition and cross metathesis, 
all mediated by a temporary phosphate tether, have established a scalable route 
toward the goal of total and analog synthesis of fostriecin and 8-epi-Fostriecin.  In 
addition to the aforementioned transformations, the coupling of orthogonal 
transformations in a multi-step, one-pot, sequential RCM/CM/H2 process has also 
allowed for facile synthesis of advanced intermediates en route to the total synthesis 
of natural products.  Application of three step, one-pot, sequential RCM/CM/H2 
protocol in a library amenable, efficient and modular synthesis of strictifolione and 
 iv 
(6R)-6-[(4R,6R)-4,6-dihydroxy-10-phenyldec-1-enyl]-5,6-dihydro-2H-pyran-2-one 
are also discussed.  Both anti-fugal natural products were synthesized in seven linear 
steps starting from readily available 1,3-anti-diene-diol without incorporating 
additional protecting groups. 
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Chapter 1 
Phosphates in Biology and Chemical Synthesis 
 
 
  
 2 
1.1 Introduction: 
Phosphates are ubiquitous in nature and play a multi-faceted role in living 
systems where enzyme-catalyzed processes predominate.  They also serve as a pivotal 
functional groups in several biologically active phosphate-containing natural products.  
In addition, the unique properties inherent to phosphates and their mono, di- and 
triester forms also enable their utility in synthesis.  This chapter will give an account 
of the importance of the phosphate-containing natural products and methods for 
phosphate installation in them.  A short account will follow on phosphate prodrug 
strategies for medicinally important non-phosphate-containing, as well as phosphate-
containing, molecules.  The chapter will end with a section on recent advances in the 
use of phosphates in synthesis, including previous studies completed in our group. 
1.2 Phosphate containing natural products 
There are several reports on phosphate-containing molecules that are known 
to possess various biological activities.  This chapter will highlight the biological 
significance of the calyculins, fostriecin, phoslactomycins, leustroducsins, cytostatin, 
enigmazole A, cyclophostin, moenomycin A, and FR901483, as well as detail 
synthetic studies for phosphate installation. 
1.2.1 Calyculins 
The calyculins are highly toxic metabolites isolated from the marine sponge 
Discodermia calyx by Fusetani and co-workers.
1
  Calyculin A, the first member in the 
family, was isolated in 1986 from a sponge collected in the gulf of Sagami, near 
 3 
Tokyo Bay (Figure 1).
1
  Calyculin A and its analogs have been found to be potent 
inhibitors of protein phosphatase-1 (PP1)
 
 and protein phosphatase-2A (PP2A),
 
 which 
are key enzymes involved in signaling pathways associated with human disease.
2
  
Most importantly, studies involving structure activity relationships (SAR) of the 
calyculins indicate that the phosphate, the C13-hydroxyl, and the 
hydrophobic polyketide tail are essential for their inhibitory activity.
3
  The fascinating 
structural features associated with calyculins, which contain 15 chiral centers, a 
cyano-capped tetraene unit, a phosphate-bearing spiroketal, !n !-chiral oxazole, and a 
trihydroxylated "-amino acid, have identified the calyculin family as a synthetically 
challenging set of natural products, and as such, only six total and formal syntheses of 
molecules within this family have been reported to date (see Evans, Masamune, 
Shioiri, Smith, Armstrong and Barrett).
4
 
 In 2010, Koskinen and co-workers broadly reviewed the synthetic efforts 
toward this interesting natural product.
5
  The purpose of this section will be to 
highlight methods aimed at the installation of the phosphate group and provide a brief 
summary of each approach (Figure 1)  
  
 4 
Figure 1: Calyculin family of molecules and a summary of the reported syntheses. 
  
Among all the fascinating structural features within the calyculin family, the 
presence of a phosphate group at C17 is of high importance, due to promising 
biological activity, as well as structural challenges for its installation.
 
  In addition, 
because of the steric environment at C17 and shielding within the spiroketal core, it 
could be assumed that a reactive electrophile would be required to introduce the 
phosphate group at C17 (Scheme 1).  
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N
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OH OMeOH
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O OH
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Group Target Year Longest linear sequence(LLS)
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Scheme 1 
 
In 1992, Evans and coworkers accomplished the first total synthesis of ent-
calyculin A (Figure 1).
4
  In their synthesis,
 
phosphorylation at C17 was accomplished 
via coupling of C1–C25 fragment 1.1 with PCl3, followed by treatment with pMeO-
benzyl alcohol (PMBOH) and in situ oxidation with H2O2, to yield phosphate triester 
1.2.  The resulting phosphate containing C1–C25 fragment was then subjected to four 
more reactions to complete the total synthesis of ent-calyculin A.
 
  In addition, model 
studies performed by Evans and coworkers to install the C17 phosphate group 
illustrated that both (BnO)2P(O)Cl and POCl3 were not electrophilic enough to react 
with the sterically-hindered C17 alcohol, while more electrophilic PCl3 was 
successful in phosphorylation (Scheme 1).
6
  Further studies revealed that all four 
evaluated protecting groups were stable under HF•pyridine conditions, while only the 
p-MeOC6H4CH2 diester protection was fully cleaved with CH3CN, 48% aq. HF and 
H2O (Scheme 2).  Most notably, the 2-(trimethylsilyl) ethyl-protecting group proved 
to be the most robust upon exposure to all conditions.
 
  
R1 O
O
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OTBSHO
MeMe
Me
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 PCl3, PMBOH 
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PCl3, TMS(CH2)2OH
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R1 O
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(RO)2P
O
25 25
OR
TMS(CH2)2OPCl2
TMS(CH2)2OH, H2O2
70%
OR
R = PMB, CH2CH2TMSR1=C1–C13 fragment
15 151.1 1.2
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Scheme 2 
 
In addition to the studies described above, the Masamune group also 
reported model studies on the stability of phosphate protecting groups—namely, allyl 
and 2-(trimethylsilyl) ethyl-protected phosphates—within the context of a similar 
fragment to 1.3 and found that the deprotection of diallyl phosphate triesters, upon 
treatment with Pd(PPh3)4, did not provide the corresponding monoester, even under a 
variety of conditions (time and temperature).
7
  More importantly, they also found that 
the 2-(trimethylsilyl) ethyl-protected triester was tolerant of a number of subsequent 
reaction conditions, including amide bases (KHMDS) and typical Stille coupling 
conditions, and can be completely removed via treatment with CH3CN/47% HF/H2O 
= 8.5/0.5/1).  Of notable importance, Masamune and coworkers were able to carry out 
12 consecutive steps, including hydrogenation, oxidation, Julia-Lythgoe olefination, 
and Stille coupling, while maintaining the integrity of a TMS-protected phosphate.
8
  
O
O
HO OTBS
Me
Me Me
OTBS
OMePivO
O
O
O OTBS
Me
Me Me
OTBS
OMePivO
(RO)2P
O
Stability of phosphates protecting groups.
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Me3SiCH2CH2     
                      
C6H5CH2             
                       
p-MeOC6H4CH2
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
1.3 1.4
PCl3, Pyridine
ROH
30 % aq H2O2, CH2Cl2
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With this information in hand, several groups applied the same protocol developed by 
the Evans and Masamune groups in their seminal syntheses of calyculin A. 
1.2.2 Fostriecin, Phoslactomycins, Leustroducsins  
Fostriecin, a phosphate monoester isolated in 1983 from Steptomyces 
pulveraceus, has shown impressive in vivo antitumor activity, as well as in vitro 
cytotoxicity against a broad range of cancer cell lines, including leukemia, lung 
cancer, breast cancer and ovarian cancer (Figure 2).
9
  Most notably, this significant 
biological activity has been tied to its remarkable ability to selectively inhibit protein 
phosphatase-2A (PP2A) and protein phosphatase-4 (PP4), which results in these 
various cytotoxic properties.
 
  In combination with these biological activities, the 
unique structure of fostriecin that consists of an !,"-unsaturated lactone, C9-
phosphate, C8 stereo center, and (Z, Z, E)-triene have attracted a substantial amount 
of attention from the synthetic community, and a number of synthetic and biological 
studies of fostriecin and its analogs have been reported, including 8 total syntheses 
and 3 formal syntheses.
10
  Furthermore, SAR studies performed by Boger and 
coworkers revealed that the !,"-unsaturated lactone, the completely deprotected 
phosphate at C9, and the C11 hydroxyl group are essential for the potent biological 
activity seen in fostriecin.
11
  A detailed account on synthetic approaches and the 
corresponding SAR studies will be discussed in chapter 2. 
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Figure 2 Fostriecin family of phosphate-containing natural products.  
 
In general, the reported total, as well as formal, syntheses of fostreicin have 
all involved the late-stage installation of the C17 phosphate group, and both 
phosphoramidite- and phosphite-mediated methods have been employed for 
phosphorylation, to yield both allyl- and PMB-protected phosphates, respectively 
(Scheme 3).
10
  In 2001, Boger and coworkers observed extensive degradation and 
olefin isomerization of the phosphorylated version of 1.5 during phosphate PMB-
deprotection with prolonged exposure to unbuffered HF, and further attempts at 
PMB-removal with HF-pyr did not afford cleanly deprotected product.  Thus, in their 
synthesis, Boger and coworkers employed a two-stage deprotection, where treatment 
with HF (15 min) resulted in PMB-deprotection and subsequent addition of pyridine 
allowed for silyl removal of C8-, C9-, and C18-protected alcohols.
10a
  Conversely, 
when allyl-protected phosphates were utilized, Pd-catalyzed reductive deallylation 
and HF-pyridine were employed to unveil deprotected-fostreicin in good overall 
yield.
10e 
O HO O
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Phoslactomycins, R= OCOR1
O O OH
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OH
H2N
P
O
Na O
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Scheme 3 
 
In 2003, Imanishi and coworkers highlighted a selective cleavage of cyclic 
phosphate en route to fostriecin.
10
  Though monophosphorylation with POCl3 of the 
C9 hydroxyl was unsuccessful within the course of their synthesis, Imanishi and 
coworkers demonstrated that dipodal coupling of POCl3 with the C8 tertiary hydroxyl 
and the C9 hydroxyl in diol substrate 1.6 provided cyclic phosphate 1.7 as an 
alternative pathway to install the phosphate group in fostreicin (Scheme 4).
10f
  Model 
studies with diol substrate 1.6 revealed that hydrolytic cleavage of cyclic 
phosphoester 1.7 in 2,2,2-trifluoroethanol (Method D) provided promising results 
with respect to both chemical yield and regioselectivity to afford phosphate 1.8.  The 
authors postulated that, upon hydrolysis, the endo-cyclic P–O bond of 1.7 is cleaved 
more easily than the exo-cyclic P–O bond due to a stereoelectronic effect resulting 
from the 5-membered ring conformation in the trigonal bipyramidal transition state.
12
  
Therefore, cleavage of the more sterically hindered P-O bond occurred preferentially 
to provide the required monoester 1.8 over the exo-cyclic P–O bond opened product 
1.9.  Notably, the authors also mentioned that phosphorylation via cyclic phosphate 
intermediate 1.7 was far more effective (23%) in comparison to direct 
phosphorylation (7%).
10f 
O
O
OR
OH OTBS
A) 1. PCl3, Pyr, PMBOH
        aq. H2O2 or t-BuO2H, 91%
      2. HF, MeCN; pyridine
     2. Pd(PPh3)4 (10 mol %), HCO2NH2
         PPh3, THF, then Dowex
-50(H+ form), MeOH
     3. Global Si deprotection, 79% over 2 steps
R= TBS, TES
B) 1. (CH2=CHCH2O)2PN(i-Pr)2
         tetrazole,CH2Cl2, 0 ºC
         t-BuO2H, 89%
1.5 Fostriecin
9 11
7
O HO O
P
OH
O ONa O
OH
1
OHTBDPSO
 10 
Scheme 4 
 
1.2.3. Phoslactomycins, Leustroducsins 
Phoslactomysins (A-F), phospholine and leustroducsins (A-C) (Figure 2) are 
phosphate-containing, natural products isolated from Streptomyces nigrescens, 
Streptomyces hygroscopicus and Streptomyces platensis, respectively.  These are 
known to possess potent antitumor, antibacterial, and antifungal activities, as well as 
inhibitory activity for human protein phosphatase 2A (PP2A), that have been directly 
linked to the interaction of the phosphate group within enzyme binding sites.
13
  Key 
structural features of these families bear striking resemblances to fostriecin but differ 
slightly at C4 (ethyl group), C8 (2-aminoethyl side-chain, instead of simple methyl 
group) and C15 (cyclohexyl substituted (Z, Z)-diene, instead of a labile (Z, Z, E)-
triene subunit).  In addition, the phospholactomycins and leustroducsins share nearly 
identical core structures, differing only at the substitution at C18.  Several synthetic 
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studies
14
 towards the construction of these families of molecules, as well as their 
analogs, have been reported, including two total syntheses for both phoslactomycin B 
(Kobayashi, 2006 and Hatakeyama, 2008 ) and leustroducsin B (Fukuyama, 2003 and 
Imanishi, 2008), as well as one total synthesis for phoslactomycin A (Koert, 2009).
15
  
In all these syntheses, the C9 phosphate was introduced via one of two previously 
described pathways: (1) allyl-protected phosphoramidite chemistry; or (2) hydrolytic 
cleavage of a cyclic phosphate, which are discussed in detail in the portion of this 
section devoted to the synthesis of fostriecin (Schemes 3 and 4).   
1.2.4. Cytostatin 
Cytostatin (Figure 2), another potent and selective PP2A and PP4 inhibitor, 
belongs to the fostriecin family of natural products and possesses similar 
characteristic structural units, including a phosphate monoester, (Z, Z, E)-triene, and 
!, !-unsaturated lactone.16  In addition to the biological activity common to this 
family, cytostatin has been shown to inhibit the adhesion of B16 melanoma cells to  
Scheme 5 
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laminin and collagen, display antimetastatic and cytotoxic activity, and induce 
apoptosis of B16 melanoma cells at sub-!M concentrations.
16
  To date, several (3) 
total and analog syntheses, as well as synthetic studies were reported.
17
  
In 2002, Waldmann reported the first total synthesis of cytostatin, involving 
the late-stage introduction of phosphate group prior to the incorporation of the  
C12–C18 triene (via Stille coupling).
17a,b
  Phosphate installation to 1.11 via 
phosphoramidite coupling, in the presence of 1H-tetrazole, followed by the oxidation 
with oxidation with I2 in THF:pyridine:H2O 7:2:1, provided phosphorylated product 
1.12 (Scheme 5).  Due to obvious incompatibilities with planned successive steps, 
acid- and Pd
0
-labile phosphate protecting groups, as well as groups sensitive to 
hydrogenation conditions (benzyl group), were avoided, and synthetic studies instead 
utilized base-labile phosphate protecting groups, such as 2-cyanoethyl group and 9-
fluorenylmethyl (Fm) group.
18
  However, efforts to fully deprotect the cyanoethyl 
group with amine bases (Me2NEt, tBuNH2 or Et3N, DBU with TMSCl) in the 
presence of various solvents (CH3OH, 2-propanol, DMF, neat, pyridine, acetonitrile) 
were fruitless; thus, this route was limited to the formation of phosphate diester 1.13, 
instead of the desired monoester (Scheme 5).  
 In contrast, the successful installation of the 9-fluorenylmethyl-protected 
phosphate diester, via the coupling of 1.14 with phosphoramidite (FmO)2PN
i
Pr2, 
followed by oxidation with I2 in THF:pyridine:H2O 7:2:1, allowed access to 1.15 that 
was smoothly deprotected with excess Et3N in CH3CN, to afford the desired 
 13 
phosphate monoester in cytostatin (Scheme 6).
17a,b
  Later syntheses of cytostatin 
reported by Boger (2006)
17c
 and Cossy (2007)
17e
 also applied this phosphorylation-
deprotection protocol.
 
Scheme 6 
 
1.2.5. Enigmazole A 
Enigmazole A, an 18-membered macrolide which contains a dianionic 
phosphate monoester, exo-methylene substituted tetrahydropyran ring and densely 
functionalized 2,4-disubstituted oxazole fragments, was one of the first 
phosphomacrolides isolated from a marine source (sponge, Cinachyrella enigmatica) 
and has been shown to exhibit significant in vitro cytotoxicity toward IC-2 mast 
cells.
19
  Even though enigmazole A also shared several functional groups and 
structural features with calyculin A, it was shown to be inactive for both phosphatases 
(17 different types) and kinases (70 different types) at high-test concentration of 40 
µg/ml.  In 2010, Molinski reported the first total synthesis of enigmazole A in 22 
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steps.
20
  Phosphorylation at the C5 hydroxyl group of 1.16 was successfully 
completed, utilizing the same protocol developed by Waldmann in cytostatin, via 
coupling with protected phosphoramidite (OFm)2PNiPr2 and subsequent oxidation 
with H2O2 to afford phosphate triester 1.17 in 61% yield.  Successive phosphate and 
acetate deprotection was achieved with K2CO3 in MeOH/H2O to generate enigmazole 
A as the disodium salt in excellent yield. 
Scheme 7 
 
 1.2.6. Cyclophostin and Cyclipostin P 
Cyclophostin and cyclipostin P (Figure 3) are naturally occurring bicyclic 
organophosphates, which share the same structural core unit and differ only in 
phosphate triester subunits.
21
  Cyclophostin (8a) is a potent acetylcholinesterase 
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(AChE) inhibitor isolated from a fermentation solution of Streptomyces lavendulae 
(strain NK901093), while closely related cyclipostin P (8b) is a potent inhibitor of 
hormone sensitive lipase (HSL).
21
  In combination with this impressive biological 
activity, the interesting structural features of these seven-membered bicyclic enol-
phosphate triesters, which possess a 7,5-fused butyrolactone ring and chirality at C3, 
as well as at phosphorus, have identified them as interesting synthetic and biological 
targets.  
Figure 3: Cyclophostin and cyclipostin P. 
 
In 2011, Spilling and coworkers reported the first total syntheses of 
cyclophostin, its unnatural diastereomer and cyclipostin P, utilizing two different 
phosphorylation approaches.
22
  The authors envisioned that cyclophostin could be 
accessed either through the phosphorylation of primary alcohol of 1.18 and 
subsequent installation and condensation with a distal acetyl group (in 1.20) or 
through the selective phosphorylation of butyrolactone to selectively provide E-enol 
phosphate 1.21, followed by PMB-deprotection and condensation with the distal 
primary alcohol (Scheme 8).  
In light of this, primary alcohol 1.18 was phosphorylated with dimethyl 
bromophosphate, prepared in situ by reaction with (MeO)3P and Br2, to afford 
phosphate triester 1.19 in 75% yield.  This phosphorylated butyrolactone was 
O
O
P
O
O
O
MeO
H
O
O
P
O
O
O
H
n-C16H33O
Cyclophostin Cyclipostin P
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converted to acetyl lactone 1.20 via a two-step acylation-deprotection protocol 
involving alkylation with LiHMDS and acetyl chloride and demethylation with NaI, 
followed by protonation with Amberlite
®
 (sulfonic acid) resin.  However, cyclization 
of 1.20 via intramolecular condensation furnished the desired product in extremely 
low yield.  Thus, utilizing the second proposed route, cyclization of enol phosphate 
1.23, prepared in several steps from 1.18 and dimethyl phosphorochloridate, provided 
the cyclic enolphosphates (natural and unnatural cyclophostin 1.24) as 1:1 mixture of 
diastereomers that were separable via silica gel chromatography.  
Scheme 8 
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alkylation with the corresponding alkyl bromides to provide the desired phosphate 
triesters in good overall yield. 
1.2.7. Moenomycin A  
Moenomycin A, a potent antibiotic that inhibits bacteria cell wall synthesis, 
consists of a highly functionalized pentasaccharide attached to a polyprenyl chain via 
a unique phosphoglycerate linkage.
23,24
  Since the isolation of moenomicin A in 1985, 
several synthetic studies have been reported.
25
  In 2006, Kahne and coworkers 
reported the first and only total synthesis of moenomycin A.
26
  In this synthesis, the 
authors utilized H-phosphonate chemistry to introduce the phosphate  
Scheme 9 
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linkage, where pentasaccharide 1.26 and moenocinyl glycerate (1.27) were coupled 
with cyclic H-phosphoryl chloride (2-chloro-1,3,2-benzodioxaphosphorin-4-one), 
followed by regioselective oxidation with NMM in the presence of CCl4, to yield 
moenomycin A in good yield (Scheme 9). 
1.2.8. FR901483 
FR901483 is a potent immunosuppressant that was isolated from the 
fermentation broth of the fungal strain Cladobotryum sp. NO. 11231 by the Fujisawa 
group in 1996.
27
  In addition to this biological significance, the novel aza-tricyclic 
structure of FR901483 was a synthetically attractive feature, which has fueled efforts 
toward the completion of several elegant total syntheses,
28
 as well as synthetic studies.
 
  
In the reported syntheses, the methods utilized to install the C9 phosphate group were 
dependent upon the stereochemistry of the C9 alcohol in starting aza-tricyclic 
substrates 1.28 and 1.29 (Scheme 10).  In the case where the C9-hydroxyl is axial 
(1.28), direct phosphorylation with dibenzyl-N,N’-diisopropyl phosphoramidite, in 
the presence of 1H-tetrazole, followed by oxidation with a peroxy acid,
29
 was utilized 
to afford 1.30 in 70–95% yield.  However, when the C9-hydroxyl is equatorial (1.29), 
Mitsunobu inversion with dibenzyl phosphoric acid (already discussed in the 
Mitsunobu section) was utilized to generate phosphorylated product 1.30 with 
suitable C9-stereochemistry.  Notably, successful phosphorylation was achieved 
selectively at C9 in both approaches in the presence of the sterically crowded C7 
hydroxy group.  Finally, amine deprotection/phosphate debenzylation allowed access 
to the natural product FR901483 as the hydrochloride salt. 
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1.2.9. Phosphate-containing natural product that have not been synthesized 
 In addition to the above discussed molecules, there are several other 
phosphate-containing macrolides, as well as other phosphorylated marine natural 
products that have been reported (Figure 4).  However, their respective syntheses 
have not been reported yet.  Eushearilide (1.31), was isolated from Eupenicillium 
shearii IFM54447 in 2006 by Kawai and co-workers.  This is the first report of a 24-
membered macrolide antibiotic having the choline phosphate ester moiety as well as 
non-conjugated double bonds with no amino sugar moiety or hydroxyl groups on the 
ring structure.
 30
  Eushearilide exhibits antifungal activity against various fungi and 
yeasts, including human pathogens Aspergillus fumigatus, Trichophyton spp. and 
Candida spp.
30
  JBIR-19 and JBIR-20 (1.38 and 1.39, respectively) are 24-membered 
macrolides isolated from the culture broth of the entomopathogenic fungus 
Metarhizium sp. fE61 that contains 2-aminoethyl phosphate esters and showed 
induced striking elongated morphology of S. cerevisiae at concentrations of 3.1 and 
13 µM, respectively. 31   
Other phosphate-containing marine natural products include pokepola ester 
(1.32),
32
 haplosamate steroids (1.33 and 1.34)
33
 celebeside cyclic depsipeptides A–C 
(1.35–1.36)
34
 and deoxynojirimycin derivatives (1.40).
35
  Pokepola ester (1.32) is a 
diester of phosphoric acid isolated from Maui sponge Sponigia oceania in 1993 and 
exhibits mild anti-HIV activity.
32
  Phosphorylated sterol sulfates 1.33 and 1.34 are 
isolated from marine sponge Cribrochalina sp. and shows metric metalloproteinase 
inhibition.
33
  Celebesides A–C (1.35–1.37) are cyclic depsipeptides, isolated from S. 
 21 
mirabilis sponge, possess the polyketide moiety and five amino acid residues, 
including !n uncommon 3–carbamoyl threonine and a phosphoserine residue, which 
is present in celebesides A and B.  Celebeside A (1.35) exhibit anti-HIV activity in a 
single-round infectivity assay with an IC50 value of 1.9 (0.4 µg/mL) while the non-
phosphorylated analog celebeside C (1.37) was inactive at concentrations as high as 
50 µg/mL.
34
  In 2006, 1-deoxynojirimycin-6-phosphate (1.40) and its N-methyl 
derivative were isolated from the sponge Lendenfeldia chondrodes.
35
  These are the  
 
Figure 4: Phosphate-containing natural product that have not been synthesized. 
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first examples of phosphate derivative of 1-deoxynojirimycin (dNM) found in nature 
and its N-alkylated derivatives are known to be potent inhibitors of !-glucosidase.36 
1.2.10 Limitations associated with phosphate-containing natural products 
 The importance of phosphate as a key moiety in chemistry and biology is 
accentuated by the fact that nearly all known phosphate-containing natural products 
have been shown to possess potent biological activities, particularly within the realm 
of protein phosphatase inhibition.  However, despite their potency, very few in vivo 
studies have been reported for phosphate-containing natural products, since their high 
inherent hydrophilicity imparts low bioavailability.  The bioavailability issue of 
phosphates, is largely the consequence of the impermeability of phosphate anions to 
cell membranes at physiological pH ranges due to the inherent pKa's associated with 
phosphate diesters––which have a pKa of ~ 2, and phosphate monoesters––which 
have two pKa's of ~ 2 and ~7, respectively.  Therefore, active transport is required for 
successful delivery of the phosphate-containing natural product into the cell. 
Furthermore, even though phosphates show remarkable stability to non-enzymatic 
hydrolysis, with half lives of hundreds years,
37
 the large distribution of various 
phosphatases––which have the capability of removing the phosphate group––can 
hinder effective delivery into the cell of the "intact" phosphate-containing natural 
product.   
 A common strategy in medicinally active synthetic phosphate drugs––such as 
phosphate monoesters––is to increase their bioavailability by protecting them as 
phosphate triester prodrugs (prodrugs-vide infra) using easily removable groups.  
 23 
However, to the best of our knowledge, this strategy has not been incorporated in 
phosphate-containing natural products.  
1.3 Phosphate Prodrugs 
  Prodrugs are bio-reversible substances of active drugs that can undergo  
in vivo enzymatic and/or chemical transformation to release the parent drug, which 
will participate in the desired action.
38
  Prodrug strategies have become a useful tool 
in optimizing absorption, distribution, metabolism, and excretion (ADME) of drugs.  
However, these chemical modifications made, must be reversible which would allow 
the prodrug to convert back to parent drug in vivo, as well as it should be safe and 
rapidly excreted from the body.
39
   
 Phosphates are one such functional group (other functional groups: esters, 
carbonates, carbamates, N-Mannich bases, oximes, imines, amides, ethers) that the 
pharmaceutical industry has used to improve the bioavailability of active drugs.
40
   
There are several different ways that phosphates have been used in developing 
prodrug strategies (Figure 5).
40
  As previously mentioned, due to the inherent pKa 
properties of phosphates at physiological pH, they carry either one or two negative 
charges.  If a compound suffers from low bioavailability due to poor water solubility 
(i.e. compound has a high clogP), phosphate mono- or diesters have been strategically 
installed to improve water solubility (lower the clogP).  In these cases, installation of 
an ionizable phosphate as a promoiety at the hydroxyl or amine functionalities will 
improve the water solubility for oral or parenteral delivery by making it more polar.
41
  
In addition, chemical stability, straightforward synthesis and rapid cleavage by 
 24 
alkaline phosphatases are the added advantages with phosphates taken as a 
promoiety.
42
  
Figure 5: Role of phosphate in prodrug strategies. 
 
Fosamprenavir is a successful phosphate prodrug, which is used for treatment 
of HIV infection, and has an improved effect on oral delivery with the introduction of 
a polar phosphate group.  This prodrug strategy reduces the dose to a 3 capsules 
twice-a-day dosage for fosamprenavir, to an 8 capsules twice-a-day dosage for the 
parent drug amprenavir.
43
  Other examples for phosphate drugs, which are successful, 
are summarized in Figure 6.
38
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Figure 6: Prodrugs employing a phosphate monoester as a promoiety. 
 
 The second scenario is when a phosphate is an active component of the parent 
drug, the negatively charged phosphate group can present a significant problem in 
drug delivery, by imparting too much water solubility (i.e. too low of a clogP) or by 
succumbing to hydrolysis by alkaline phosphatase enzymatic reactions.  In this latter 
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in the form of phosphate diesters or triesters in order to decrease water solubility 
[increase lipophilicity (i.e. raise the clogP)].
38,39
  Moreover, since phosphate triesters 
are not common in nature––and enzymes that could cleave those triesters have not 
been reported––the issues with rapid alkaline phosphatase hydrolysis were 
circumvented by employing this protected-phosphate strategy.  The most common 
strategy employed to mask phosphate dianion is conversion to phosphate triesters 
utilizing easily removable protecting groups such as acyloxyalkyl esters, S-acyl 
groups, and sulfidyl groups etc. 
In the early 1980's, Farquhar and coworkers applied a protocol that has been 
used to mask the penicillin carboxy group in order to enhance its bioavailability, to 
mask phosphates with acyloxymethyl esters and after different masking approaches 
were reported.
44
  Acyloxyalkyl esters were synthesized simply by alkylation of the 
phosphate with acyloxyalkyl halogenide in the presence of hindered base.  Esters 
were cleaved through enzymatic hydrolysis and upon spontaneous hydrolysis of the 
resulting hydroxymethylene esters, the active parent drug was released [Figure 7, (eq 
1)].  Prodrugs of ACE inhibitor fosinopril and antiviral compound (R)-9-
([phosphonomethoxy]propyl)adenine (PMPA) were synthesized utilizing 
alkoxycarbonyloxyalkyl groups to control the elimination of formaldehyde and 
carboxylic acids during the hydrolysis (eq 2).
45
   In addition, 4-acetoxybenzyl esters, 
!-acyloxyalkyl esters, and acetoxy-phenyl esters and cyclic phosphates have been 
successfully utilized as masking groups (Figure 7).
46
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Figure 7: Different approaches to phosphate triester prodrugs. 
 
 A variety of esterase-labile thioesters have also been employed in prodrug 
strategies.  As enzymatically removable moieties, S-acylthioethyl (SATE) esters or  
S-[(2-hydroxyethyl)-sulfidyl]-2-thioethyl (DTE) esters have been utilized in masking 
antiviral nucleoside monophosphates and phosphonates (Figure 8).
47
  The active drug 
with the monophosphate was released by enzymatic cleavage followed by 
spontaneous elimination of thiirane.  However, further development was limited due 
to the associated toxicity risk with the byproduct ethylene sulfide.
39
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Figure 8: Prodrugs of phosphate triesters with sulfidyl and S-acyl groups. 
 
1.3. Use of phosphates in synthesis 
In addition to the promising role in biochemistry, phosphates are also useful 
tools in synthetic chemistry.  Due to the lower reactivity of phosphates esters, halides 
and sulfonates are preferred in nucleophilic substitution reactions over phosphates. 
However, the leaving group ability of phosphates, coupled with their electrophilic 
nature, multipodal coupling abilities––and orthogonal selective cleavage profiles 
using acid, base or reductive condition––impart a unique and impressive portfolio of 
reactivity that have allowed them to emerge as viable intermediates in synthesis.  In 
this regard, several recent reports have shown impressive synthetic applications of 
phosphates, including their use in allylic substitution,
48
 reductive cyclizations,
49
 
phosphate extension reactions/iodolactonization,
50
 transition metal-mediated cross 
coupling reactions,
51
 and temporary tether-mediated, one-pot sequential processes.  
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1.3.1. Allylic phosphates 
There are several reports published on different substitution reactions of allyl 
phosphates depending on the nature of the nucleophile and the catalyst.  In 1958, it 
was first reported that soft bases (PhS
–
, I
–
, CN
–
) attack at alkyl group of alkyl 
phosphates showing clean SN2 displacement reaction, while hard bases (NaOMe and 
alkyllithium) attack the phosphorus atom.
52
  In 1991, Yamamoto and co-workers 
demonstrated the superiority of phosphates as leaving groups in comparison to 
chlorides and mesylate in a seminal copper-mediated anti-SN2' displacement reaction 
of secondary allylic phosphate 1.50, affording allylic substituted product 1.51 in high 
E:Z selectivity while maintaining the excellent chirality transfer with 94% 
enantiomeric excess (Scheme 11).
53
  However, addition of a Grignard reagent into an 
allylic phosphate in the presence of Fe- and Ni-based catalysts [Fe(acac)3, NiBr2] 
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resulted in SN2 displacement instead of exclusive SN2´ displacement reaction which 
was observed with Cu(I) catalyst (CuCN•2LiCl) (Scheme 11).
54
  In 2001, Chong and 
coworkers, and in 2003, Knochel and coworkers also reported similar observations in 
acyclic and cyclic allylic phosphate displacement reactions.
55
 
Asymmetric variants of allylic displacement reactions via an anti–SN2' 
pathway with chiral Schiff bases, BINAP and an N-heterocyclic carbene have also 
been reported (Scheme 12 and 13).  In 2004, Hoveyda and co-workers reported the 
Cu-catalyzed asymmetric alkylation of unsaturated esters bearing a primary 
 !-phosphate with alkyl zinc in the presence of peptidic Schiff base 1.59 and 
application of this protocol in the synthesis of topoisomerase II inhibitor (R)-elenic 
acid.
56
  In addition, application of the same protocol in the synthesis of quaternary all- 
Scheme 12 
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carbon stereocenters in high yield, as well as high regio- and enantioselectivities, 
were also reported. 
In 2003, Gennari and co-workers disclosed another application of the 
enantioselective Cu-catalyzed organo-zinc addition in the presence of chiral, non-
racemic Schiff reagents (1.67 and 1.70) in a highly regio-, diastereo-, and 
enantioselective desymmetrization of the meso, cyclic allylic bis-diethylphosphates 
1.66 and 1.69 (Scheme 13).
57a 
Scheme 13 
 
In 2006, Hanson and coworkers reported the desymmetrization of the pseudo-C2-
symmetric cyclic phosphate 1.72 via an anti-SN2' Cu–mediated allylic phosphate 
displacement, which afforded the syn-(E)-phosphate 1.73 as a single diastereomer 
(Scheme 14).
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  According to the proposed transition state 1.74, observed excellent 
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which is less prominent in 1.74, allowing proper alignment of !* and "* orbitals with 
approaching cuprates.  However, with asymmetric cyclic phosphates, the electronic 
bias of more labile phosphate (secondary in 1.75 and tertiary in 1.78) leaving group 
determined the higher regioselectivity obtained in allylic displacement with cuprates.  
After removal of primary phosphate with Red-Al
®
, chiral, non-racemic homoallylic 
alcohol anti-(E)-1.79 was obtained in good yield. 
Scheme 14 
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In addition to organo-zinc and Grignard reagents, alkyl aluminum reagents
59
 
as well as alkyl boron reagents
60
 were also utilized in asymmetric Cu-catalyzed allylic 
displacement reactions of allyl phosphates.  In 2008, Hoveyda and co-workers 
reported the asymmetric, Cu-catalyzed SN2' displacement reaction with in situ 
prepared vinyl aluminum reagents 1.82 to synthesize 1,4-dienes 1.84 on gram-scale 
(Scheme 15).  Furthermore, synthesis of all carbon quaternary centers was also 
accomplished via enantioselective allyl substitution of allyl phosphates with vinyl 
aluminum reagents or propargyl aluminum reagents in the presence of sulfonate–
bearing, chiral, bidentate N-heterocyclic carbene (NHC) complexes.
59
  The aryl-, 
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n-hex
DIBAL-H, 55 ºC
hexane
n-hex
Al(i-Bu)2
n-hex
Ph
Me
OPO(OEt)2
Me
Ph
0.5 mol % catalyst
1 mol % CuCl2•2H2O
THF, - 15 ºC
 94% yield
> 98% E, 92% ee
Me OPO(OEt)2
Me Me
1.0 eq. DIBAL-H
Al(i-Bu)2
0.5 mol % catalyst
Me OPO(OEt)2
Me Me
Ph
 92% yield, > 98% SN2', 93:7 er
3 mol% Ni(PPh3)2Cl2
Al(i-Bu)2
1 mol % catalyst
Me OPO(OEt)2
Me Me
Ph
1 mol % CuCl2•2H2O
THF, -50 ºC
2 mol % CuCl2•2H2O
THF, - 15 ºC
0 to 22 ºC
5 mol % Et3N
1.3 eq. DIBAL-H
THF, 4 ºC
81% yield, > 98% SN2', 90:10 er
1.81 1.82
1.83
1.84
1.85
1.86
1.87
1.88
1.89
1.90
 34 
vinyl-substituted aluminum reagents 1.86, which are difficult to synthesize with 
DIBAL-H, were prepared employing Ni-catalyzed hydroalumination.
61
 
In 2010, Sawamura and co-workers described a highly regio- and stereo- 
selective Cu-catalyzed allylic substitution of acyclic and cyclopentane-diol-based 
allylic phosphates with alkyl boranes.
60
  Notably, these couplings proceeded with 
excellent !- and E-selectivities and preferential 1,3-anti selectivity and the synthetic 
utility of this route was demonstrated in the synthesis of steroid derivative 1.93 
(Scheme 16).  The additional advantages of this protocol included facile preparation 
of boryl compounds via hydroboration of olefin and functional group tolerability.  
Several other groups have also reported the synthetic utility of alkyl/aryl borane and 
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allyl phosphate couplings.
60
  In 2012, Hoveyda and co-workers described the chiral 
NHC-Cu-1.97-catalyzed, enantio- and regio-selective, allylic substitution reaction 
with allene borane 1.95 and allylic phosphate 1.94.  Allene-bearing tertiary or 
quaternary carbon stereogenic centers were generated with excellent yield (95%), 
enantiomeric ratio (99:1), and SN2' selectivity (> 98 %, Scheme 16). 
In 2012, Sawamura’s group further illustrated that the stereochemical outcome 
of the Cu-catalyzed coupling reactions of an alkyl borane and chiral allylic phosphate 
can be switched from 1,3-anti to 1,3-syn by varying the reaction conditions (Scheme 
17).
60 
 When a bulky alkoxide (t-BuOK) and a polar solvent such as THF were 
employed, the coupling proceeded with anti-selectivity to provide product 1.99 in 
excellent yield (85–95%).  However, when less sterically demanding MeOK and a 
non-polar solvent (toluene) were used, the reaction proceeded with syn-selectivity to 
generate 1.102 in high yield.  Mechanistic studies revealed that Cu-catalyzed allyl- 
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alkyl coupling reactions operate via the addition–elimination mechanism of neutral 
organo copper reagents to provide excellent !-selectivity.  When a bulky alkoxide was 
utilized, anti-addition followed by anti-elimination resulted.  Conversely, the use of a 
sterically less-hindered alkoxide afforded syn-addition of the alkyl copper complex 
with overall syn-stereochemistry with respect to the leaving group; subsequently syn-
elimination provided stereochemically reversible products (Scheme 17). 
Propargyl phosphates were also employed in Cu-catalyzed coupling reactions with 
aryl-or alkenyl-boronates to synthesize aryl- and alkenyl-conjugated allenes (Scheme 
18).
62
  The reaction of enantiomerically pure propargylic phosphates showed 
excellent point-to-axial chirality transfer with anti stereochemistry to provide axially 
chiral conjugated allenes. 
Scheme 18 
 
In addition to the above-mentioned, Cu-catalyzed allylic alkylations, allylic 
phosphates have been used in Pd-mediated alkylation reactions as well.
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1.3.2. Thiophosphates: 
Thiophosphates have also been utilized in variety of synthetic strategies, 
including allylic substitution reactions, allylic fluorination reactions, as well as 
surrogates for H2S.  In 2010, Wu and coworkers reported transition-metal-free allylic 
displacement reactions of cyclic and acyclic allylic phosphothioates 1.112 with 
Grignard reagents.  These thiophosphates were synthesized employing 
photochemically-promoted substitution of alcohols 1.110 with phosphorothioic acids 
1.111, which can be synthesized in multi-gram scale with diethyl phosphite and S8 
(Scheme 72).
64
  However, this thiolation reaction occurred only with allylic alcohols, 
such as 1.110.  Primary, secondary, and tertiary aliphatic alcohols as well as benzyl 
alcohols did not provide the desired thiophosphates. Despite this limitation, un-
catalyzed alkylation reactions (Grignard addition) were shown to be broadly 
applicable to a wide range of nucleophiles and tolerant of both electron-withdrawing 
and donating groups as well as vinylic substrates.  Moreover, both primary and 
secondary alkyl Grignard reagents also participate in the substitution reaction.  
Interestingly, aromatic and alkenyl nucleophiles underwent the SN2–type 
displacement to provide 1.114 selectively; whereas, secondary aliphatic Grignard 
reagents provide the SN2'-type displacement product 1.115 as the major product.  To 
circumvent the limitation of the above-discussed thiolation reaction, Ga(OTf)3-
catalyzed direct displacement reaction of alcohols with sulfur nucleophiles were 
developed and it possessed greater substrate scope to include a larger variety of 
alcohol starting materials.
65
  However, although tertiary alcohols were smoothly 
 38 
converted to their corresponding thiophosphates, allylic or aromatic substitution is 
required for the reaction to proceed with secondary and primary alcohols.  
Another application of thiophosphate is the synthesis of thioethers via direct coupling 
of phosphorothioate ester 1.112 with an appropriate alkoxide, generated by treatment 
with NaH in THF (Scheme 19).  Most notably, this protocol is compatible with 
substrates containing a series of potentially sensitive functionalities, including nitriles, 
esters, and unprotected indole nitrogens, as well as a wide range of nitrogen-, oxygen-, 
and sulfur-containing heterocycles.
 
  Wu and coworkers further illustrated the 
application of phosphorothioate ester 1.117 in the synthesis of chiral, non-racemic 
thioethers 1.119 with overall inversion of stereochemistry from 1.118 (Scheme 19).
66
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In 2012, Wu and coworkers reported two additional applications of thiophosphates: 
(i) as H2S surrogates in synthesis of chiral tetrahydrothiophenes 1.124, and (ii) Pd-
catalyzed allylic fluorination in the synthesis of allylic, fluoro compound 1.126 
(Scheme 20).
67
  The key reaction involved in the synthesis of tetrahydrothiophenes is 
the base-promoted, intra-molecular, carbon–sulfur bond formation that was obtained 
through a highly stereospecific double SN2 displacement mechanism.  Thiophosphate 
1.120 was obtained from an iodoester intermediate, which was obtained from 
corresponding chloroester 1.119 via the alkylation of a phosphorothioic acid 
precursor.  Weinreb amide formation followed by Grignard addition, afforded keto 
thioesters 1.121 in good to excellent yield.  Asymmetric reduction of 1.121 with 
Corey-Bakshi-Shibata catalyst 1.122 provided the cyclization precursor 1.123, which, 
upon treatment with NaH, afforded the tetrahydrothiophenes 1.124 in excellent yields.  
In the synthesis of allylic fluoro- compounds, AgF was used as the “F
–
” source and 
mechanistic investigations revealed that the reactions are stereospecific and proceeds 
through a Pd !-allyl intermediate resulting in complete retention of stereochemical 
configuration in the corresponding fluorinated products. 
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Scheme 20 
 
1.3.3. Enol phosphates (vinyl phosphates) 
Enol phosphates represent another versatile phosphate-based synthetic 
intermediate that has been heavily utilized in organic synthesis, namely in metal-
catalyzed cross-coupling reactions.  Their widespread use is due to their greater 
stability, cost effectiveness, and benign chemistry when compared to their triflate 
counterparts, as well as a number of methods for their efficient synthesis.
68,69
  The 
chemistry and properties of enol phosphates was first reviewed in 1961.
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several methods for the synthesis, as well as reactions of enol phosphates have been 
reported, some of which are summarized below.   
1.3.3.1. Synthesis of enol phosphates 
The earliest reported protocol for enol phosphate formation is the reaction of  
!-haloketones 1.128 with trialkyl phosphites from the seminal studies, by Michaelis, 
Arbuzov and Perkow.
71
  In a related variant, Rosen and coworkers reported the 
reaction of di-halo-compound 1.30 (3,4-dichlorobutanone) with trialkyl phosphites, 
which resulted in a mixture of dialkyl enol phosphate 1.133 as the major product, and 
phosphonate esters 1.134 (Scheme 21).
72
  However, greater utilization of this protocol 
was limited due to lack of commercial sources as well as the difficulties in 
synthesizing the required !-haloketone. 
Scheme 21 
 
The most common method to generate enol phosphates involves the treatment 
of ketones/aldehydes 1.135 with an appropriate base to allow for the trapping of the 
resulting enolate with a suitable phosphorus electrophile, most commonly a dialkyl 
phosphorochloridates (Scheme 21).
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In 2000, Comasseto and coworkers reported the formation of Z-vinylic 
cyanocuprates 1.139 via the transmetallation reaction between Z-vinylic tellurides 
1.137 and 1.138 and higher order cyanocuprates (Scheme 61).
74
  Subsequent 
conjugate addition of the cuprates to enone 1.140, followed by trapping of the 
resultant enolate via O-phosporylation, and afforded enol phosphate 1.141 in 
excellent yield.  
Scheme 22 
 
Even though, kinetically controlled enolization can be achieved very 
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In 2010, Lee, Kim and coworkers developed a catalytic 
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with high selectivity.  In addition, conversion of kinetic enol phosphates 1.144 
(generated by the reaction of phosphate 1.142 with alkyne 1.143) to thermodynamic 
enol phosphates 1.145 was also accomplished with catalyst (C6F5)3PAuOTf.  In 2011, 
the same group synthesized alkynyl hydrogen phosphates 1.146 by the treatment of 
alkynols with phosphorodichloridate.
76
  These alkynyl hydrogen phosphates 
underwent 6-endo-dig, 6-exo-dig, or 7-exo-dig cyclization in the presence of a Au(I) 
catalyst to furnish 6- and 7-membered cyclic enol phosphates 1.147–1.153 in good to 
excellent yields. 
Scheme 23 
 
In 2012, Nolan and coworkers reported a Ag-free synthesis of alkenyl enol 
phosphates 1.156 from alkyne 1.154 and diphenylphosphate diesters 1.155 with high 
selectivity by cationic Au(I) complexes generated in situ from the pre-
catalyst[ (IPr)Au(OH)] and Bronsted acid (HX) (Scheme 24).
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When TfOH was employed thermodynamic vinyl phosphate 1.157 resulted with high 
selectivity (92:8), whereas, for kinetic enol phosphate 1.156 complete selectivity was 
achieved with HBF4.   
Scheme 24 
 
In 2012, Gevorgyan and coworkers reported the use of Cu- or Au-catalysis in a 
selective migratory cascade reaction with !-halogen-substituted propargylic 
phosphates 1.158 to generate highly functionalized 1,3-dienes (Scheme 25).
 78
  
Occurring through either of two catalytic pathways (Cu- or Au-mediated), this stereo-  
Scheme 25 
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divergent method allowed the generation of both (Z)-1.159 and the (E)-1,3-dienes 
1.60 from propargylic phosphates 1.158.  Thus (E)-dienes was provided exclusively 
with a gold catalyst while a copper catalyst afforded (Z)-dienes predominately. 
In 2009, Beier and coworkers utilized the phosphorus-Brook rearrangement of 
difluorophosphonate 1.162 in the synthesis of (Z)-fluoro-enol phosphate 1.163 
(Scheme 26).
79
  Aldol coupling of difluoromethylphosphonate 1.161 and 
benzaldehyde, in the presence of LDA, generated intermediate 1.162, which, upon 
alkoxide formation with tBuOK, underwent a [1,4]-phosphorus-Brook rearrangement 
to yield (Z)-fluoro-enol phosphate 1.163 in excellent yield and selectivity. 
Scheme 26  
 
In 2008, Gager and coworkers demonstrated the first stereoselective method of 
preparation of (E)-dienol phosphates 1.165 from unsaturated aldehydes such as 1.164, 
via the stereoselective enolization of a conjugated alkenal by tBuOK in the presence 
of N-methylpyrrolidinone (NMP) (Scheme 27).
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Scheme 27 
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1.3.3.2. Reactions of enol phosphates 
As previously mentioned, the synthesis of enol phosphates has gained 
prominence due to their application in a wide range of cross coupling reactions (such 
as Stille, Suzuki-Miyaura, Negishi, Kumada, Sonogashira, and Mizoroki-Heck 
reactions) en route to complex synthesis.
68
  In particular, the Pd-catalyzed synthesis 
of N- and O-heterocycles from enol phosphate precursors has emerged as a significant 
faction in the realm of Pd-couplings and was highlighted in a recent review.
69
  In 
addition, enol phosphates are more stable than their enol triflate counterparts, which 
tend to be expensive, corrosive, and more robust than their silyl-ether analogs, which 
are, in general, more sensitive to a variety of reaction conditions.  Thus, enol 
phosphates have emerged as useful alternatives to traditional protecting/trapping 
groups in reactions that incorporate the use/generation of carbon enolates. 
In 1969, Ireland and coworkers reported the first synthetic use of enol 
phosphates in their synthesis of alkene 1.167 from the ketone-derived enol phosphate 
1.166 under reductive conditions using Li/EtNH2 in t-BuOH (Scheme 28).
81
  Since 
then, a number of reductive variants were developed, including Et3Al/Pd(PPh3)4 (eq 
2), and classical hydrogen transfer conditions such as HCOOH in the presence of 
silanes (eq. 3, Scheme 28).
82
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Scheme 28 
 
 In 1976, Blaszak and coworkers were the first to demonstrate the conversion 
of enol phosphates to substituted alkenes using organo cuprates (RCuLi) (eq 1; 
Scheme 29).
83
  Seminal reports by Oshima and coworkers followed and showed that 
Pd-mediated alkylation with trialkyl aluminum reagents provided better 
chemoselectivity as well as stereocontrol (eq 2).
84
  Utilization of BBN derivatives, 
zinc reagents and alkyl Grignard reagents (with iron catalysts) have provided the 
solution for !-hydride elimination that sometimes hampers use of trialkyl aluminum 
reagents.
85
  Recently Knochel and co-workers showed that, tetra-substituted enol 
phosphates 1.181 can be synthesized via alkylation of the magnesiated enol phosphate 
derivatives 1.178 and 1.179 derived from enol phosphate 1.177 and "-halo enol 
phosphate 1.176.
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Scheme 29 
 
 
In 1997, Nicolaou and coworkers reported the first example of Pd-mediated 
cross coupling reactions of enol phosphates with vinyl organometallic reagents en 
route to the synthesis of functionalized cyclic enol ethers (Scheme 30).
51
  Enol 
phosphate 1.183 was synthesized from lactone 1.182 utilizing KHMDS, HMPA and 
(PhO)2POCl.  Subsequent Stille coupling with stannane 1.184 provided cyclic enol 
ether 1.185 in 89% yield.  In addition, a series of enol phosphates derived from 
ketones, oxazines, pyrazines and lactams was utilized in Stille couplings with 
vinylstannanes to provide the corresponding dienes (Scheme 30).
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Scheme 30 
 
In 1999, Sasaki and coworkers demonstrated that enol phosphates [R = 
P(O)(OPh)2] were superior to enol triflates (R = SO2CF3) in the Suzuki–Miyaura 
coupling between alkylborane 1.191 (synthesized from hydroboration of alkene 
1.190) and the enolic compound 1.192 en route to the enol ether subunit 1.193 
(Scheme 31).
88
  Utilizing the same conditions in the Suzuki–Miyaura coupling of a 
variety of medium-sized cyclic enol phosphates (6- to 9-membered), the authors 
completed the synthesis of the ABCD-ring fragment of the natural product CTX3C. 
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Scheme 31 
 
In 1999, Yang and Nan reported the first utilization of cyclohexenylphosphate 
1.194 in the Ni(0)-catalyzed Suzuki cross-coupling reaction with various aryl boronic 
acids to furnish coupled products 1.195 (Scheme 32).
89
  In 2001, Yang and Wu 
described the Ni-catalyzed Negishi cross-couplings of 4-
diethylphosphonooxycoumarins 1.196 with a variety of organozinc reagents to 
generate 4-substituted coumarins 1.197 at room temperature.
90
  The yields are 
generally high for arylzinc halides, although alkylzinc bromides generated product in 
only moderate yields. 
Scheme 32 
 
In 2000, Coe and coworkers developed an intramolecular Heck cyclization on 
enol phosphate 1.198 to construct the tricyclic skeleton of compound 1.199 in their 
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total synthesis of (±)-cytisine (Scheme 33).
91
  While both enol triflate and phosphate 
underwent the cyclization, the phosphate-activated intermediates were found to be 
more robust. 
In 2003, Hanson and coworkers demonstrated the first RCM of an 
enolphosphate using the Grubbs second-generation catalyst 
[(IMesH2)(PCy3)(Cl)2Ru=CHPh] and showed facile generation of a variety of cyclic 
enol phosphates 1.201( Scheme 33).
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Scheme 33 
 
In 2011, Kim, Lee and coworkers demonstrated an impressive regio- and 
stereoselective synthesis of trisubstituted alkenes via different Pd-catalyzed 
consecutive cross-coupling reaction sequences (Scheme 34).  Bisfunctional (Z)-
alkenyl iodophosphates 1.202, prepared via a previously reported Au-catalyzed 
reaction, were coupled in a Sonogashira/Kumada reaction sequence with 
ethynylbenzene and PhMgBr, through intermediate 1.203, to yield (Z)-3-en-1-yne 
product 1.204.  Similarly, product 1.206 was synthesized through a Suzuki/Kumada 
reaction sequence involving intermediate 1.205.  In an alternative Suzuki/Kumada 
sequence, 1.207 was treated with vinylboronic acid pinacol ester 1.208, followed by 
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coupling with PhMgBr, to afford (Z)-1,3-diene 1.209.  Moreover, the authors also 
utilized a Stille/Kumada sequence to afford the (Z)-1,3-diene 1.210 from (Z)-alkenyl 
iodophosphates 1.202 (Scheme 34). 
Scheme 34  
 
1.3.4. Phosphate tethers 
Hanson and coworkers demonstrated the utility of phosphates as temporary 
tethers capable of uniting advanced intermediates using di-and tripodal coupling 
characteristics of phosphates.  In addition, orthogonal protection and innate leaving 
group properties of phosphate tethers was demonstrated.
93
  In 2005, Hanson and 
coworkers reported a phosphate-tether-mediated desymmetrization of the C2-
symmetric 1,3-anti-diol diene 1.211 to generate the unique bicyclo[4.3.1]phosphate 
(S,S,SP)-1.213 using [(IMesH2)(PCy3)(Cl)2Ru=CHPh; G-II cat] (Scheme 35).
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phosphate-tether-mediated desymmetrizations
95
  It should be noted that this 
temporary tether could be removed by treatment with LiAlH4  to afford triol 1.214 as 
a single diastereomer.  
Scheme 35  
 
The inherent properties of phosphate, as well as the overall stability of its 
[4.3.1]-bicyclic variant (particularly stability to acid promoted hydrolysis), have led 
to the development of a number of synthetically useful transformations of the 
bicyclo[4.3.1]phosphate (S,S,SP)-1.213, [or its diastereomeric (R,R,RP)-counterpart] 
(Scheme 36).  In particular, a chemo-selective hydrogenation of the exocyclic olefin 
(1.215), a diastereoselective cuprate addition (1.216 and 1.217), and successful cross-
metathesis of type I and type II olefins with the exocyclic double bond (as in example 
1.220), along with a variety of other transformations, have allowed for the generation 
of other mono- and bicyclic phosphates.
58c, 96
  Most notably, the coupling of 
orthogonal transformations in a multi-step, one-pot, sequential RCM/CM/H2 
process.
58c,97
 has allowed for the facile generation of advanced intermediates en route 
to the total synthesis of natural products (Figure 9).
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Scheme 36   
 
Figure 9: Natural products synthesized utilizing phosphate tether methodology. 
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1.4 Conclusion 
 The importance of phosphates in biology as well as in organic synthesis has 
been highlighted.  Prominent biological activities inherent to phosphate-containing 
natural products, as well as medicinally important active drugs and associate prodrug 
strategies, have also been discussed.  While the use of phosphates in synthesis has 
historically been overshadowed by their ubiquity in nature––where key enzyme-
catalyzed processes dominate several biological pathways––a number of new 
synthetic methods are beginning to counter this historical viewpoint.  This trend will 
undoubtedly continue to emerge as new studies aimed at shedding light on the unique 
chemistry and biology of phosphates, carry on. 
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2.1 Introduction 
2.1.1 Overview of fostriecin 
Fostriecin (2.1, CI-920, Figure 1) is a structurally unique phosphate monoester 
isolated from Streptomyces pulveraceus by workers at Warner Lambert-Parke Davis 
in 1983,
1
 and is a potent PP2A inhibitor (IC50 1.5 nM) as well as a weak inhibitor of 
type I serine/threonine protein phosphatase (PP1; IC50 131!M).
2
  It exhibits in vitro 
antitumor activity against a broad range of cancerous cell lines including lung cancer, 
breast cancer, and ovarian cancer, and displays in vivo inhibitory activity against 
mouse leukemia cell lines (L1210, IC50 0.46 !M and P338).
3
  Based on early studies, 
its antitumor activity was suggested to be due to the inhibition of topoisomerase II.
4
  
However, recently it has been shown to operate via an inhibitory pathway of the 
mitotic entry checkpoint through a more potent inhibition of protein phosphatase 2A 
(PP2A), selectively over the PP1 (selectivity: PP2A/PP1>10
4
–10
5
).
2,5
  Despite this 
promising activity, NCI-supported clinical trials were suspended due to the drug 
instability and unpredictable purity of the natural product. 
In 1997, Boger and coworkers determined the relative and absolute 
stereochemistry in fostriecin that confirmed previous assignments in a family of 
biologically active and structurally related natural products, including leustroducsin B 
(LSN-B, 2.2), cytostain (2.3) and phoslactomycin C (2.7).
6,7
  In 2013, Tang and 
coworkers reported a comprehensive post-PKS (polyketide synthase) modification 
mechanism for fostriecin biosynthesis via elucidation of the fostriecin biosynthetic 
gene cluster.
8
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Figure 1: Fostriecin family of phosphate-containing natural products. 
 
2.1.2 Structure-Activity Relationship (SAR) studies of 2.1 and analogs 
As mentioned previously, fostriecin is the most selective protein phosphatase 
(PP2A) inhibitor (IC50 1.5 nM) studied to date among the well-known naturally 
occurring PP2A selective inhibitors such as okadaic acid (IC50 0.2 nM), cantharidin 
(IC50 40 µM) and the calyculin family (IC50 0.1–1.0 nM, Figure 2).
 9
  The selectivity 
of fostriecin is on the order of 10
4
–10
5
 times more selective for PP2A and its 
homolog PP4, than PP1.  In contrast, the selectivity for PP2A/PP4 over PP1 is only 
100 times for okadaic acid, 10 fold for cantharidin and 5 fold for calyculin (Figure 
2).
9
 
Fostriecin also has many of the elements of the common pharmacophore that 
was proposed for the natural inhibitors such as the calyculins, okadaic acid and 
cantharidin.  These inhibitory structural features include (i) the acidic group 
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[carboxylate (masked) or phosphate] that is proposed to interact with key metal ions 
residing within a phosphatase, (ii) the methyl substituent proximal to the acidic 
moiety, that are proposed to mimic the methyl group in phosphothreonine, and (iii) 
the hydrophobic segment that is assumed to mimic the hydrophobic amino acid 
residues adjacent to phosphothreonine.
9
  However, the most significant feature that 
sets apart the fostriecin family from other previous PP2A inhibitors is the unsaturated 
lactone.  The Michael-accepting capabilities of this moiety, vide infra, have driven 
speculation from the beginning that it is responsible for the observed selectivity in 
fostriecin.  
Figure 2: Natural PP2A inhibitors.  
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fostriecin, which addressed the relevance of the !,"-unsaturated lactone and the free 
phosphate moiety in selective PP2A activity.
10
  In 2009, Boger, Honkanen and others 
reported SAR studies for fostriecin and the structurally related natural 
serine/threonine phosphatase inhibitor cytostatin, and their respective analogs, against 
PP1, PP2A, and PP5.
11
  According to these studies, it was found that the phosphate 
moiety is critical for PP2A inhibition as demonstrated by a 10
5
-fold loss of activity 
for both dephosphofostriecin 2.11 and dephosphocytostatin (Figure 3).  Furthermore, 
C8–C9 phosphodiester analogs of 2.1 displayed 10
3
-fold loss in activity, while an 
acetate-protected C11 analog demonstrated a further 50-fold loss in activity, 
indicating the importance of the C11-hydroxy group to fostriecin potency.!!  
Moreover, the hydrolyzed lactone also experienced a 10
5
-fold loss in activity.  
However, compound 2.15, void of a lactone, also shows significant, but diminished 
PP2A inhibitory activity (200-fold loss in activity).  Fostriecin analogs with variation 
in the eastern triene moiety were also studied. In particular, analog 2.20 (Figure 3) 
lacking the entire (Z,Z,E)-triene, also strongly inhibits PP2A, while having little effect 
on PP1 or PP5.  Therefore, it was suggested that both lactone and the triene contribute 
to the overall selectivity.   
Despite the aforementioned studies, comprehensive stereochemical SAR 
studies––highlighting the effects of the four-stereogenic centers in fostriecin––are 
lacking in the literature.  Studies performed on cytostatin diastereomers 2.17, 2.18, 
and 2.19 showed that they are less potent inhibitors of PP2A compared to the natural 
compound.
12
  Shibasaki and Kanai reported that the inhibitory activity for PP2A and 
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PP1 is slightly weaker 8-epi-fostriecin, but more selective for PP2A inhibition 
compared to natural fostriecin.
13
 
Figure 3: IC 50 values for PP2A inhibition of fostriecin and its analogs. 
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moiety coordinated to active-site metals and forming H-bonds with active site 
residues.!"
,!!  In addition, the triene was found to reside in the acidic groove, and the 
lactone is located in a pocket formed by Arg
89
 and four residues in the !12-!13 loop 
(Tyr
265
, Cys
266
, Arg
268
, Cys
269
) suggesting that it was prepositioned for nucleophilic 
attack at the "-position of the lactone.  Interestingly, it should be noted that the Cys269 
residue containing a thiolate nucleophile is unique to PP2A and PP4 and absent in 
PP1, PP2B, PP5 and PP7, thereby potentially explaining the highest selectivity for 
PP2A over PP1 (> 10
4
–10
5
) and PP5 (> 10
4
–10
5
).
 
  Hence, it is now assumed that the 
200-fold increased potency in fostriecin is due to Cys
269 
alkylation within the active 
site loop, which also explains the higher selectivity observed for the fostriecin family 
for PP2A inhibition in comparison to the other natural PP2A inhibitors (calyculin, 
okaidic acid, etc.) that do not possess a lactone subunit.!!  
In 2009, Sugawara and coworkers reported an in vitro study and showed that 
fostriecin covalently binds to the Cys
269
 residue of PP2A in Hela S3 cells.
14
  In this 
study, they employed pull-down assays using synthetically prepared, biotin-labeled, 
fostriecin (bio-fos) in conjunction with, matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometric analysis.  Additionally, binding models constructed 
for PP2A-conjugated fostriecin (via binding of the lactone with the Cys
269
 residue), 
demonstrated that the C9 phosphate binds or interacts with manganese cations within 
the active site of PP2A.  Overall, this results in conjugation of fostriecin to PP2A, and 
thus prevents natural substrate from entering the active site, which also further 
explains the decreased activity for dephosphorylated fostriecin (2.11, Figure 3).  
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Figure 4: Important structural features associated with PP2A inhibition. 
 
 
2.1.3 Synthetic studies of fostriecin: 
Boger and coworkers determined the 3-D structure of 1 through synthetic and 
degradation studies.
15
  Since this seminal work, several total syntheses
16
 and synthetic 
studies
17
 have been reported.  Key synthetic strategies utilized in these total syntheses 
are highlighted below.   
In the 2001 seminal synthesis of 2.1 by Boger and coworkers, the C5 and C11 
stereocenters were established employing Sharpless asymmetric dihydroxylation of 
dihydrofuran 2.22, while the C9 center was generated from D-glutamic acid (2.21, 
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C8 carbonyl of 2.31, and operated under Felkin-Ahn control.  The sensitive Z,Z,E-
triene subunit was introduced in a step-wise manner utilizing Still-Gennari conditions 
to install the C12–C13 Z olefin in 2.24, as well as Wittig olefination for generation of 
the C14–C15 Z olefin.  Subsequent Stille coupling of 2.25 and 2.26 enabled 
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was introduced at a late-stage of the synthesis using Wadsworth–Horner–Emmons 
(HWE) coupling of ketophosphonate 2.27 and aldehyde 2.30, while also constructing 
the C7–C8 E-configured olefin.  The phosphate group at C9 was introduced as a bis-
PMB-protected ester and final deprotection was achieved through a two-stage 
protocol using HF (5% H2O–CH3CN, 15 min) to remove the PMB esters, followed by 
addition of pyridine (25 % pyr–CH3CN/H2O) for slow exhaustive deprotection of all 
silyl ethers. 
Scheme 1 
 
In 2001, Jacobsen completed the total synthesis of fostriecin in a route comprised of a 
longest linear sequence (LLS) of 19 steps,
16a
  highlighting the use of a Cr-mediated 
catalyst in a hetero-Diels-Alder (HDA) reaction to obtain alkyne lactol 2.36.  
Subsequent zirconium-mediated addition to chiral epoxy ketone 2.40––which was 
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obtained via the [(salen)Co] catalyst 2.38––catalyzed the hydrolytic kinetic resolution 
of the racemic epoxy ketone 2.39, which established three of the four stereogenic 
centers at C5, C8 and C9.
16a
  The carbinol stereochemistry at C11 was installed by 
Noyori reduction of propargyl ketone 2.42 and the C12–C13-Z-configured olefin was 
produced by cis reduction of the alkyne using diimide conditions.  The “ligand free” 
Stille coupling of vinyl iodide 2.44 and vinyl stannane 2.45 was next employed to 
construct the remaining C14/C15-Z and C16/C17-E configured olefin geometries in 
2.1.  Phosphate installation and deprotection were achieved using the previously 
reported conditions of Boger.   
Scheme 2 
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In 2002, Falck and coworkers reported the total synthesis of 2.1 with an LLS 
of 22 steps.!"
b
  The secondary hydroxy stereocenters at C11 and C5 were installed 
employing Brown asymmetric allylation of aldehyde 2.46 and 2.50, respectively.  The 
Sharpless asymmetric dihydroxylation with AD-mix ! of the trisubstituted olefin at 
C8–C9 in 2.48 established both stereocenters at C8 and C9 in a single step.  Diimide 
cis reduction of the alkyne generated the requisite C12–C13-Z olefin geometry.  The 
triene moiety was constructed utilizing Suzuki–Miyaura cross coupling between vinyl 
bromide 2.51 and vinyl boronate 2.52 and the phosphate function at C9 was 
introduced as a bis-(2-trimethylsilylethyl) phosphate triester, while global desilylation 
was achieved by treatment with HF•pyridine at room temperature. 
Scheme 3 
 
In 2002, Imanishi and coworkers accomplished the total synthesis in 24 linear 
steps via a highly convergent route involving a 3-segment coupling procedure and the 
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(Chapter 1).
16c
  (R)–Malic acid served as the source for the C11 carbinol center, while 
the C8 and C9 stereocenters were introduced using Sharpless asymmetric 
dihydroxylation of the trisubstituted allylic alcohol moiety in 2.55.  The unsaturated 
lactone subunit was constructed applying HWE reagent 2.57, while stereoselective 
reduction of the resulting ketone 2.58 with (R)–BINAL–H established the required C5 
stereocenter with excellent selectivity (dr = 20:1).  It should be noted that since 
attempts on direct substitution of the Z, Z, E, triene under Wittig conditions were not 
successful, a 2-step protocol was employed installing the C12–13-Z olefin via 
iodomethylation, followed by Stille coupling with Z,E-configured stannane 2.62.   
In the final stages of the Imanishi fostriecin synthesis, introduction of the C9 
phosphate group was achieved by formation of a cyclic phosphate triester, followed 
by regioselective hydrolytic cleavage using CF3CH2OH:H2O:Et3N (20:1:1) to afford 
good selectivity (~7:1).  This selectivity was assumed to be governed by a 
combination of stereoelectronic (in the 5-membered cyclic phosphate, the endo–
cyclic P–O bond is cleaved more easier than the exo-cyclic P–O bond) and steric 
effects (sterically more hindered P–O bond is cleaved easily). 
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Scheme 4 
 
In 2002, Hatakeyama and coworkers!"
d
 reported the synthesis of 2.1 from 
dihydrofuran in 21 steps using the following key reactions: (i) Brown allylation of 
aldehyde 2.68 to establish the C5 stereocenter, (ii) Sharpless dihydroxylation of 2.70 
to install the hydroxyl centers at C8 and C9 and (iii) Evans anti-selective reduction of 
ketone 2.71 with Me4NBH(OAc)3 to introduce the C11 hydroxy stereochemistry 
(Scheme 5).  The Z,Z,E triene fragment was installed following a similar protocol 
used in the Jacobsen synthesis, whereby Z-selective iodination using the Stork 
protocol was followed by Stille coupling.  In this synthesis, an allyl group was 
employed to protect the phosphate in order to circumvent problems associated with 
final global deprotection in previous syntheses (i.e. long reaction times and moderate 
CO2H
HO2C
OH
O
OOBz
OMPM
OTBSOBz OH
OH
MPMO
OTBSO
O
O
EtO2C
MPMO
O
O
OHEtO2C
CHO
OTBSO
O
O
O
OTBSOHOH
OH
O
O
I
Bu3Sn OTBDPS
OTBS
OH
OHO
O
TBDPSO
OTBS
O
OO
O
TBDPSO
P
O
Oallyl
2.1
Sharpless AD
92% (dr = 95:5)
(R)–BINAL–H
85%, (> 20:1)
Stille coupling
POCl3 
pyridine
OH
Regioselective 
hydrolytic cleavage 
of cyclic phosphate
9 11
11
7
9 11
5 9 11
12
13
5 9 11
(R) –malic acid
Ph3P
+CH2I•I
-
 (Z:E = 4:1)
Iodomethylenation
2.54
2.55 2.56
2.57
2.58
2.592.602.61
2.62
2.63
52%
81% (2 steps)
CF3CH2OH 
Et3N,H2O,rt
MeO
P
O
MeO
O
CO2Et
2.64
2.65
i. TPAP
ii.2.57, DBU
79% 
(2-steps)
 87 
yields).  Mild deprotection of the allyl group was successfully achieved under Pd-
catalysis [Pd(PPh3)4, HCONH2]. 
Scheme 5 
 
 In 2009, McDonald and coworkers!"
e
 reported a highly convergent synthesis 
of fostriecin in 16 linear steps (Scheme 6).  The key reactions in their synthesis, 
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cross coupling of 2.81 and 2.82 in the presence of thallium carbonate (Tl2CO3) at 
room temperature to afford a higher yield as well as shorter reaction time. 
Scheme 6 
 
 In 2010, O’Doherty and coworkers reported another total synthesis for 2.1 
that entailed an LLS of 26 steps highlighting the utility of !n iterative Sharpless AD 
reaction to establish the C11, C9 and C8 stereogenic centers (Scheme 7).!"
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synthesis of vinyl boronate 2.88 by Rh-catalyzed trans-hydroboration and Suzuki-
Miyaura cross-coupling with vinyl iodide 2.92.  An additional innovative feature of 
the O’Doherty route was the remarkable stability of the vinyl pinacol boronate 2.88 
that was stable to silica gel chromatographic separations, as well as several 
subsequent chemical transformations, including: DIBAL reduction, MnO2 oxidation, 
Leighton allylations, and Cl2(PCy3)2Ru=CHPh-catalyzed ring-closing metathesis 
(RCM). 
Scheme 7 
 
In addition to the aforementioned total syntheses, several formal total 
syntheses to 2.1 were also reported.!"  In 2005, Trost completed dephospho-fostriecin 
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central stereogenic centers, including cyanosilylation of a ketone to install the C8 
tertiary alcohol, Yamamoto allylation to set C5, use of a Bronsted base, two-centered 
asymmetric catalyst LLB (L=La, L=Li, B=BINOL)
19
 to control the aldol reaction and 
set the C9 carbinol, as well as employment of Noyori hydrogenation for generation of 
the C11 carbinol.
20,21 
2.2 Results and discussion 
Despite the breadth of synthetic efforts reported toward fostriecin,  
library-amenable synthetic routes are still challenging and in high demand due to its 
overall potency and selectivity.  Moreover, currently there is a lack of SAR studies 
assessing the effects of the four stereogenic centers within 2.1, as well as the potential 
effect of lactone surrogates.  In considering a synthetic route for fostriecin, attention 
in our work was particularly focused on designing a route that not only accessed 
fostriecin, but would also enable generation of useful analogues as probes.  For this 
purpose, we disclose a phosphate-tether mediated, modular approach en route towards 
fostriecin and its C8 epimer.  In addition, effort toward developing a viable synthetic 
route for installation of lactone surrogates, are also reported. 
2.2.1 Retrosynthetic analysis 
In considering the architecture of fostriecin, a route was envisioned entailing 
the use of 2.95 as a key intermediate bearing all four requisite stereogenic centers and 
olefin geometries (Scheme 8).  The anticipated synthetic pathway centered on  
cross-metathesis (CM) between the isopropyl-lactol 2.97 or lactone 2.98 with 
 91 
phosphate 2.96 that would eventually provide flexibility in potential analog 
generation.  Phosphate 2.96 can be synthesized from organometallic addition to the 
ketone 2.99 and depending on the organometallic reagent, the selectivity for the C8 
center or the C8 epimer can be altered.  The entire sequence starts from the previously 
reported bicyclic phosphate (R,R,RP)-2.100.
22 
  Installation of the key C8–C14 subunit 
employs a simple terminus differentiation strategy of the C2-symmetric anti-diol 
(R,R)-2.101 using a phosphate tether/RCM strategy to derive (R,R,RP)-2.100.  
Notably, in addition to desymmetrization of the central 1,3-anti-diol subunit, this 
phosphate tether-mediated process serves to further establish in a single step the 
requisite C12/C13 Z-configured olefin, the C7 terminal olefin armed for 
regioselective oxidation, and triol protection at the C9, C11, and C14 carbinol centers. 
Scheme 8: Retrosynthetic analysis 
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2.2.2 Synthetics studies to 2.1 
 Synthetic studies began with a regioselective oxidation of (R,R,RP)-2.100 
(Scheme 9).  The enantiomeric pair of bicyclic phosphates, (R,R,RP)-2.100 and 
(S,S,SP)-2.100,
23
 have been previously utilized in the total synthesis of dolabelide C, 
tetrahydrolipstatin and salicylihalamide and gram-scale syntheses of either 
enantiomer of 2.100 can now be routinely carried out.  Initially, it was discovered that 
reactions using standard Wacker conditions,
24
 resulted in complete recovery of 
starting material in 80–90% yield.  However, this outcome was not unexpected since 
protected allylic alcohols are known to be problematic, if not completely unreactive, 
towards Wacker oxidation.
25
  Upon rigorous investigation, it was found that 
employing modified-Wacker conditions
26 ,27 , 28
 provided initial yields of 40% of 
desired ketone.  Optimization of this protocol utilizing (R,R,RP)-2.100, yielded 
(R,R,RP)-2.103 in 65% yield on gram-scale.   
Additional optimized conditions were next developed where oxy-mercuration, 
was employed followed by addition of CuCl2 to yield alcohol 2.102, after which the 
solvent was removed and the crude alcohol was directly subjected to Jones oxidation 
to provide (R,R,RP)-2.103 in gram-scale affording yields of 80–95% (Scheme 9).  
Purification involved simple passage of the crude mixture through a silica plug to 
remove any associated metal ions.  This protocol also highlights the exquisite acid 
stability of the bicyclic phosphate system while being more robust than the Pd-
mediated route. 
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Scheme 9 
 
 Investigations next focused on developing a diastereoselective addition of 
vinyl magnesium bromide into methyl ketone (R,R,RP)-2.103 to generate phosphate 
2.104, the key intermediate in both total and analog syntheses.  Based on model 
studies, and literature precedent,
29
 it was postulated that the less hindered Re face 
attack (see 2.105 in Scheme 10) of the vinyl Grignard addition under chelation 
control would generate the requisite C8 stereocenter in fostriecin.  First, vinyl 
magnesium addition was examined and addition of 3 equivalents of freshly prepared 
vinyl Grignard to (R,R,RP)-2.103 at -78 ºC in THF for 7 hours provided vinyl 
phosphate 2.104 in 43 % isolated yield (77 % BRSM) and 15:1 diastereomeric ratio  
(It should be noted that use of commercially available vinyl magnesium bromide gave 
inferior results as compared to freshly prepared Grignard).  Increasing the 
temperature or addition of more equivalents of vinyl Grignard reagent, did not 
improve the yield, but led instead to the attack at phosphorus.  Interestingly, Lewis 
acid activation of the ketone with addition of 1.0 equivalent of BF3•Et2O was able to 
complete the reaction within 1–1.5 hours even at a temperature of -82 ºC (73% yield) 
and with excellent diastereoselectivity (12:1).  With this promising result in hand, the 
stereochemical outcome of the reaction was further examined with X-ray 
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crystallography (Scheme 10).  Surprisingly, it was found that the major isomer was 
the C8 (8S)-2.104 (8-epi-2.104), not the requisite C8 center (8R)-2.104, as expected.  
Hence, efforts were focused on understanding the outcome of the Grignard addition 
reaction into the bicyclic ketone 2.103. 
Scheme 10: Diastereoselective Grignard addition 
 
Figure 5: X-Ray structure of (8S)-2.104 (8-epi-2.104).  
 
O
P O
O
O
O
MgL2
H
BrMg
Re face
attack
MgBr
-78 ºC
BF3•Et2O
dr = ~15:1
 73%
O
P
O O
O
OH
H3C
Expected
O
P
O O
O
OHH3C
Observed
O
P O
O
O
O
MgL2
H
BrMg
Si face
attack
Favorable 
Re face
attack
O
CH3
H2C
H
Mg
O
O
P
O O
O
O
O
P
O O
O
OH
H3C
Expected
O
P O
O
O
O
MLn
H
Si face
attack
O
P
O O
O
OHH3C
Observed
2.103 (8R)-2.104 (8S)-2.104
2.105 2.106
2.107
2.108
(8R)-2.104
(8S)-2.104
 95 
Table 1 
 
We anticipated that applying chelating reagents
30
 superior to than Mg would 
provide enhanced hindrance at the Si face (see 2.107) of the ketone and thereby 
facilitate Re-face attack to form the chelation-controlled product (8R)-2.104 (Scheme 
10).  Several vinyl metallic reagents were added to ketone 2.104 at -78 ºC to 
investigate this hypothesis (Table 1).  Diminishing our expectations empirical results 
further proved that better chelating reagents drastically increased the selectivity for 
the C8 epimer 8-epi-2.104 [(8S)-2.104].  Vinyl Grignard addition, in the presence of 
TiCl4,
31
 produced the C8-epimer with enhanced selectivity (18:1) (Table 1, entry 3), 
whereas use of CeCl3•LiCl,
32
 gave reduced selectivity (6:1) (Table 1, entry 7).  In all 
the aforementioned cases, metal reagents were added as Lewis acids without pre-
incubation with the organometallic reagent.   
Use of vinyl ytterbium–generated from vinyl magnesium bromide and 
ytterbium trichloride 
33
 was next studied and showed that additions to the ketone 
carried out at -78 ºC afforded the C8 epimeric product exclusively (50:1 ratio) in 77% 
yield (Table 1, entry 6).  Based on these empirical observations, we propose that the 
BF3•Et2O 13:1
BF3•Et2O, -0 ºC 9:1
18:1
Not obs.
dr
TiCl4
CuI
YbCl3-Vinyl MgBr 50:1
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5:1
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vinyl group addition may occur in !n intramolecular fashion (Scheme 10, 2.108) 
while chelating to the oxygen atoms of the ketone and the phosphate.  Vinyl Grignard 
addition in the presence of HMPA and DMPU further supported this assumption 
reducing the ratio towards the C8 epimer to 5:1 and 4:1 respectively.  However, use 
of a vinyl cerate gave the highest ratio of the desired target (8R)-2.104 with a 
selectivity of 1:2 (C8:C8-epi) (Table 1, entry 12).  Furthermore, vinyl cerate addition 
to ketone 2.103 using THF:HMPA (2:1) afforded the best ratio for the expected 
product formation as 1.0:1.5 (C8:C8-epi).  A plausible explanation for this 
observation is the higher nucleophilicity and larger ionic radii of the vinyl cerium 
complexes.!" 
Even though it is understood that non-chelating reagents would provide for 
better selectivity, lithium reagents could not be tested in this reaction, since all 
organolithiums tested were prone to attack presumably at phosphorus.
34
  Furthermore, 
none of the organozinc additions that were studied, including those in the presence of 
organo-catalyst,
35
 gave addition to the ketone, but rather unreacted starting ketone 
was recovered in all cases.  Surprisingly, TMS-acetylene addition
36
 also resulted in no 
reaction.  Additional studies are still in progress. 
Realizing that merely switching the "nature" of ketone and Grignard reagent 
would generate the desired C8 stereocenter, studies were next focused on the 
synthesis of vinyl ketone 2.109 using methyl Grignard addition into vinyl ketone 
2.109 (Scheme 11). 
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Scheme 11 
 
2.2.2.1 Synthetics studies to vinyl ketone 
 The synthesis of vinyl ketone was expected to be readily accomplished by 
employing several conditions, vide infra.  Attempts were first focused on generation 
of vinyl ketone through vinyl Grignard addition to a C8 aldehyde intermediate, or 
C7/C8 terminal epoxide opening with dimethylsulfonium methylide (Me2S
+
CH2
-
)
37
 
which was anticipated to be synthesized from dihydroxylated bicycle-phosphate 
(R,R,RP)-2.100  (Scheme 12).  Thus dihydroxylation of exocyclic double bond was 
next studied.  To our delight, dihydroxylation of exocyclic olefin of (R,R,RP)-2.100 
was successfully achieved using Sharpless conditions with ADmix-! in 
 t-BuOH:H2O (1:1)  in excellent regio-and chemo-selectivity (dr = 15:1) but in 
moderate yields (Table 2, entry 1).
 38
  However, by employing Upjohn 
dihydroxylation conditions (OsO4, NMO), the reaction was completed in good yield 
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(65 %) in 10–20 hours at 10 ºC, and the product 2.110 was produced with moderate 
diastereoselectivity (dr = 4:1) (Table 2, entry 2).
39
  It should be noted that 
chemoselectivity was varied depending on the temperature.  Dihydroxylation of both 
exo- and endo-cyclic olefins was observed if the reaction was performed at room 
temperature, while it was totally selective to the C7/C8 exocyclic olefin at 0 ºC.  
Additional studies carried out with metathesis catalyst demonstrated that 
chemoselective dihydroxylation can also be achieved with G-II in the presence of 
PhI(OAc)2 and Lewis acid (YbCl3 or CeCl3) (Table 2, entry 6, 7, 8). This result  
Scheme 12 
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 indicates that a potential chemoselective, one-pot protocol for RCM/dihydroxylation 
could also be employed, and efforts along these lines are currently underway.  It 
should be noted that examples of Ru-catalyzed, one-pot protocols for chemoselective 
dihydroxylation are notably absent in the literature.
40
  With these developed 
conditions in hand, synthesis of desired vinyl ketone was next studied via synthesis of 
aldehyde followed by vinyl Grignard addition (Scheme 13).   Oxidative cleavage of 
dihydroxylated product 2.110 (Scheme 12) with NaIO4 followed vinyl Grignard 
addition and subsequent oxidation afforded the requisite vinyl ketone 2.109, but in 
very low yield.  While optimization of this sequence is still being investigated, studies 
were next focused on epoxide opening with dimethylsulfonium methylide generated  
Scheme 13 
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from nBuLi addition to Me3S-I (Me3S-I, nBuLi).  Even though, direct epoxidation of 
the exocyclic double bond with m-CPBA was not promising, reaction with mesyl 
chloride followed by treatment of the resulting crude sulfonate with K2CO3 in MeOH 
afforded the requisite epoxide 2.115 in good yield (59 % for 2 steps).  It should be 
noted that K2CO3/MeOH did not affect the phosphate group.  However, the 
homologation of this epoxide with dimethylsulfonium methylide in THF to the 
desired allylic alcohol was not successful.  [Note: It is assumed; nucleophilic addition 
of dimethylsulfonium methylide to the electrophilic phosphorus atom would also be 
possible and would be the reason for the observed-degraded products].  
Having difficulties with the generation of vinyl ketone from either aldehyde 
2.113 or epoxide 2.115, studies were directed toward the isomerization reactions of 
allylic alcohol 2.116 generated from CM between (R,R,RP)-2.100 and allylic alcohol.  
However, this allylic isomerization with different Re-mediated catalysts (Re2O7, 
O3ReOSiPh3) also did not provide the required product 2.114.  Thus, studies will next 
be on the 3-step sequence as illustrated in Scheme 14.  
While studies are still ongoing to develop an efficient synthesis of vinyl 
ketone 2.109, installation of C1–C5 lactone functionality to the central core of 
fostriecin via CM was thoroughly examined.  Both vinyl lactol 2.97 and vinyl lactone 
2.98 were utilized in these studies.  Their preparation is outlined below. 
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Scheme 14 
 
2.2.2.2 Synthesis of vinyl lactol 2.97 and vinyl lactone 2.98 
The desired vinyl lactol 2.97 and vinyl lactone 2.98 were generated utilizing 
the Jacobsen hetero-Diels-Alder method.
41
  The sequence was initiated with 
generation of the pre-catalyst 2.123, following the reported protocol by Jacobsen and 
coworkers (Scheme 15).  Friedel-Crafts adamantylation of p-cresol followed by 
formylation via electrophilic addition of formaldehyde and subsequent oxidation by 
excess formaldehyde through a Oppenauer-type
42
 oxidation generated aldehyde 2.121.  
After the condensation reaction with (1R,2S)-(+)-cis-1-amino-2-indanol (2.122), the 
resulting ligand was treated with CrCl3(THF)3 complex to afford the HDA catalyst 
2.123.  
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Scheme 15 
 
Treatment of diene 2.124 and TIPS-protected aldehyde 2.125 in the presence 
of HDA catalyst 2.123 provided alkyne-lactol 2.126 in 90% yield.  Desilylation, 
followed by isopropylation of benzyl acetyl alkyne lactol 2.127, generated isopropyl-
protected alkyne lactol 2.128.  Subsequent Lindlar hydrogenation with Pd-CaCO3 in 
the presence of freshly distilled quinoline in EtOAc under H2, afforded alkene lactol 
2.97 in 80% yield on gram-scale (Scheme 16). 
Scheme 16: Formation of the Desired Cross-Metathesis Partner. 
 
The required vinyl lactone 2.98 was obtained in good yield via direct 
oxidation of the isopropyl acetal 2.97 with PCC in CH2Cl2 in the presence of AcOH 
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(Scheme 17).
43
  When only PCC was used with Celite
®
 in CH2Cl2, the vinyl lactone 
2.98 and the rearranged product 2.129 were formed in 4:1 ratio with 80% overall 
yield over a 2 hour period.  However, addition of 2 equivalents of AcOH decreased 
the formation of the rearranged product 2.129 and the vinyl lactone 2.98 was obtained 
in 83% yield in 5 hours.  This prolonged reaction time, as well as the diminished 
amount of rearranged product formation, suggested that the presence of Lewis acidic 
reagent (AcOH, SiO2, CaCO3) in the reaction medium reduced the nucleophilicity of 
the oxyanion, which would initiate the rearrangement.   
Scheme 17 
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with the acyclic, allylic CM partner 2.134 to derive 2.135 in good yield and with 
excellent C6/C7 stereoselectivity (Scheme 18).
44
  However, attempted coupling of 
phosphate (8S)-2.104 and lactol 2.97, while initially showing promise (in the absence 
of CuI), did not succeed as expected, and dimerized lactol product 2.136 was 
generated in large amounts with only small amounts of coupled product 2.95.  Use of 
an excess amount of lactol, change of solvent and the concentration as well as a 
longer reaction time did not improve the yield of this reaction.   
Scheme 18 
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acyclic C6–C14 subunit, before returning at a later stage to the phosphate-tethered 
system, vide infra.  It should also be noted, that all studies to this stage were 
performed in the absence of CuI, with CuI-promoted studies soon to prove quite 
pivotal in this story. 
Initial CM studies without the phosphate tether were carried out using the 
acyclic core fragment 2.139, which was prepared as outlined in Scheme 19.!! Cross-
metathesis of 2.98 with 2.139, proceeded with good E-selectivity, but in very low 
yield.  This yield was not improved, despite several changes in solvent, concentration, 
and catalyst (Scheme 19).  In addition, the production of varying amounts of lactone 
dimer 2.140 in these CM studies, suggested that the lactone olefin does not possess 
typical type II olefin behavior, but instead is acting as a sluggish type II olefin.
 45
  
Based on these empirical observations, efforts were next directed toward altering the 
olefin reactivity of both CM partners.   
Scheme 19 
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In order to increase the reactivity of the lactone fragment, CM studies were 
directed toward installation of the more reactive isopropyl-protected lactol 2.97.  In 
addition, initial studies were carried out on the completely deprotected-triol fragment 
2.141, bearing a C8-TES-protected carbinol in order to probe the potential impact of 
the C9 phosphate.  The synthesis of 2.141 (Scheme 20) commenced from the 
Grignard adduct (8S)-2.104 and involved an initial TES-protection of the C8 tertiary 
alcohol, followed by tether removal with LiAlH4 to produce triol 2.141, primed for 
CM.  In addition, we concurrently generated the unprotected, tertiary, allylic C8-
alcohol-containing substrate 2.143 to examine the reactivity differences between C8-
TES-protected substrate 2.141 and C11/C14-TBS-protected substrate 2.143 with the 
previously reported results for the fully protected acyclic phosphate 2.138 previously 
outlined in Scheme 19.  
Scheme 20 
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Hatakeyama,
16
 2.142 was then subjected to selective bis-TBS-protection of the less 
sterically hindered C11 and C14 carbinols with TBSOTf at -78 ºC to cleanly generate 
the central core segment 2.143 (Scheme 20). 
The initial CM studies of triol 2.141 and lactol 2.97 were conducted in CH2Cl2 at 0.1 
M concentrations employing the Hoveyda-Grubbs second-generation catalyst (HG-II)
 
46
 (Scheme 21).  However, this resulted in a mixture of degradation products, revealed 
by thin layer chromatographic (TLC) analysis of the crude reaction mixture, as well 
as the identification of product 2.144 by mass spectral analysis, indicating that the 
CM was not initiated at the C6–C7 allylic terminal olefin, but instead at the internal 
disubstituted C12–C13 Z-olefin.  These results further confirmed that TES-protection 
of the C8 carbinol was the main culprit for decreased reactivity in substrate 2.141.  
Scheme 21 
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With these studies in hand, the acyclic substrate 2.143 was next investigated 
in CM studies with lactol 2.97, whereby, the unprotected, C8-tertiary allylic alcohol 
would undoubtedly provide a more favorable environment to enhance the reactivity 
and selectivity of the C6–C7 terminal olefin (Scheme 21).  In addition, studies set out 
to determine if TBS-protection of the C11 and C14 carbinols in 2.143 would impart 
enough steric hindrance to reduce the reactivity of the C12/C13 internal olefin to CM.  
While the CM issue with the C12/C13 olefin was circumvented, unfortunately the 
desired coupling product 2.145 was only obtained in 10% yield, while an undesired 
RCM product 2.146 predominated in 62% yield.  To avoid RCM, the CM was run at 
higher concentration (2.5 M).  In this case, as expected, CM did provide an increased 
yield of the desired CM adduct 2.145 in 45% yield however, it did not result in 
significant reduction in the formation of the RCM product 2.146. 
As the previous investigation outlined in Scheme 21 indicated, regioselective 
CM with the terminal C6/C7 olefin was complicated by RCM-reactivity with the 
internal C12/C13 Z-configured olefin, as well as the unforeseen CM-reactivity of the 
C12/C13 olefin.  Of notable importance is the fact that these CM studies were in stark 
contrast to successful and clean CM reactions between the exocyclic double bond in 
the bicyclic phosphates R,R,RP-2.100 and S,S,SP-2.100 with numerous type 1 and type 
2 olefins none of which resulted in any side reactions of the endocyclic  
Z-configured olefin.!"
47
  Taken collectively, these CM studies revealed "another 
protective role" of the phosphate tether, which effectively prevents RCM of the 
external olefin with the internal Z-configured double bond.  Based on these empirical 
 109 
observations, studies were again focused on the bicyclic phosphate-containing vinyl 
Grignard adduct (8S)-2.104.  However, these studies would employ use of CuI as an 
additive, vide infra, which was first reported by Blechert and coworkers in 2003.
48
 
In 2004, Spilling and coworkers reported accelerated rates of sluggish CM 
reactions employing CuI as a co-catalyst.
49
  In this method, they were able to derive 
phosphono allylic carbonates 2.149 via CM of alkenols 2.147 and acrolein-derived 
phosphono carbonates 2.148 (Scheme 22).  In addition to phosphonate-containing 
substrates, CuI was also utilized in low-yielding CM reactions with substrates like 
acrylonitrile, vinyl ketone, acrylic acid that require higher catalyst load and heat.
50
   
Increased reactivity in this protocol was explained by the phosphine-sequestering 
effect of copper (I), which result in longer lifetimes of reactive open coordinate  
Ru-intermediates thus facilitating CM. 
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Taking advantage of these precedents, CM was performed in the presence of 
CuI in CH2Cl2 in 2.5 M concentrations with Grubbs-II (Scheme 23).  To our delight, 
CM product 2.95 was cleanly obtained in a much-improved isolated yield of 50% 
(77% BRSM).  Furthermore, the unreacted phosphate SM (8S)-2.104 was fully 
recovered.  Overall, this CM route effectively enables the generation of the C1–C14 
stereotetrad of fostriecin possessing the C6–C7 E-olefin and C12–C13 Z-olefin 
geometries in a 7 linear step sequence (LLS), which represents the shortest route to 
the C1–C14 stereotetrad-containing subunit when compared to all previously reported 
syntheses.  In addition, as previously noted, this successful CM demonstrated a 
protective role of the phosphate tether, which effectively prevents RCM of the C6/C7 
external olefin with the internal C12/C13 double bond. 
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Despite this success, the separation of product 2.95 and the starting vinyl 
phosphate (8S)-2.104 was still deemed problematic since it required TES-protection 
of the C8 carbinol in the crude reaction mixture to cleanly separate TES-protected 
product 2.95 from unreacted TES-protected starting material [(8S-TES)-2.104].  
However, even though TES-protection allowed for clean separation, as previously 
noted, C8-TES protection imparts type IV olefin behavior and thus TES-removal was 
needed for the starting material to be recycled for use in subsequent CM (Scheme 24).  
It should be noted that this type IV CM behavior was further substantiated with relay 
partner 2.155, previously carried out in our group,!! whereby CM-relay was not seen, 
but instead provided CM product 2.156 as the major product (Scheme 24).   
Scheme 24 
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products and starting materials (Scheme 25).  Very pleasingly, it was found that CM 
reaction between lactone 2.98 and vinyl phosphate (8S)-2.104 provided well-
separable products 2.157 and unreacted starting vinyl phosphate (8S)-2.104 [TLC in 
EtOAc, 2.157, Rf = 0.4; (8S)-2.104, Rf = 0.1] with only a small amount of the 
dimerized lactone by-product.  An optimum isolated yield of 56% (BRSM 88%) was 
obtained via sequential addition of 0.3 equivalents of lactone 2.98 in 2-hour intervals 
in the presence of CuI and at 2.5 M concentration in CH2Cl2.  Both HG-II and 
Grubbs-II catalysts provided equally good yields.  Subsequent TES-protection of the 
isolated CM product, followed by DIBAL opening and mixed-acetal formation with 
isopropanol in the presence of a catalytic amount of PTSA afforded the requisite C1–
C14 fragment containing all 4 stereogenic centers and olefin geometries (Scheme 25).  
Even though this route required two additional steps overall, i.e. (i) a one-pot 
Scheme 25 
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protocol to convert the lactone 2.157 to the isopropyl-protected lactol 2.95 and (ii) a 
late-stage conversion back to the lactone, many added advantages were deemed 
important to enhancing the overall practicality of the route.  These added benefits, 
included: (i) direct reusability of the starting vinyl phosphate, (ii) a higher yield, and 
(iii) reduction in the amount of dimer formation.  In addition, success of this late-
stage CM reaction showed the viability of this route in potential library development, 
vide infra.Having established a viable and effective route for both total and analogues 
synthesis, we set out to complete the total synthesis of fostriecin (Scheme 26).  After 
TES-protection of CM adduct 2.95 with TESOTf and 2,6 lutidine at 0 ºC, the 
phosphate tether was removed under reductive conditions with LiAlH4 in Et2O at 0 ºC.  
Scheme 26 
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The resulting triol 2.158 was subjected to selective bis-TBS protection at the C11 and 
C14 carbinols following a similar procedure that was discussed earlier. 
Efforts were next directed towards installation of the phosphate group at the 
C9 hydroxyl, which we deemed orthogonal to all subsequent steps.  Early-stage 
introduction of the C9 phosphate is in stark contrast to all previously reported 
synthetic routes to fostriecin that utilize late-stage installation of the phosphate as 
either a PMB-protected or allyl-protected phosphate ester.  This strategy was adopted 
largely impart due to group experience with phosphate stability as well as literature 
precedent reported by Masamune and coworkers in synthetic studies to calyculin A 
(discussed in chapter 1).
51
  In this study, they demonstrated the remarkable stability of 
a Me3SiCH2CH2-protected phosphate over 12 consecutive steps, including 
hydrogenation, oxidation, Julia-Lythgoe olefination, and Stille coupling.  Studies 
were therefore initiated with acyclic substrate 2.160 to introduce the Me3SiCH2CH2-
protected phosphate following the Masamune protocol to provide phosphate 2.161 in 
65% yield (Scheme 27).  At this stage, scale-up of this process is underway.  
Phosphate installation, followed by selective deprotection of the C14-TBS group, and 
subsequent oxidation with PCC will be used to install the requisite aldehyde that is 
armed for Z-selective Wittig olefination to introduce the eastern triene subunit 
(Scheme 26). 
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Scheme 27 
 
2.2.3 Biological testing and library development. 
One of the long-term goals of this project is to develop new routes to access 
the “fostriecin-like” core subunits and thereby enable efficient analog generation.  As 
explained in Section 2.1.2, clinical trials for fostriecin have been halted because of the 
stability (phosphate group) issues encountered with fostriecin, and analogues that 
were synthesized and tested did not meet the level of greater activity comparable to 
fostriecin.  Despite enormous efforts by chemists and biologists, the continued search 
for more stable and potent fostriecin analogs that are more easily synthesized is still 
an enormous challenge.   
As previously discussed, seminal SAR studies clearly showed that the C9 
phosphate is a key structural feature in dictating potent activity against PP2A.  In 
comparison to all literature reported routes, a major advantage of the route presented 
herein is the existence of cyclic phosphate intermediates throughout the synthesis 
(except for two intermediates), all of which represent new phosphate analogs for 
biological screening.  Even though these phosphotriesters are not common in usual 
phosphotriester prodrugs (Chapter 1), they represent a potential solution for the low 
bioavailability of fostriecin.  One such example of the high importance of our 
phosphate tether methodology is clearly demonstrated with ketone 2.103, having 
OTBS
OH OTBS
9 11
7
H3C
OTES
OTBS
O OTBS
9 11
H3C
OTES
P
O
Me3SiCH2CH2O
Me3SiCH2CH2O
PCl3, Pyridine
Me3SiCH2CH2OH
30 % aq H2O2, CH2Cl2
65 %
2.160 2.161
 116 
shown remarkable activity for the polo-like kinase (PLK1) assays out of 36,000 
compounds.  Detailed account of these biological hits will be reported in near future. 
In addition to screening all intermediates in the synthetic pathway, we are 
currently focusing on the development of a fostriecin-like library using CM of 
modified lactone surrogates, with the goal of improving stability and selectivity for 
PP2A.  The proposed library is shown in Figure 6.  As the synthetic plan explains, 
incorporation of heteroatoms for the lactone carbonyl carbon should attenuate the 
Michael accepting nature of the western subunit. 
Figure 6: Proposed library for fostriecin. 
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96:1, Scheme 28).  It was reported that the high anti selectivity during the formation 
of alcohol is obtained as these reactions proceed via a Felkin-Anh model
53
 rather than 
by a chelation-Cram model
54
 since the water solvates the metal ions and thereby 
competes with the chelate complex. 
Sulfonylation with sulfonyl chloride 2.163, followed by RCM with Grubbs-II, 
provided sulfone 2.164, which was subsequently subjected to a deprotection-
elimination sequence to afford the lactone-coupling partner 2.165 (Scheme 28).  
Scheme 28 
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phosphate (R,R,RP)-2.100 and products 2.171 and 2.172 were obtained in moderate 
yield.  With these encouraging results, studies will be continued with C6–C14 
fragment to complete the fostriecin-like library compounds.  In addition, generation 
of diastereomeric analogs via CM with bicyclic phosphate (S,S,SP)-2.100 will also be 
synthesized in the future. 
Scheme 29 
 
2.3 Conclusions and future direction 
A library amenable, concise, and efficient CM route has been established for 
the synthesis of both fostriecin and its C8-epimer.  In addition to the latent leaving 
group ability and the protective role for C9, C11 and C14 triols, the distinct role 
played by electronically poor phosphate group in shielding C12–C13 Z-configured 
olefin in CM studies has also been discussed.  Furthermore, as a result of the 
phosphate tether/RCM approach the requisite C12–C13 Z-configured olefin was 
established in a single step without any Z selective protocols (Z selective Wittig, Z 
selective alkyne reduction), which have been used in each and every reported 
synthesis.  Final efforts to fostriecin and C8-epi-fostriecin, along with the library 
synthesis and SAR-guided library development for all active intermediates will be 
discussed in due course.  
O
OO
P
O
O
S
OO
CuI, CH2Cl2, 40 ºC, 12 h
40 % (unoptimized)
O
OO
P
O O
OO
P
O
O
P
OEtO
Grubbs-II
  35 % (unoptimized)
Lactone A or B
(R,R,RP)-2.100 
4 steps
2.171 2.172
 119 
2.4 References  
!
(1)  (a) Tunac, J. B.; Graham, B. D.; Dobson, W. E. "Novel Antitumor Agents CI-
920, PD 113,270 and PD 113,271. I. Taxonomy, Fermentation and Biological 
Properties." J. Antibiot.(Tokyo) 1983 , 36, 1595–1600. (b) Stampwala, S. S.; 
Bunge, R. H.; Hurley, T. R.; Willmer, N. E.; Brankiewicz, A. J.; Steinman, C. 
E.; Smitka, T. A.; French, J. C. "Novel Antitumor Agents CI-920, PD 113,270 
and PD 113,271. II. Isolation and Characterization." J. Antibiot.(Tokyo) 
1983 , 36, 1601–1605. (c) Hokanson, G. C.; French, J. C. "Novel Antitumor 
Agents CI-920, PD 113 270, and PD 113 271. 3. Structure Determination." J. 
Org. Chem. 1985 , 50, 462–466. 
(2)  Walsh, A. H.; Cheng, A.; Honkanen, R. E. "Fostriecin, an Antitumor 
Antibiotic with Inhibitory Activity Against Aerine/threonine Protein 
Phosphatases Types 1 (PP1) and 2A (PP2A), is Highly Selective for PP2A." 
FEBS Lett. 1997 , 416, 230–234.  
(3)  (a) Leopold, W. R.; Shillis, J. L.; Mertus, A. E.; Nelson, J. M.; Roberts, B. J.; 
Jackson, R. C. "Anticancer Activity of the Structurally Novel Antibiotic CI-
920 and its Analogs." Cancer Res. 1984 , 44, 1928–1932. (b) Scheithauer, W.; 
Von Hoff, D. D.; Clark, G. M.; Shillis, J. L.; Elslager, E. F. "In Vitro Activity 
of the Novel Antitumor Antibiotic Fostriecin (CI-920) in a Human Tumor 
Cloning Assay." Eur. J. Cancer Clin. Oncol. 1986 , 22, 921–926. (c) Jackson, 
R. C.; Fry, D. W.; Boritzki, T. J.; Roberts, B. J.; Hook, K. E.; Leopold, W. R. 
"The Biochemical Pharmacology of CI-920, a Structurally Novel Antibiotic 
with Antileukemic Activity." Adv. Enzyme Regul. 1985 , 23, 193–215. (d) de 
Jong, R. S.; de Vires, E. G. E.; Mulder, N. H. "Fostriecin: a Review of the 
Preclinical Data." Anti-Cancer Drugs 1997 , 8, 413–418. (e) Honkanen, R. E.; 
Golden, T. "Regulators of Serine/Threonine Protein Phosphatases at the Dawn 
of a Clinical Era." Curr. Med. Chem. 2002 , 9, 2055–2075. 
(4)  Boritzki, T. J.; Wolfard, T. S.; Besserer, J. A.; Jackson, R. C.; Fry, D. W. 
"Inhibition of Type II Topoisomerase by Fostriecin." Biochem. Pharmacol. 
1988 , 37, 4063–4068. 
(5)  (a) Roberge, M.; Tudan, C.; Hung, S. M. F.; Harder, K. W.; Jirik, F. R.; 
Anderson, H. "Antitumor Drug Fostriecin Inhibits the Mitotic Entry 
Checkpoint and Protein Phosphatases 1 and 2A." Cancer Res. 1994 , 54, 
6115–6121. (b) Guo, X. W.; Th'ng, J. P. H.; Swank, R. A.; Anderson, H. J.; 
Tudan, C.; Bradbury, E. M.; Roberge, M. "Chromosome Condensation 
Induced by Fostriecin does not Require p34cdc2 Kinase Activity and Histone 
H1 Hyperphosphorylation, but is Associated with Enhanced Histone H2A and 
H3 Phosphorylation." Embo J. 1995 , 14, 976–985. (c) Ho, D. T.; Roberge, M. 
"The Antitumor Drug Fostriecin Induces Vimentin Hyperphosphorylation and 
Intermediate Filament Reorganization." Carcinogenesis 1996 , 17, 967–972. 
 120 
!
(d) Hastie, C. J.; Cohen, P. T. W. Purification of protein phosphatase 4 
catalytic subunit: inhibition by the antitumor drug fostriecin and other tumor 
suppressors and promoters. FEBS Lett. 1998 , 431, 357–361. (e) Cheng, A.; 
Balczon, R.; Zuo, Z.; Koons, J. S.; Walsh, A. H.; Honkanen, R. E. Fostriecin- 
Hastie, C. J.; Cohen, P. T. W. "Purification of Protein Phosphatase 4 Catalytic 
Subunit: Inhibition by the Antitumor Drug Fostriecin and other Tumor 
Suppressors and Promoters." FEBS Lett. 1998 , 431, 357–361. (e) Cheng, A.; 
Balczon, R.; Zuo, Z.; Koons, J. S.; Walsh, A. H.; Honkanen, R. E. "Fostriecin-
Mediated G2-M-Phase Growth Arrest Correlates with Abnormal Centrosome 
Replication, the Formation of Aberrant Mitotic Spindles, and the Inhibition of 
Serine/Threonine Protein Phosphatase Activity." Cancer Res. 1998 , 58, 
3611–3619.  
(6)  Boger, D. L.; Hikota, M.; Lewis, B. M. "Determination of the Relative and 
Absolute Stereochemistry of Fostriecin (CI-920)." J. Org. Chem. 1997, 62, 
1748–1753. 
(7)  (a) Ozasa, T.; Tanaka, K.; Sasamata, M.; Kaniwa, H.; Shimizu, M.; 
Matsumoto, H.; Iwanami, M. "Novel Antitumor Antibiotic Phospholine. 2. 
Structure Determination." J. Antibiot. 1989 , 42, 1339–1343. (b) Kohama, T.; 
Enokita, R.; Okazaki, T.; Miyaoka, H.; Torikata, A.; Inukai, M.; Kaneko, I.; 
Kagasaki, T.; Sakaida, Y. "Novel Microbial Metabolites of the 
Phoslactomycins Family Induce Production of Colony-Stimulating Factors by 
Bone Marrow Stromal Cells. I. Taxonomy, Fermentation and Biological 
Properties." J. Antibiot. 1993 , 46, 1503–1511. (c) Jung, W.-H.; Guyenne, S.; 
Riesco-Fagundo, C.; Mancuso, J.; Nakamura, S.; Curran, D. P. "Confirmation 
of the Stereostructure of (+)-Cytostatin by Fluorous Mixture Synthesis of Four 
Candidate Stereoisomers." Angew. Chem., Int. Ed. 2008 , 47, 1130–1133. (d) 
Matsuhashi, H.; Shimada, K. "Chemical Transformation of Leustroducsins: 
Synthesis of Leustroducsin B." Tetrahedron 2002 , 58, 5619–5626. (e) 
Shimada, K.; Kapuragi, Y.; Fukuyama, T. "Total Synthesis of Leustroducsin 
B." J. Am. Chem. Soc. 2003 , 125, 4048–4049. (f) Miyashita, K.; Tsunemi, 
T.; Hosokawa, T.; Ikejiri, M.; Imanishi, T. "Total Synthesis of Leustroducsin 
B." J. Org. Chem. 2008 , 73, 5360–5370. (g) Wang, Y.-G.; Takeyama, R.; 
Kobayashi, Y. "Total Synthesis of Phoslactomycin B and its Biosynthetic 
Deamino Precursor." Angew. Chem., Int. Ed. 2006 , 45, 3320–3323. (h) 
Shibahara, S.; Fujino, M.; Tashiro, Y.; Takahashi, K.; Ishihara, J.; 
Hatakeyama, S. "Asymmetric Total Synthesis of (+)-Phoslactomycin B." Org. 
Lett. 2008 , 10, 2139–2142. (i) Amemiya, M.; Someno, T.; Sawa, R.; 
Naganawa, H.; Ishizuka, M.; Takeuchi, T. "Cytostatin, a Novel Inhibitor of 
cell Adhesion to Components of Extracellular Matrix Produced by 
Streptomyces sp. MJ654-NF4. II. Physico-Chemical Properties and Structure 
Determination." J. Antibiot. 1994 , 47, 541–544. (j) Amemiya, M.; Ueno, M.; 
Osono, M.; Masuda, T.; Kinoshita, N.; Nishida, C.; Hamada, M.; Ishizuka, 
 121 
!
M.; Takeuchi, T. "Cytostatin, a Novel Inhibitor of Cell Adhesion to 
Components of Extracellular Matrix Produced by Streptomyces sp. MJ654-
NF4. I. Taxonomy, Fermentation, Isolation and Biological Activities." J. 
Antibiot. 1994 , 47, 536–540. 
(8)  Kong, R.; Liu, X.; Su, C.; Ma, C.; Qiu, R.; Tang, L. "Elucidation of the 
Biosynthetic Gene Cluster and the Post-PKS Modification Mechanism for 
Fostriecin in Streptomyces pulveraceus." Chem. Biol. 2013, 20, 45–54. 
(9)  Lewy, D. S.; Gauss, C.-M.; Soenen, D. R.; Boger, D. L."Fostriecin: Chemistry 
and Biology" Curr. Med. Chem. 2002, 9, 2005–2032 and references cited 
therein. 
(10)  Buck, S. B.; Hardouin, C.; Ichikawa, S.; Soenen, D. R.; Gauss, C. M.; Hwang, 
I.; Swingle, M. R.; Bonness, K. M.; Honkanen, R. E.; Boger, D. L. 
"Fundamental Role of the Fostriecin Unsaturated Lactone and Implications for 
Selective Protein Phosphatase Inhibition." J. Am. Chem. Soc. 2003, 125, 
15694–15695. 
(11) (a) Swingle, M. R.; Amable, L.; Lawhorn, B. G.; Buck, S. B.; Burke, C. P; 
Ratti, P.; Fischer, K. L.; Boger, D. L.; Honkanen, R. E. "Structure-Activity 
Relationship Studies of Fostriecin, Cytostatin, and Key Analogs, with PP1, 
PP2A, PP5, and (beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), 
Provide further Insight into the Inhibitory Actions of Fostriecin Family 
Inhibitors." J Pharmacol Exp Ther. 2009, 331, 45–53. (b) Burke, C. P.; 
Swingle, M. R.; Honkanen, R. E.; Boger, D. L. "Total Synthesis and 
Evaluation of Phostriecin and Key Structural Analogues." J. Org. Chem. 
2010 , 75, 7505–7513.! 
(12) (a) Bialy, L.; Waldmann, H. "Synthesis of the protein phosphatase 2A 
inhibitor (4S,5S,6S,10S,11S,12S)-cytostatin." Angew. Chem., Int. Ed. 2002, 
41, 1748–1751. (b) Bialy, L.; Waldmann, H. "Total Synthesis and Biological 
Evaluation of the Protein Phosphatase 2A Inhibitor Cytostatin and 
Analogues." Chem. Eur. J. 2004, 10, 2759–2780. (c) Lawhorn, B. G.; Boga, S. 
B.; Wolkenberg, S. E.; Colby, D. A.; Gauss, C.-M.; Swingle, M. R.; Amable, 
L.; Honkanen, R. E.; Boger, D. L. "Total Synthesis and Evaluation of 
Cytostatin, Its C10-C11 Diastereomers, and Additional Key Analogues: 
Impact on PP2A Inhibition." J. Am. Chem. Soc. 2006, 128, 16720–16732. (d) 
Jung, W.-H.; Guyenne, S.; Riesco-Fagundo, C.; Mancuso, J.; Nakamura, S.; 
Curran, D. P. "Confirmation of the Stereostructure of (+)-Cytostatin by 
Fluorous Mixture Synthesis of Four Candidate Stereoisomers." Angew. Chem., 
Int. Ed. 2008, 47, 1130–1133. 
(13) Maki, K.; Motoki, R.; Fujii, K.; Kanai, M.; Kobayashi, T.; Tamura, S.; 
Shibasaki, M. "Catalyst-Controlled Asymmetric Synthesis of Fostriecin and 8-
epi-Fostriecin." J. Am. Chem. Soc. 2005, 127, 17111–17117. 
 122 
!
(14)   Takeuchi, T.; Takahashi, N.; Ishi, K.; Kusayanagi, T.; Kuramochi, K.; 
Sugawara, F. "Antitumor Antibiotic Fostriecin Covalently Binds to Cysteine-
269 Residue of Protein Phosphatase 2A Catalytic Subunit in Mammalian 
Cells." Bioorg. Med. Chem. 2009, 17, 8113–8122. 
(15)  Boger, D. L.; Ichikawa, S.; Zhong, W. "Total Synthesis of Fostriecin (CI-
920)." J. Am. Chem. Soc. 2001 , 123, 4161–4167. 
(16)  (a) Chavez, D. E.; Jacobsen, E. N. "Total Synthesis of Fostriecin (CI-920). "  
Angew. Chem, Int. Ed. 2001 , 40, 3667–3670. (b) Reddy, Y. K.; Falck, J. R. 
"Asymmetric Total Synthesis of (+)-Fostriecin." Org. Lett. 2002 , 4, 969–971. 
(c) Miyashita, K.; Ikejiri, M.; Kawasaki, H.; Maemura, S.; Imanishi, T. "Total 
synthesis of fostriecin (CI-920) via a convergent route." Chem. Comm. 2002 , 
742–743. (d) Esumi, T.; Okamoto, N.; Hatakeyama, S. "Versatile 
enantiocontrolled synthesis of (+)-fostriecin." Chem. Comm. 2002 , 3042–
3043. (e) Miyashita, K.; Ikejiri, M.; Kawasaki, H.; Maemura, S.; Imanishi, T. 
"Total Synthesis of an Antitumor Antibiotic, Fostriecin (CI-920)." J. Am. 
Chem. Soc. 2003 , 125, 8238–8243. (f) McDonald, E. F.; Robles, O. 
"Convergent Synthesis of Fostriecin via Selective Alkene Couplings and 
Regioselective Asymmetric Dihydroxylation." Org. Lett. 2009 , 11, 5498–
5501.(g) Dong D.; O'Doherty, G. A. "Total Synthesis of Fostriecin: Via a 
Regio- and Stereoselective Polyene Hydration, Oxidation and Hydroboration 
Sequence." Org. Lett. 2010 , 12, 3752–3755. 
(17)  (a) Cossy, J.; Pradaux, F.; BouzBouz, S. "Synthesis of the C1!C12 Fragment 
of Fostriecin." Org. Lett. 2001 , 3, 2233–2235. (b) Kiyotsuka, Y.; Igarashi, J.; 
Kobayashi, Y. "A Study toward a Total Synthesis of Fostriecin." Tetrahedron 
Lett. 2002 , 43, 2725–2729. (c) Wang, Y.-G.; Kobayashi, Y. "Formal Total 
Synthesis of Fostriecin." Org. Lett. 2002 , 4, 4615–4618. (d) Fujii, K.; Maki, 
K.; Kanai, M.; Shibasaki, M. "Formal Catalytic Asymmetric Total Synthesis 
of Fostriecin." Org. Lett. 2003 , 5, 733–736. (e) Hayashi, Y.; Yamaguchi, H.; 
Toyoshima, M.; Okado, K.; Toyo, T.; Shoji, M. "Formal Total Synthesis of 
Fostriecin via 1,4-Asymmetric Induction Using Cobalt-Alkyne Complex." 
Org. Lett. 2008 , 10, 1405–1408.  
(18)  Trost, B. M.; Frederiksen, M. U.; Papillon, J. P. N.; Harrington, P. E.; Shin, 
S.; Shireman, B. T. "Dinuclear Asymmetric Zn Aldol Additions:" Formal 
Asymmetric Synthesis of Fostriecin." J. Am. Chem. Soc. 2005 , 127, 3666–
3667. 
(19)  (a) Kanai, M.; Funabashi, K.; Shibasaki, M. "Recent Progress in Asymmetric 
Two-Center Catalysis." Chem. commun. 2002 , 1989–1999. (b) Yoshikawa, 
N.; Yamada, Y. M. A.; Das, J.; Sasai, H.; Shibasaki, M. "Direct Catalytic 
Asymmetric Aldol Reaction." J. Am. Chem. Soc. 1999 , 121, 4168–4178. (c) 
Yamada, Y. M. A.; Yoshikawa, N.; Sasai, H.; Shibasaki, M. "Direct Catalytic 
 123 
!
Asymmetric Aldol Reactions of Aldehydes with Unmodified Ketones."  
Angew. Chem. Int. Ed. Engl. 1997 , 36, 1871–1873. 
(20)  Maki, K.; Motoki, R.; Fujii, K.; Kanai, M.; Kobayashi, T.; Tamura, S.; 
Shibasaki, M. "Catalyst-Controlled Asymmetric Synthesis of Fostriecin and 8-
epi-Fostriecin." J. Am. Chem. Soc. 2005 , 127, 17111–17117. 
(21)  Shibasaki, M.; Kanai, M. "Synthetic Strategies of Fostriecin." Heterocycles 
2005 , 66, 727–741. 
(22)  (a) Whitehead, A.; McReynolds, M. D.; Moore, J. D.; Hanson, P. R. 
"Multivalent Activation in Temporary Phosphate Tethers:! A New Tether for 
Small Molecule!Synthesis." Org. Lett. 2005 , 7, 3375–3378. (b) Thomas, C. 
D.; McParland, J. M.; Hanson, P. R. "Divalent and Multivalent Activation in 
Phosphate Triesters: A Versatile Method for the Synthesis of Advanced 
Polyol Synthons." Eur. J. Org. Chem. 2009 , 5487–5500.  
(23)  (a) Venukadasula, P. K. M.; Chegondi, R.; Maitra, S.; Hanson, P. R. "A 
Concise, Phosphate-Mediated Approach to the Total Synthesis of (–)-
Tetrahydrolipstatin." Org. Lett. 2010 , 12, 1556–1559. (d) Hanson, P. R.; 
Chegondi, R.; Nguyen, J.; Thomas, C. D.; Waetzig, J. D.; Whitehead, A. 
"Total Synthesis of Dolabelide C: A Phosphate-Mediated Approach." J. Org. 
Chem. 2011 , 76, 4358–4370. (e) Chegondi, R.; Tan, M. M. L.; Hanson, P. R. 
"Phosphate Tether-Mediated Approach to the Formal Total Synthesis of (–)-
Salicylihalamides A and B." J. Org. Chem. 2011 , 76, 3909–3916.  
(24)  Tsuji, J. Addition Reactions with Formation of Carbon-Oxygen Bonds:(iv)The 
Wacker Oxidation and Related Reactions. In Comprehensive Organic 
Synthesis, Vol. 7, Trost, B. M.; Fleming, I.; Ley, S. V., Eds., Pergamon: New 
York, 1991, pp. 449–468. 
(25)  Muzart, J. "Aldehydes from Pd-catalysed oxidation of terminal olefins." 
Tetrahedron. 2007 , 63, 7505–7521. 
(26)  Rodeheaver, G. T.; Hunt, D. F. "Conversion of Olefins into Ketones with 
Mercuric Acetate and Palladium Chloride." Chem. Commun. 1971 , 818–819.  
(27)  Nicolaou, K. C.; Xu, J. Y.; Kim, S.; Pfefferkorn, J.; Ohshima, T.; Vourloumis, 
D.; Hosokawa, S. "Total Synthesis of Sarcodictyins A and B." J. Am. Chem. 
Soc. 1998 , 120, 8661–8673. 
(28)  Crimmins, M. T.; Brown, B. H.; Plake, H. R. "An Intramolecular Diels"Alder 
Approach to the Eunicellins:! Enantioselective Total Syntheses of Ophirin B 
and Astrogorgin." J. Am. Chem. Soc. 2006 , 128, 1371–1378. 
(29)  Ramachandran, P. V.; Liu, H.; Reddy, M. V. R.; Brown, H. C. "Synthesis of 
Chiral Tertiary Homoallylic Alcohols via Chelation Controlled 
Diastereoselective Nucleophilic Addition on #-Alkoxyketones: Application 
 124 
!
for the Synthesis of C1-C11 Subunit of 8-epi-Fostriecin." Org. Lett. 2003,  5, 
3755–3757.  
(30)  (a) Knochel, P.; Gavryushin, A.; Metzger, A. "LaCl3!2LiCl-Catalyzed 
Addition of Grignard Reagents to Ketones." Synlett, 2009, 9, 1433–1436. (b) 
Krasovskiy, A.; Kopp, F.; Knochel, P. "Soluble Lanthanide Salts 
(LnCl3!2"LiCl) for the Improved Addition of Organomagnesium Reagents to 
Carbonyl Compounds." Angew.Chem. Int. Ed. 2006, 45, 497–500. 
(31)  Reetz, M. T.; Kyung, S. H.; Huellmann, M. "Methyllithium-Titanium 
Tetrachloride. A Non-Basic and Highly Selective Grignard Analog." 
Tetrahedron 1986 , 42, 2931–2935. 
(32)  (a) Imamoto, T.; Kusumoto, T.; Tawarayama, Y.; Sugiura, Y.; Mita, T.; 
Hatanaka, Y.; Yokoyama, M. "Carbon-carbon Bond-Forming Reactions using 
Cerium Metal or Organocerium(III) Reagents." J. Org. Chem. 1984, 49, 
3904–3912. (b) Imamoto, T.; Takiyama, N.; Nakamura, K.; Hatajima, T.; 
Kamiya, Y. "Reactions of Carbonyl Compounds with Grignard Reagents in 
the Presence of Cerium Chloride." J. Am. Chem. Soc. 1989, 111, 4392–4398. 
(c) Matsukawa, S.; Funabashi, Y.; Imamoto, T. "Regioselective Allylation 
Reactions using Crotyl Grignard Reagent–CeCl3 Systems." Tetrahedron Lett. 
2003, 44, 1007–1010. (d) Juo, W-J.; Lee, T-H.; Liu, W-C.; Ko, S.; Chittimalla, 
S. M.; Rao, C. P.;  Liao, C. L. "Facial Selectivity in the Nucleophilic 
Additions of Vinylmagnesium Bromide to Bicyclo[2.2.2]oct-5-en-2-one 
Derivatives#"!J. Org. Chem. 2007, 72, 7992–8000.!
(33)  (a) Utimoto, K.; Nakamura, A.; Matsubara, S. "Highly Diastereoselective 
Reactions of Ytterbium-Mediated Alkynyllithium and Alkynylmagnesium 
Reagents with Chiral 2-acyl-1,3-oxathianes: Reversal of Diastereoselectivity." 
J. Am. Chem. Soc. 1990 , 112, 8189–8190. (b) Molander, G. A.; Burkhardt, 
E. R.; Weinig, P. "Diastereoselective Addition of Organoytterbium Reagents 
to Carbonyl Substrates." J. Org. Chem. 1990 , 55, 4990–4991. (c) Matsubara, 
S.; Ikeda, T.; Oshima, K.; Utimoto, K. "Preparation of Organoytterbium 
Reagent from Ytterbium Trichloride and Organomagnesium" Chem. Lett. 
2001 , 1226–1227. (d) Sada, M.; Matsubara, S. "Transition-metal Chloride 
Mediated Addition Reaction of Diorganomagnesium to Easily Enolizable 
Ketones." Tetrahedron 2011 , 67, 2612–2616.  
(34)  (a) Harper, D. C.; Hudson, R. F. "The Reactivity of Esters of Quinquevalent 
Phosphorus Towards Anions." J. Chem. Soc. 1958, 1356–1360. (b) Araki, S.; 
Minami, K.; Butsugan, Y. "Reaction of Allyl Diphenyl Phosphate with Soft 
Bases." Bull. Chem. Soc. Jpn. 1981, 54, 629–630. 
(35)   (a) Wals, P. J.; Li, H. "Catalytic Asymmetric Vinylation and Dienylation of 
Ketones" J. Am. Chem. Soc. 2005 , 127, 8355–8361. (b) Ishihara, K.; Suzukii, 
 125 
!
S.; Hatano, M. " Highly Efficient Alkylation to Ketones and Aldimines with 
Grignard Reagents Catalyzed by Zinc(II) Chloride." J. Am. Chem. Soc. 2006 , 
128, 9998–9999. (c) Yus, M.; Ramon, D. J. "Chiral Tertiary Alcohols made 
by Catalytic Enantioselective Addition of Unreactive Zinc Reagents to Poorly 
Electrophilic Ketones?." Angew. Chem. Int .Ed. 2004, 43, 284–287. (d) 
Hatano, M.; Suzuki, S.; Ishihara, K. "Highly Chemoselective Stoichiometric 
Alkylation of Ketones with Grignard Reagent Derived Zinc(II)ate 
Complexes." Synlett 2010 , 321–324. (e) Hatano, M.; Ito, O.; Suzuki, S.; 
Ishihara, K. "Zinc(II)-Catalyzed Grignard Additions to Ketones with RMgBr 
and RMgI." Chem. Commun. 2010 , 46, 2674–2676. 
(36)  (a) Frantz, D. E.; Fässler, R.; Carreira, E. M. "Facile Enantioselective 
Synthesis of Propargylic Alcohols by Direct Addition of Terminal Alkynes to 
Aldehydes." J. Am. Chem. Soc. 2000 , 122, 1806–1807. (b) Jiang, B.; Chen, 
Z.; Tang, X. "Highly Enantioselective Alkynylation of !-Keto Ester:" An 
Efficient Method for Constructing a Chiral Tertiary Carbon Center." Org. 
Lett. 2002 , 4, 3451–3453. (c) Cozzi, P. G.; Rudolph, J.; Bolm, C.; Norrby, P.-
O.; Tomasini, C. "Me2Zn-Mediated Addition of Acetylenes to Aldehydes and 
Ketones." J. Org. Chem. 2005 , 70, 5733–5736. 
(37)  Alcaraz, L.; Harnett, J. J.; Mioskowski, C.; Martel, J. P.; Gall, T. L.; Shin, D.-
S.; Flack, J. R. "Novel Coversion of Epoxides to One Carbon Homolagated 
Allylic Alcohols by Dimethylsulfonium Methylide." Tetrahedron Lett. 1994, 
5449–5452. 
(38)  (a) Sharpless, K. B.; Akashi, K. "Osmium Catalyzed Vicinal Hydroxylation of 
Olefins by tert-butyl Hydroperoxide Under Alkaline Conditions." J. Am. 
Chem. Soc. 1976, 98, 1986–1987. (b) Sharpless, K. B.; Amberg, W.; Bennani, 
Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K. S.; Kwong, H. L.; Morikawa, 
K.; Wang, Z. M. "The Osmium-Catalyzed Asymmetric Dihydroxylation:  a 
New Ligand Class and a Process Improvement." J. Org. Chem. 1992. 57, 
2768–2771. (c) Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. 
"Catalytic Asymmetric Dihydroxylation." Chem. Rev. 1994 , 94, 2483–2547.! 
(39)  (a) VanRheenen, V.; Kelly, R. C.; Cha, D. Y. "An Improved Catalytic OsO4 
Oxidation of Olefins to cis-1, 2-glycols using Tertiary Amine Oxides as the 
Oxidant." Tetrahedron Lett. 1976 , 17, 1973–1976. 
(40)  (a) Shing, T. K. M.; Tam, E. K. W.; Tai, v. W. F.; Chung, I. H. F.; Jiang, Q. 
"Ruthenium-Catalyzed cis-Dihydroxylation of Alkenes: Scope and 
Limitations." Chem. Eur. J. 1996 , 2, 50–57 (b) Pagliaro, M.; Campestrini, S.; 
Ciriminna, R. "Ru-based Oxidation Catalysis." Chem. Soc. Rev. 2005 , 34, 
837–845. (c) Plietker, B. "Selectivity versus Reactivity - Recent Advances in 
RuO4-catalyzed Oxidations." Synthesis 2005 , 2453–2472. (d) Beligny, S.; 
Eibauer, S.; Maechling, S.; Blechert, S. "Sequential Catalysis: a 
metathesis/dihydroxylation Sequence." Angew. Chem., Int. Ed. 2006 , 45, 
 126 
!
1900–1903. (e) Scholte, A. A.; An, M. H.; Snapper, M. L. "Ruthenium-
Catalyzed Tandem Olefin Metathesis-Oxidations." Org. Lett. 2006 , 8, 4759–
4762. (f) Lietker, B.; Niggemann, M. "RuCl3/CeCl3/NaIO4: A New 
Bimetallic Oxidation System for the Mild and Efficient Dihydroxylation of 
Unreactive Olefins." J. Org. Chem. 2005 , 70, 2402–2405. (g) Che, C.-M.; 
Yip, W.-P.; Yu, W.-Y. "Ruthenium-Catalyzed Oxidation of Alkenes, Alkynes, 
and Alcohols to Organic Acids with Aqueous Hydrogen Peroxide." Chem. 
Asian J. 2006 , 1, 453–458. (h) Tiwari, P.; Misra, A. K. "An Efficient 
Stereoselective Dihydroxylation of Glycals using a Bi-metallic System, 
RuCl3/CeCl3/NaIO4." J. Org. Chem. 2006 , 71, 2911–2913. (h) Neisius, N. 
M.; Plietker, B. "Diastereoselective Ru-Catalyzed Cross-Metathesis-
Dihydroxylation Sequence. An Efficient Approach toward Enantiomerically 
Enriched syn-Diols." J. Org. Chem. 2008 , 73, 3218–3227. 
(41)  (a) Chavez, D. E. "The Total Synthesis of Fostriecin (CI-920). The 
Development and Applications of an Asymmetric Hetero-Diels-Alder 
Reaction." Ph. D. Thesis, Harvard University, Cambridge, MA, 2003. (b) 
Gademann, K.; Chavez, D. E.; Jacobsen, E. N. "Highly Enantioselective 
Inverse-Electron-Demand Hetero-Diels–Alder Reactions of !,"-Unsaturated 
Aldehydes." Angew. Chem. Int. Ed. 2002, 41, 3059–3061. (c) Chavez, D. E.; 
Jacobsen, E. N.; Grabowski, E. J. J.; Kubryk, M. "#n Efficient, Highly 
Diastereo-and Enantioselective Hetero Diels-Alder Catalyst. Preparation of 
(2S,6R)-6-(tert-butyldimethyl-silyloxymethyl)-2-methoxy-2,5-dihydropyran."  
Organic Synthesis 2005, 82, 34. (d) Chavez, D. E.; Jacobsen, E. N. "Total 
Synthesis of Fostriecin (CI-920)." Angew. Chem, Int. Ed. 2001, 40, 3667– 
3670. 
(42)  Corma, A.; Domine, M. E.; Valencia, S. "Water-resistant solid Lewis acid 
catalysts: Meerwein-Ponndorf-Verley and Oppenauer Reactions Catalyzed by 
tin-beta Zeolite." J. Catal. 2003, 215, 294–304. (c) Boronat, M.; Corma, A.; 
Renz, M. "Mechanism of the Meerwein-Ponndorf-Verley-Oppenauer 
(MPVO) Redox Equilibrium on Sn and Zr-Beta Zeolite Catalysts." J. Phys. 
Chem. B 2006, 110, 21168–21174. 
"#$%!! (a) Rollin, P.; Sinay, P. "A Convenient, One-Step Oxidation of Glycals to 
Lactones using Pyridinium Chlorochromate." Carbohydr. Res. 1981, 98, 139–
142. (b) Cossy, J.; Bouzbouz, S.; Lachgar, M.; Hakiki, A.; Tabyaoui, B. 
"Specific Oxidative Cleavage of Allylic and Benzylic Ethers by using 
Pyridinium Chlorochromate." Tetrahedron Lett. 1998, 39, 2561–2564. (c) 
Fernandes, R. A.; Kumar, P. "PCC-mediated Novel Oxidation Reactions of 
Homobenzylic and Homoallylic Alcohols." Tetrahedron Lett. 2003, 44, 1275–
1278. (d) Couladouros, E. A.; Strongilos, A. T.; Papageorgiou, P, V.; Plyta, Z. 
F. "A New Efficient Route for Multigram Asymmetric Synthesis of Alkannin 
and Shikonin." Chem. Eur. J. 2002, 8, 4272–4284. (e) Luzzio, F. A.; Fitch, R. 
W.; Moore, W. J.; Mudd, K. J. "A Facile Oxidation of Alcohols Using 
 127 
!
Pyridinium Chlorochromate/Silica Gel." J. Chem. Ed. 1999, 974–975. (f) Li, 
D.; Zhao, Y.; Ye, L.; Chen, C.; Zhang, J. A "Formal Total Synthesis of 
Fostriecin by a Convergent Approach." Synthesis 2010, 19, 3325–3331. 
(44)  McParland, J. P. "Multivalent Activation Imparted by Phosphate Tethers: 
Metathesis Efforts Towards Fostriecin." Ph. D. Thesis, University of Kansas, 
Lawrence, KS, 2009. 
(45)  Chatterjee, A. K.; Choi, T.-L.; Sanders, D. P.; Grubbs, R. H. "A General 
Model for Selectivity in Olefin Cross Metathesis." J. Am. Chem. Soc. 2003 , 
125, 11360–11370. 
(46)  (a) Kingsbury, J. S.; Harrity, J. P. A.; Bonitatebus, P. J., Jr.; Hoveyda, A. H. 
“A Recyclable Ru-Based Metathesis Catalyst.” J. Am. Chem. Soc. 1999 , 121, 
791–799. (b) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. 
"Efficient and Recyclable Monomeric and Dendritic Ru-Based Metathesis 
Catalysts." J. Am. Chem. Soc. 2000, 122, 8168–8179; (c) Gessler, S.; Randl, 
S.; Blechert, S. "Synthesis and Metathesis Reactions of a Phosphine-free 
Dihydroimidazole carbene Ruthenium Complex." Tetrahedron Lett. 2000, 41, 
9973–9976. 
(47)  (a) Waetzig, J. W.; Hanson, P. R. "Temporary Phosphate Tethers: A 
Metathesis Strategy to Differentiated Polyol Subunits." Org. Lett. 2006 , 8, 
1673–1676. (b) Venukadasula, P. K. M.; Chegondi, R.; Suryn, G. M.; Hanson, 
P. R. "A Phosphate Tether-Mediated, One-Pot, Sequential Ring-Closing 
Metathesis/Cross-Metathesis/Chemoselective Hydrogenation Protocol." Org. 
Lett. 2012 , 14, 2634–2637. 
(48) Rivard, M.; Blechert, S. "Effective and Inexpensive Acrylonitrile Cross-
Metathesis: utilisation of Grubbs II Precatalyst in the Presence of Copper(I) 
Chloride." Eur. J. Org. Chem. 2003 , 2225–2228. 
(49) He, A.; Yan, B.; Thanavaro, A.; Spilling, C. D. "Synthesis of Nonracemic 
Allylic Hydroxy Phosphonates via Alkene Cross Metathesis." J. Org. Chem. 
2004 , 69, 8643–8651.  
"#$%! (a) Lipshutz, B. H.; Aguinaldo, G. T.; Ghorai, S.; Voigtritter, K. "Olefin 
Cross-Metathesis Reactions at Room Temperature Using the Nonionic 
Amphiphile “PTS”:  Just Add Water." Org. Lett. 2008, 10, 1325–1328. (b) 
Lipshutz, B. H.; Ghorai, S.; Leong, W. W. Y. "Deprotection of Homoallyl 
(hAllyl) Derivatives of Phenols, Alcohols, Acids, and Amines." J. Org. Chem. 
2009, 74, 2854–2857. (c) Voigtritter, K.; Ghorai, S.; Lipshutz, B. H. "Rate 
Enhanced Olefin Cross- Metathesis Reactions: The Copper Iodide Effect." J. 
Org. Chem. 2011, 76, 4697–4702.!!
(51) (a) Sawabe, A.; Filla, S. A.; Masamune, S. "Use of 2-trimethylsilylethyl as a 
Protecting Group in Phosphate Monoester Synthesis." Tetrahedron Lett. 
 128 
!
1992 , 33, 7685–7686; (b) Tanimoto, N.; Gerritz, S. W.; Sawabe, A.; Noda, 
T.; Filla, S. A.; Masamune, S. "The Synthesis of Naturally Occurring (–)-
Calyculin A." Angew. Chem. Int. Ed. 1994 , 33, 673–675. 
(52) (a) Chattopadhyay, A.; Mamdapur, V. R. "(R)-2,3-O-
Cyclohexylideneglyceraldehydea, Versatile Intermediate for Asymmetric 
Synthesis of Chiral Alcohol." J. Org. Chem. 1995, 60, 585–587; (b) 
Chattopadhyay, A. "(R)-2,3-O-Cyclohexylideneglyceraldehyde, a Versatile 
Intermediate for Asymmetric Synthesis of Homoallyl and Homopropargyl 
Alcohols in Aqueous Medium." J. Org. Chem. 1996, 61, 6104–6107. 
(53) (a) Anh, N. T. "Regio- and Stereo-Selectivities in Some Nucleophilic 
Reactions." Top. Curr. Chem. 1980, 88, 145. (b) Cherest, M.; Felkin, H. 
"Torsional Strain Involving Partial Bonds. The Steric Course of the Reaction 
between Allyl Magnesium Bromide and 4-t-butyl-cyclohexanone." 
Tetrahedron Lett. 1968, 9, 2205–2208.  
(54) (a) Cram, D. J.; Kopecky, K. R. "Studies in Stereochemistry. XXX. Models 
for Steric Control of Asymmetric! Induction." J. Am. Chem. Soc. 1959, 81, 
2748–2755. (b) Cram, D. J.; Abd Elhafez, F. "A.!Studies in Stereochemistry. 
X. The Rule of “Steric Control of Asymmetric Induction” in the Syntheses of 
Acyclic!Systems." J. Am. Chem. Soc. 1952, 74, 5828–5835. 
 129 
 
 
 
 
 
 
 
Chapter 3 
 
Total Synthesis of Strictifolione and  
(6R)-6-[(4R,6R)-4,6-dihydroxy-10-phenyldec-1-enyl]-5,6-dihydro-2H-pyran-2-one 
 
 
 
 
 
 
 130 
3.1 Introduction: 
 The development of chemical methods that allow for the facile preparation of 
bioactive natural products and analogs is highly important to early phase drug 
discovery efforts aimed at improving human health.  In particular, the discovery of 
drugs for the treatment of systemic antifungal diseases is highly important in light of 
the fact that over a million human deaths occur annually due to fungal associated 
diseases. 1  In addition, increasing mechanisms of resistance against current antifungal 
therapies, coupled with challenges with treating fungal infections of immune-
compromised patients, warrant the search for new and improved therapeutic agents 
for combating fungal diseases. 2   This chapter describes the development of a 
synthetic route for facile preparation of the antifungal natural products, strictifolione 
(3.1) and a related natural product (6R)-6-[(4R,6R)-4,6-dihydroxy-10-phenyldec-1-
enyl]-5,6-dihydro-2H-pyran-2-one (3.2), in a manner that is highly amenable to the 
production of analogs (Figure 1).! 
Figure 1:  Strictifolione and related natural products. 
 
3.1.1 Overview of strictifolione and related natural products: 
(+)-Strictifolione (3.1) was isolated and structurally characterized by Aimi and 
coworkers from the stem bark of Cryptocarya strictifolia, a member of the family 
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Lauraceae that grows in the rainforests of west Kalimantan, Indonesia.3  The relative 
and absolute stereochemistry of 3.1 was proposed employing spectroscopic analysis.  
The relative stereochemistry of the C4'/C6' 1,3-diol functionality was elucidated from 
analysis of 13C NMR chemical shifts of the acetonide derivative.4   Of note is that the 
two methyl groups of the acetonide of the 1,3-anti-diol exhibited almost identical 
chemical shifts of 24.88 and 24.85 ppm, while in the corresponding 1,3-syn-diol, the 
characteristic methyl groups exhibited significantly distinct chemical shifts of 19.93 
and 30.44 ppm.3,4  In order to substantiate the acetonide analysis, the absolute 
configurations of their stereogenic centers were also determined utilizing Mosher 
analysis.5  The structure of 3.1, including the absolute configuration of all stereogenic 
centers, was further confirmed by Aimi and co-workers upon completion of the first 
total synthesis, employing (S)-malic acid and (S)-glycidol in 25 total steps and a 
longest linear sequence (LLS) of 18 steps.6  Thereafter, various approaches for the 
synthesis of strictifolione have been reported in the literature.7 
A related compound (6R)-6-[(4R,6R)-4,6-dihydroxy-10-phenyldec-1-enyl]-
5,6-dihydro-2H-pyran-2-one (3.2), along with another structurally similar compound 
(6S)-5,6-dihydro-6-[(2R)-2-hydroxy-6-phenylhexyl]-2H-pyran-2-one (3.3) were 
isolated by Hostettmann and coworkers in 2001 from the leaves and bark of 
Ravensara crassifolia (Figure 1).8  Krishna and coworkers accomplished the first total 
synthesis of 3.2 by iterative use of Jacobsen’s hydrolytic kinetic resolution in 17 total 
steps and with a longest linear sequence (LLS) of 17 steps.9  Interestingly, all three 
compounds (3.1–3.3) have been shown to possess antifungal activity. 
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Key structural features in 3.1 and 3.2 include a Michael-accepting 5,6-
dihydro-!-pyrone moiety in the eastern subunit, a central 1,3-anti-diol, and lipophilic 
substitution in the western subunit.  It is generally believed that the !,"-unsaturated 
pyranone functional group can react with the nucleophilic warhead of a target enzyme 
and thus attenuate its activity.10  Moreover, structure-activity relationships (SAR) 
among different pyranone-containing molecules demonstrate that substituents on the 
side chain play a critical role.10   
A number of natural products possessing the 5,6-dihydro-!-pyrone subunit 
with an accompanying C6 aryl-alkyl side chain, have been found to exhibit myriad 
biological activity and are outlined as follows (Figure 1).11  Lactones 3.38 and 3.4,12 
as well as massoi lactone (3.5),13 have been found to exhibit antifungal activity, while 
fostriecin (3.6) is a known anticancer agent with potent and selective inhibitory 
properties against PP2A.14  Phomalactone (3.7) has shown herbicidal, antibacterial 
and insecticidal activity,15 while pironetin (3.8) has been found to inhibit cell cycle 
progression in the M-phase.16  Furthermore, callystatin A (3.9),17 gonodiol (3.10)18 
and obolactone (3.11)19 all exhibit cytotoxic activity, while goniothalamin (3.12)20 
induces apoptotic activity.  Taken collectively, these attributes have prompted 
substantial interest in the total synthesis of compounds bearing the 5,6-dihydro-!-
pyrone moiety.  
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Figure 1: 5,6-Dihydro-!-pyrone-containing natural products. 
 
 In addition to the above-mentioned antifungal agents, there are several 
antifungal natural products whose structural frameworks differ widely, and which 
also lack the !-lactone moiety.21  Overall, the disparate array of structure, the inability 
of predicting key pharmacophores, the growth of life-threatening human fungal 
infections in immunosuppressed individuals, and the rising development of resistance 
to current drugs,22 warrants continued investigations towards filling the unmet need 
for new antifungal drugs.  Hence, there is still a high importance and urgency for the 
development of new antifungal compounds with improved properties.  In particular, 
the development of a library-amenable synthetic route will aid in subsequent SAR 
and biological studies, while incorporating important structural features. 
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Figure 2: Some examples for natural anti-fungal compounds 
 
3.1.2 Overview of strictifolione synthetic strategies 
After the seminal total synthesis of 3.1 by Aimi and coworkers, several 
elegant syntheses have been reported in the literature.6,7  A brief overview of each 
synthesis will be discussed in this section, outlining key transformations employed in 
each approach to establish the requisite stereogenic centers as well as the olefin 
geometries. 
As previously stated, in 2002, Aimi and coworkers reported the total synthesis 
of 3.1 using a synthetic pathway entailing a LLS of 19 steps.6  The C4' and C6' 1,3-
anti-diol were generated from the (S)-malic acid-derived epoxide 3.14 opening with 
the anion of dithiane 3.15, followed by dithiane deprotection and subsequent 
stereoselective reduction of the resultant !-hydroxy ketone 3.16 with Me4NBH(OAc)3 
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(Scheme 1).  The masked pyranone aldehyde 3.20 was synthesized from (S)-glycidol, 
employing the reported route by Crimmins and coworkers23 in 6 steps and the C6 
stereogenic center was derived (S)-glycidol.  The C1!–C2! E olefin geometry was 
obtained via the Kocienski-modified Julia olefination of masked pyranone aldehyde 
3.20 with sulfone 3.18 in 34% yield and moderate selectivity (E:Z = 4:1). 
Scheme 1 
 
In 2003, Shibasaki and coworkers reported synthetic studies to synthesize key 
intermediate 3.26, employing a catalytic asymmetric epoxidation of !,"-unsaturated 
amide 3.23 utilizing a Sm–BINOL–Ph3As=O (1:1:1) complex.
7b  The resulting 
optically pure !,"-epoxyamide 3.23 was then transformed to ",#-epoxy $-keto ester 
and subsequent reductive epoxide opening with selenium reagent (prepared from 
PhSeSePh and NaBH4)
24 afforded the C6! carbinol containing "-hydroxy $-keto ester 
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3.24 in good yield.  The diastereoselective anti reduction of keto ester 3.24 with 
Me4NBH(OAc)3
25  generated the 1,3-anti-diol-containing intermediate 3.25 
possessing the requisite C4' stereogenic center in 79% yield and good selectivity 
(syn:anti = 1:9).  Subsequent acetonide protection of diol followed by LiAlH4 
reduction of the ester functionality afforded the key intermediate 3.26 in 92% overall 
yield over 2-steps. 
Scheme 2 
 
In 2003, Cossy and coworkers reported an efficient synthesis of 3.1 with  
9 total steps, employing 3 enantioselective allyltitanations 26  starting from  
3-phenylpropionaldehyde (3.27) to establish the stereogenic centers at C6, C4' and 
C6'.  Cross-metathesis (CM) of the protected homoallylic alcohol with acrolein 
established the C1'–C2' E-configured olefin geometry (Scheme 3).7a  The lactone 
subunit was constructed via esterification of homoallylic alcohol 3.33 with acryloyl 
chloride, followed by RCM. 
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In 2004, the Enders group reported an asymmetric synthesis of strictifolione in 
11 linear steps (Scheme 4).7c  The highlight of this approach includes utilization of 
SAMP-hydrazone 3.34 in conjunction with !,!'-bis-alkylation/deoxygenation 
protocol to produce the C4'/C6'-anti diol subunit 3.37 (Scheme 4).  Enzymatic 
reduction with baker's yeast was employed to establish the C6 stereogenic center in 
the subsequent preparation of the lactone unit 3.41 from the diketoester 3.39.27  
Alternatively, (S)-proline-catalyzed !-oxyamination of pent-4-enal was used to 
introduce the requisite C6 stereogenic center within the lactone precursor, !-siloxy-
substituted aldehyde 3.42.  The C1'–C2' E-configured olefin was introduced via Julia-
Kocienski olefination28 of sulfone 3.38 with aldehyde 3.41 or 3.42 in moderate yield 
(61%) and selectivity (E/Z = 8.5:1).7c 
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Scheme 4 
 
In 2005, the Ramana group reported the chiral pool synthesis of 3.1 from  
D-glucose in a route with a LLS of 19 steps (TS = 26).7d  Mitsunobu inversion of 3.46 
installed the C6! carbinol of 3.47 (Scheme 5).  The C2'–C3' bond formation 
employing Yamaguchi protocol29 with lithium acetylide 3.51 and epoxide 3.48 C2!–
C3! afforded the advanced intermediate 3.52 in good yield (85%).  The C1'–C2'  
E-configured olefin was installed via Red-Al® reduction of alkyne 3.52 and the 
employment of a Z-selective HWE olefination established the C3–C4 Z-configured 
olefin geometry.   
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Scheme 5 
 
In 2009, the Sabitha group accomplished the total synthesis of 3.1 in a short 
route with a LLS of 10 steps (TS = 19).7e  The highlight of this synthesis was 
utilization of !n asymmetric Prins reaction of homoallylic alcohol 3.54 and 
benzaldehyde to generate the 1,3–anti-diol stereochemistry (Scheme 6).  The MOM-
protected tetrahydropyran 3.55 (generated from asymmetric Prins reaction) was 
opened with Li in liquid NH3, which upon epoxidation, followed by Li-acetylide 
opening and subsequent Lindlar’s reduction, provided the corresponding homoallylic 
alcohol 3.57.  The vinyl lactone 3.60 was synthesized in 5 steps, starting from 
homoallylic alcohol 3.58 utilizing HWE olefination to establish the C2–C3 Z-
configured olefin geometry.  The C1'–C2' E olefin geometry was installed via CM 
with vinyl lactone 3.60 and key fragment 3.57.7e 
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Scheme 6 
 
In 2010, Kumar and co-workers reported a 14-step synthesis of 3.1.7f  The key 
transformations utilized include, two enantioselective proline-catalyzed sequential  
!-amino hydroxylations30 starting from the aldehyde 3.60 to obtain the 1,3-anti-diol 
subunit (Scheme 7).  Subsequent Brown asymmetric allylation of 3.67 installed the 
stereogenic center at C6.  Cross metathesis and RCM were utilized to produce the 
C1'–C2' E-configured olefin and the C3–C4 Z-configured olefin geometries,  
Scheme 7 
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respectively.7f  In addition, as !n alternative approach, the Jacobsen hydrolytic kinetic 
resolution was used to generate the 1,3-anti diol subunit as well as BINAL-H-
mediated asymmetric reduction to obtain the C6 stereogenic center.7f 
In 2010, She and coworkers accomplished the total synthesis of 3.1 in 9 steps 
utilizing a one-pot, double allyl boration reaction31 of boryl-substituted allylborane 
3.69 with aldehyde 3.70 and 3.71 to afford an enantio-and diastereoselective synthesis 
of (E)-1,5-anti-ene-diol 3.72 which contains the C4' and C6 stereogenic centers as 
well as the C1'–C2' E olefin geometry (Scheme 8).7g  The C3–C4 Z-configured olefin 
geometry was generated via RCM of biacrylate tetraene precursor 3.73 using Grubbs 
1st generation catalyst under high dilution conditions in refluxing CH2Cl2.  Hydroxy-
directed 1,3-anti-reduction of the !-hydroxy ketone 3.74 with Me4NBH(OAc)3 
established the C6' stereocenter in good yield and with high anti-diastereoselectivity 
(91 %, dr = 96:4) 
Scheme 8 
 
In the same year, Das and co-workers achieved the synthesis of 3.1 with a 
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LLS of 10 steps and TS count of 15 steps.7h  This approach entailed utilization of 
Sharpless kinetic resolution to furnish optically pure epoxy alcohol 3.77.  Subsequent 
epoxide ring opening with Red-Al generated the 1,3-anti diol fragment 3.78.   Vinyl 
lactone 3.82 was separately synthesized starting from L-ascorbic acid and the Z-olefin 
geometry was achieved via Still-Gennari-Wittig reaction.  The (E)-configured C1'–
C2' double bond was synthesized via cross metathesis with 3.78 with vinyl lactone 
3.82.  
Scheme 9 
 
In addition to these synthetic studies, in 2012, Sharma and coworkers reported 
the chemo enzymatic asymmetric synthesis of 3.1 utilizing lipase-catalyzed 
(Novozyme 435, candida antarctica lipase B immobilized on macroporous acrylic 
resin) acetylation to obtain both fragments 3.85 and 3.90 to establish the stereocenters 
at C6' and C6, respectively.  !n asymmetric allylstannation of 3.86 with allyl(Bu)3Sn 
alongside a chiral In(III) catalyst (prepared from  (R)-BINOL and InCl3) established  
the C4' carbinol stereogenic center and furnished the 1,3-anti-diol subunit 3.87 in 
88 % overall yield and excellent diastereomeric ratio (dr=95:5).7i  Z and E olefin 
Ph
CHO
Ph OH Ph OH
O
Ph OHOH
O
HO
O
OHHO
HO
COOMe
O
O
O
HO
O
O
O
(3.1)
Sharpless kinetic resolution
L-ascorbic acid
CM
3.75 3.76 3.77 3.78
3.79
3.80
3.81 3.82
Ti(iOPr4)
(+)-DIPT,TBHP
45 %, 97 % ee
Red-Al
77 %
 143 
geometries were produced with Z-selective HWE reaction and cross metathesis of 
vinyl lactone 3.91 and diol subunit 3.87. 
Scheme 10 
 
Among several elegant methods, Cossy, Das, and She were able to construct 
strictifolione (3.1) in efficient synthetic pathways with concise longest linear 
sequences of 9-, 10- and 9-steps, respectively.  These syntheses of 3.1 are among the 
most efficient reported to date.  Despite noted attributes of these syntheses,7 the 
development of simple, efficient, and scalable strategies remains challenging and 
important. In this regard, multi-step one-pot protocols that facilitate 
total/intermediate/analog synthesis have emerged as powerful synthetic strategies, 
due to their ability to form multiple bonds and stereocenters, while invoking step, 
atom and green economy.32,33   In the remainder of this chapter, we disclose an 
efficient, simple modular approach for the total synthesis of both naturally occurring 
antifungal compounds 3.1 and 3.2 that employes a phosphate tether-mediated one-pot, 
sequential, RCM/CM/chemoselective hydrogenation protocol.34  
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3.2 Results and discussion 
3.2.1 Retrosynthetic analysis of (+)-strictifolione 
Retrosynthetic analysis reveals that both natural products 3.1 and 3.2 can be 
readily derived from key diol-containing intermediates 3.92 and 3.97, respectively, 
via CM with vinyl lactone 3.93 (Scheme 11).  The pivotal diol 3.92 and 3.97 in turn 
can be synthesized from phosphates 3.94 and 3.98, employing a regioselective Pd(0)-
catalyzed reductive allylic transposition and phosphate tether removal under reductive 
conditions.  The phenyl-substituted, bicyclic phosphate 3.94 can be synthesized from 
triene (R,R)-3.95 via a one-pot, sequential RCM/CM/"H2" with cis-stilbene as the CM 
partner, followed by chemoselective hydrogenation with o-nitrobenzenesulfonyl 
hydrazine (o-NBSH).35  The triene (R,R)-3.95 is readily prepared in 2-steps via 
sequential tripodal coupling of the C2-symmetric anti-diene diol (R,R)-3.96 and allyl 
alcohol with POCl3, or in one step utilizing phosphoramidite chemistry.
36  Similarly, 
phosphate 3.98 can be synthesized following the same sequence of RCM/CM/"H2" 
starting with enantiomeric triene (S,S)-3.95 that is obtained from 1,3-anti-diene diol 
(S,S)-3.96 utilizing phenyl-but-3-ene as a CM coupling partner.  Vinyl lactone 3.93 
can be readily derived from the Diels-Alder reaction of diene 3.99 and TIPS-
protected propargyl aldehyde 3.100 employing the Jacobsen hetero Diels-Alder 
(HDA) catalyst.37 
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Scheme 11. Retrosynthetic analysis of natural products 1 and 2. 
 
3.2.2 Total synthesis of (+)-strictifolione and (6R)-6-[(4R,6R)-4,6-dihydroxy-10-
phenyldec-1-enyl]-5,6-dihydro-2H-pyran-2-one 
The key starting substrate phosphate triester (R,R)-3.95 was synthesized from 
tripodal coupling of C2-symmetric 1,3-anti diol (R,R)-3.96 and allylic alcohol with 
POCl3.
36  Previous studies have shown pseudo-C2-symmetric phosphate triene (R,R)-
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3.95 can be desymmetrized via RCM metathesis and the resulting P-chiral, non-
racemic bicyclic phosphate (R,R,RP)-3.102 can undergo various regio-and chemo-
selective reactions.36  In addition, subtle stereoelectronic properties innate to 
phosphate tethers further enable the one-pot, sequential RCM/CM/"H2" protocol to 
provide streamlined synthesis of advanced polyol synthons.  The general protocol for 
the RCM/CM/"H2" is shown in Scheme 12. 
Scheme 12. 
 
Following the previously reported optimized conditions for RCM/CM/H2,
34 triene 
(R,R)-3.95 was first subjected to RCM reaction with the second-generation Hoveyda–
Grubbs (HG-II) catalyst 3.10438 (6 mol %) in CH2Cl2 (0.007 M) and upon completion 
of the reaction, solvent was evaporated and CM partner, cis-stilbene, in 
dicholoroethane (DCE) was introduced along with HG–II and refluxing was 
continued for 6 hours (Scheme 13).  It should be noted that CM with styrene was not 
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productive in comparison to cis-stilbene due to deleterious homodimerization of 
styrene which is a type I olefin partner. 39   Subsequent chemoselective diimide 
reduction with o-NBSH provided the phenyl-substituted phosphate 3.94 in 52% 
overall yield, representing an 81% average yield for the 3 reactions involved in the 
one-pot, sequential protocol.  Pd-catalyzed, reductive allylic transposition [Pd(OAc)2, 
HCOONH4] on phosphate 3.108 generated the requisite terminal olefin in excellent 
regioselectivity, which when followed by tether removal with LiAlH4, provided diol 
3.92 as a single diastereomer in 42% overall yield for the two steps.   
Scheme 13.  
 
The desired vinyl lactone 3.93 was generated utilizing the Jacobsen HDA 
methodology37 and the synthesis was discussed in Chapter 2 (Section 2.2.2.3). 
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HG-II in CH2Cl2 to afford 3.1 in 77% yield and excellent E-configured olefin 
selectivity.  The spectral data (1H, 13C, IR, HRMS) and optical rotation of 3.1 were in 
complete agreement with those reported in the literature.3   
Scheme 14. 
 
The exploitation of this modular approach to enable chemical library 
production of analogs of 3.1 is an added advantage.  In particular, late-stage 
CM/RCM/"H2" (at step 4) and CM at step 7, streamlines this approach.  This aspect is 
further demonstrated in the synthesis of 3.2 starting with the enantiomeric triene 
(S,S)-3.95 and a different CM partner 3.109 as outlined in Scheme 15. 
Synthesis of (6R)-6-[(4R,6R)-4,6-dihydroxy-10-phenyldec-1-enyl]-5,6-
dihydro-2H-pyran-2-one (3.2) is achieved following a similar sequence starting with 
the enantiomerically pure diene diol (S,S)-3.96 (Scheme 16).  After completing the 
RCM reaction with triene (S,S)-3.95, CM was proceeded with the phenyl-but-1-ene 
(3.109) and subsequent hydrogenation generated phosphate 11.7 in 54% overall yield 
in 3 steps.  Pd-catalyzed, reductive allylic transposition afforded monocyclic 
phosphate 3.110 in 65% yield and tether removal with LiAlH4 provided the key 
intermediate 3.97 in 60% yield.  Cross-metathesis with vinyl lactone 3.93 and 3.97 
Ph
OH OH
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O
HG-II, CH2Cl2, 40 ºC
77%
O
O
Ph
OH OH
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3.92
3.93
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furnished the natural product 3.2 in 70% overall yield, and with excellent E-olefin 
selectivity.   
Scheme 15  
 
3.3 Future directions and Conclusion 
The key advancement of the current route is further development of one-pot 
procedures, which incorporate all 4 steps in !n efficient one-pot, sequential protocol.  
In this regard, ongoing efforts are focused on the combination of Pd-catalyzed allylic 
transposition into the one-pot RCM/CM/H2 sequence.  However, reduction with 
diimide conditions did not facilitate Pd-catalyzed reductive allylic transposition due 
to excess Et3N that used in the preceding reaction.  A potential solution to this issue is 
to find a different method for the chemoselective reduction of the exocyclic double 
bond without encountering additional problems with Ru catalysis, which were used in 
the previous RCM and CM reactions.  Cossy and coworkers reported olefin 
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tandem CM/reduction or RCM/reduction protocols. 40   Initial studies attempted with 
triene (R,R)-3.95, and RCM followed by reduction with Et3SiH/ Grubbs–II showed 
satisfactory results for the chemo-selective reduction of exocyclic double bond.  
However, application of the same protocol for the RCM/CM product, was not 
successful and cross metathesis product 3.112 was recovered.  In addition Pt2O/H2, as 
well as Lindlar cat:Pd/C(1:2)/H2, were also tested, but none of them provided 
satisfactory results.  Exploration of new reaction conditions,41  as well as further 
development of Et3SiH-mediated reduction conditions for an alternative to diimide 
reduction are in order and will be discussed later. 
Scheme 16 
 
Another important aspect of the development of new methodologies to 
facilitate the total synthesis of biologically active natural products is the utilization of 
such approaches in the synthesis of their simplified analogs.  In this regard, various 
SAR studies related to natural occurring antifungal products highlight the importance 
of the analog synthesis in searching for new antifungal compounds, which have 
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shown an improved activities compared to the parent natural products.42   However, 
the lack of SAR studies and analog synthesis with respect to natural products 3.1 and 
3.2 may be due to the less feasibility of accessing different segments efficiently, 
according to the known reported synthetic routes. With enhanced interest of these 
precedents, we have designed the analog synthesis of both 3.1 and 3.2 modifying the 
substituents in the A, B and C-subunits (Figure 3) via a modular approach, which 
incorporates a phosphate tether-mediated one-pot, sequential RCM/CM/H2 protocol.  
All generated analogues will then be sent for biological screening to our collaborators. 
Figure 3: Proposed library for Strictifolione 
 
 
In conclusion, the synthesis of the antifungal agents 3.1 and 3.2 was 
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3.95, respectively, employing an RCM/CM/"H2" sequence with simple variation of 
the CM partners.  Of notable importance is the multi-faceted role of the phosphate 
tether, which avoids the additional use of protecting groups and enables the facile and 
efficient synthesis for both natural products.  Moreover the potential application of 
aforementioned route in library synthesis of both 3.1 and 3.2 is apparent and will be 
discussed in the near future. 
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General Experimental Methods 
 All reactions were carried out in an oven- or flame-dried glassware under argon 
atmosphere using standard gas-tight syringes, cannulae, and septa.  Stirring was achieved 
with oven-dried magnetic stir bars. Et2O, THF and CH2Cl2 were purified by passage 
through a purification system (Solv-Tek) employing activated Al2O3  (Grubbs, R. H.; 
Rosen. R. K.; Timmers, F. J. Organometallics 1996, 15, 1518–1520).  Et3N was purified 
by passage over basic alumina and stored over KOH.  Butyllithium was purchased from 
Aldrich and titrated prior to use.  All olefin metathesis catalysts were acquired from 
Materia and used without further purification.  Flash column chromatography was 
performed with Sorbent Technologies (30930M-25, Silica Gel 60A, 40-63 um) and thin 
layer chromatography was performed on silica gel 60F254 plates (EM-5717, Merck).  
Deuterated solvents were purchased from Cambridge Isotope laboratories. 1H and 13C 
NMR spectra were recorded in CDCl3 (unless otherwise mentioned) on a Bruker DRX-
500 spectrometer operating at 500 MHz, and 125 MHz, respectively and calibrated to the 
solvent peak. 31P NMR spectra was recorded on Bruker DRX-400 spectrometer operating 
at 162 MHz. High-resolution mass spectrometry (HRMS) was recorded on a LCT 
Premier Spectrometer (Micromass UK Limited) operating on ESI (MeOH).  Observed 
rotations at 589 nm, were measured using AUTOPOL IV Model automatic polarimeter.  
IR was recorded on Shimadzu FTIR-8400S instrument. 
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1-((1S, 6R, 8R)-1-oxo-2,9,10-trioxa-1-phosphabicyclo[4.3.1]dec-4-en-8-
yl)ethanone(2.103) 
 
To a 100 mL round bottom flask under Ar (g) was added mercuric acetate (3.1 g, 
9.84 mmol, 2 equiv.) followed by degassed deionized H2O (12 mL).  To this stirring 
mixture was added via cannula a solution of phosphate (R, R, RP)-2.100
1 (1.0 g, 4.92 
mmol) in degassed THF (37 mL).  The mixture was stirred vigorously until completion 
(16-24 h, monitored by TLC, 100% EtOAc).  A mixture of solid NaHCO3 (0.827 g, 9.8 
mmol, 2 equiv.) and CuCl2•2H2O (1.0 g, 5.9 mmol, 1.2 equiv.) was added and was stirred 
for 15 minutes.  EtOAc (100 mL) was added, the mixture was vigorously stirred, and the 
layers were separated.  The small aqueous layer was extracted with EtOAc (3 x 100 mL) 
to ensure recovery of the very polar product, and the combined organic layer was washed 
with NaHCO3, dried (Na2SO4), filtered, and concentrated under reduced pressure.   
 To a 250 mL round bottom flask was added crude alcohol (1.086 g), acetone (49 
mL, 0.1 M) and Celite® (7.3 g, 1.5 g/mmol).  The reaction was cooled to 0 ºC and stirred 
for 15 min. and Jones reagent (6.28 mL, 16.77 mmol, 1.2 equiv.) was added dropwise.  
The reaction was stirred at 0 ºC until completion (TLC 1:10 Acteone/EtOAc; ~ 2 h) and  
i-PrOH (0.5 mL) was added to consume any leftover Jones reagent, and filtered.  The 
filtrate was concentrated to 15 mL, EtOAc (50 mL) was added and aq. NaHCO3 (4 mL) 
O
P
O O
O
9
11O
O
P
O O
O
i. Hg(OAc)2
THF:H2O
rt, then CuCl2
ii. Jones reagent
Celite
acetone, 0 ºC
80-95% 
over 2 steps
2.103(R,R,RP)-2.100 
4 steps
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was added carefully.  The solution was mixed and the layers separated, and the aqueous 
layer was extracted with EtOAc (3 x 100 mL).  The combined organic layers were 
washed with brine, dried (Na2SO4), filtered and dry-loaded onto silica.  Placement of the 
substrate impregnated silica on a very short silica gel column and elution with 100% 
EtOAc (1 column volume) removed any less polar constituents, followed by elution with 
1:10 Acetone/EtOAc provided 1.22 g of ketone 2.103  (80% yield) as a while solid. 
Rf = 0.3 (100% EtOAc) 
M.P: 110–112 ºC;  
FTIR (thin film): 2970, 2924, 2893, 2850, 1724, 1615, 1292, 1259, 1091, 1058, 991, 
946, 921, 885, 770 cm-1;  
Optical Rotation: [!]D= -21 (c = 0.63, acetone);  
1
H NMR (500 MHz, acetone-d6) " (ppm) 6.11 (dddd, J = 11.9, 6.5, 3.0, 2.2 Hz, 1H), 
5.65 (ddd, J = 11.9, 4.0, 2.7 Hz, 1H), 5.31 (dddd, J = 24.6, 3.9, 2.1, 1.9 Hz, 1H), 5.05 
(dddd, J = 14.8, 11.2, 5.0, 2.7 Hz, 1H), 4.97 (dt, J = 12.1, 2.3 Hz, 1H), 4.43 (ddd, J = 
28.3, 14.8, 6.7 Hz, 1H), 2.37 (s, 3H), 2.26 (ddddd, J = 14.8, 6.5, 5.2, 3.8, 2.5 Hz, 1H), 
2.15 (dddd, J = 14.8, 2.6, 2.5, 1.5 Hz, 1H); 
13
C NMR (125 MHz, acetone-d6) " (ppm) 205.8 (d, JCP = 12.0 Hz), 129.3, 128.7, 79.6 
(d, JCP = 7.2 Hz), 77.4 (d, JCP = 7.1 Hz), 63.5 (d, JCP = 6.4 Hz), 31.3 (d, JCP = 6.0 Hz), 
26.2; 
31
P NMR (162 MHz, acetone-d6) " (ppm) -3.64; 
HRMS  cald for C8H11NaO5P (M+Na)
+ 241.0242; found 241.0235 (TOF MS ES+). 
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(R)-2-((1S,6R,8R)-1-oxo-2,9,10-trioxa-1-phosphabicyclo[4.3.1]dec-4-en-
8-yl)but-3-en-2-ol:(2.104)  
 
A 15 mL flask containing ketone 2.103  (10 mg, 0.05 mmol) was added Na dried THF 
(0.5 mL, 0.1 M), BF3•OEt2 (5.8 µL, 0.05 mmol) and stirred for 15 min. and it was cooled 
to -82 ºC (dry Ice and EtOAc).  Freshly prepared vinyl magnesium bromide (0.28 mL, 1.0 
M in THF, 3 equiv.) was added slowly along the side of the flask.  The reaction mixture 
was stirred at -82 ºC for 1.5 h (monitored by TLC analysis 3:1 CH2Cl2/Acetone) and 
reaction was cannulated in to 10 % HCl (1 mL) at 0 ºC.  The reaction mixture was 
extracted with EtOAc (3 x 4 mL) and the organic layers collected.  The combined organic 
layers were then washed with 20 mL brine, dried with Na2SO4.  Purification by flash 
chromatography with a gradient 5:1 CH2Cl2/Acetone to 3:1 CH2Cl2/Acetone afforded 
tertiary alcohol (8S)-2.104  (7.4 mg, 73 % yield) as a white crystalline solid.  
 
Rf = 0.3 (3:1 CH2Cl2/Acetone) ;  
M.P: 118–121 ºC;  
FTIR (thin film): 3406, 2981, 2935, 1610, 1263, 1224, 1161, 1072, 1031, 983, 921, 883, 
771 cm-1;  
Optical Rotation: [!]D  = -68.6 (c = 3.45, CH2Cl2);  
MgBr
-78 ºC
BF3•Et2O
dr = ~15:1
 73%
O
P
O O
O
OHH3C
O
P
O O
O
O
2.103
(8S)-2.104
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1
H NMR (500 MHz, CDCl3) ! (ppm) 6.04 (dddd, J = 11.9, 6.7, 3.1, 2.2 Hz, 1H), 5.80 
(dd, J = 17.3, 10.9 Hz, 1H), 5.58 (ddd, J = 11.9, 3.9, 2.7 Hz, 1H), 5.39 (dd, J = 17.3, 1.2 
Hz, 1H), 5.23 (m, 1H), 5.21 (dd, J = 10.9, 1.2 Hz, 1H), 5.00 (dddd, J = 14.7, 5.6, 5.6, 2.7 
Hz, 1H), 4.39 (dddd, J = 18.6, 16.8, 12.0, 6.7 Hz, 2H), 2.37 (ddd, J = 14.9, 12.2, 6.4 Hz, 
1H), 2.24 (br s, 1H), 1.75 (ddd, J = 14.8, 3.6, 2 Hz, 1H), 1.38 (s, 3H); 
13
C NMR (125 MHz, CDCl3) ! (ppm) 139.2, 129.9, 127.9, 115.5, 81.4 (d, JCP = 7.2 Hz), 
77.2 (d, JCP = 6.6 Hz), 73.9 (d, JCP = 9.1 Hz), 63.2 (d, JCP = 6.4 Hz), 29.1 (d, JCP = 5.5 
Hz), 24.4; 
31
P NMR (162 MHz, CDCl3) ! (ppm) -2.9; 
HRMS  cald for C10H15NaO5P (M+Na)
+ 269.0555; found 269.0532 (TOF MS ES+). 
 
Procedure B 
 
Lithium chloride (15.5 mg, 0.4 mmol) and anhydrous cerium (III) trichloride (23 mg, 0.2 
mmol) were measured in to a round-bottomed flask and dried under vaccum at  
60 ºC for 2 hours, 80 ºC for 2 h and 150 ºC for 8 h.  To the dried salt mixture, Na dried 
THF (0.1 mL) was added under argon atmosphere and stirred vigorously for 2.5 h at RT, 
producing a near colorless solution and then cooled to -78 ºC.  To this solution freshly 
prepared vinyl magnesium bromide (0.2 mL, 0.2 mmol, 1 M in THF) was added and 
ML
ML= YbCl2, dr = ~ 50:1  70%
ML= CeCl2, dr = ~ 1.5:1 87 %
O
P
O O
O
O
P
O O
O
O
H3C OH
6.
THF, -78 ºC
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stirred for 1 h at -78 ºC.  This yellowish tan color solution was then added to ketone 
2.103 (10 mg, 0.05 mmol) in THF (0.5 mL) by cannula with a THF (0.1 mL) rinse.  The 
reaction mixture was stirred for 1–1.5 h at -78 ºC until all the starting materials were 
consumed (monitored by TLC 3:1 CH2Cl2/Acetone).  The solution was cannulated back 
to 10 % HCl (0.5 mL) solution at 0 ºC and vigorously stirred for 15 min.  After the 
solution had warmed to rt, the layers were separated. The aqueous layer was extracted 
with EtOAc (2 x 3 mL). The combined organic layers were washed sequentially with 
brine (3 mL) and dried over Na2SO4, filtered, and concentrated in vacuo. Purification by 
flash chromatography with a gradient 5:1 CH2Cl2/Acetone to 3:1 CH2Cl2/Acetone 
provided 2:1 mixture of 2.104 ((8S)-2.104: (8R)-2.104 = 2:1) (10 mg, 87% yield) as a 
crystalline white solid. [Note: Both (8S)-2.104 and (8R)-2.104 have same Rf value for all 
most all the solvent gradients attempted.] 
Procedure C 
The commercially available YbCl3•6H2O (76 mg, 0.28 mmol) was dried in vacuo at  
140 ºC for 2 h.  To the dried salt, 0.4 mL of Na dried THF was added under Ar 
atmosphere, and the mixture was sonicated for 0.5 h using an ultrasonic cleaner. The 
obtained suspension was cooled at -78 ºC, and freshly prepared vinyl magnesium 
bromide (0.2 mL, 0.18 mmol, 1 M in THF) was added and stirred at same temperature for 
30 min. The ketone 2.103 (10 mg, in THF (0.5 mL) was cannulated to this solution 
slowly and rinsed with THF (0.2 mL). The mixture was stirred at -78 ºC for 1-1.5 h until 
all the starting materials were consumed by TLC analysis (3:1 CH2Cl2/Acetone) and 
quenched with 1 M aqueous HCl via back cannulation of the reaction mixture to the 1 M 
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HCl solution (0.5 mL) at 0 ºC.  The layers were separated and the aqueous layer was 
extracted with EtOAc (2 x 2 mL) and combined organic layers were dired over NaSO4. 
Purification by flash chromatography with a gradient 5:1 CH2Cl2/Acetone to 3:1 
CH2Cl2/Acetone provided (8S)-2.104 ( 8 mg, 70%) as a crystalline white solid. 
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(1S,6R,8R)-8-(1-hydroxyallyl)-2,9,10-trioxa-1-phosphabicyclo[4.3.1]dec-
4-ene-1-oxide (2.114) 
 
To a stirred solution of 2.100 (100 mg, 0.5 mmol) in acetone (4.5 mL) and H2O (0.5 
mL) at 12 ºC, was added OsO4 (2.5 mg, 0.01 mmol) followed NMO (75 mg, 0.6 mmol). 
The reaction mixture was stirred for 6–8 h until all the starting materials were consumed 
(monitored by TLC 10:1 EtOAc/Acetone). Solid Na2SO3 (~20 mg) was then added and 
the reaction mixture was left to stir at RT for further 1 h. The mixture was then filtered 
through Celite® and concentrated under reduced pressure.  This crude diol was subjected 
to next reaction with out further purification. 
The solution of the preceding diol (78 mg, 0.33 mmol) in THF (23 mL) and pH 7 
buffer (4.5 mL) was treated with NaIO4 (424 mg, 1.98 mmol) in one portion. The 
resulting mixture was stirred for 2 h until all the starting materials were consumed 
(monitored by TLC, 10:1 EtOAc/Acetone). The mixture was then filtered through Celite® 
and resulting solution was extracted with CH2Cl2 (4 x 15 mL).  The combined organic 
layers were washed with brine, dried over Na2SO4.  Simple passage of the crude reaction 
mixture through a short silica plug (100 % EtOAc) afforded aldehyde 2.113 as a 
colorless oil and immediately used in next reaction. 
 OsO4, NMO
Acetone:H2O (10:1)
O
OO
P
O
H
O
9 11
 NaIO4
   THF:H2O (5:1)
MgBr
(R,R,RP)-2.100
O
OO
P
O
9 11
O
OO
P
O
9 11
OH
BF3•Et2O 
-78 ºC
2.113
2.114
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To a stirring solution of aldehyde 2.113  (25 mg, 0.12 mmol) in Na dried THF 
(1.2 mL, 0.1 M) and BF3•OEt2 (15.5 µL, 0.12 mmol) at -78 ºC, was added freshly 
prepared vinyl magnesium bromide (0.5 mL, 1.0M in THF, 4 equiv.) slowly along the 
side of the flask.  The reaction mixture was stirred at the same temperature ºC for 2 h 
(monitored by TLC analysis 3:1 CH2Cl2/Acetone) and reaction was cannulated in to 10 % 
HCl (1 mL) at 0 ºC.  The reaction mixture was extracted with EtOAc (3 x 4 mL) and the 
organic layers collected.  The combined organic layers were then washed with 20 mL 
brine, dried with Na2SO4.  Purification by flash chromatography with a gradient 5:1 
CH2Cl2/Acetone to 3:1 CH2Cl2/Acetone afforded desired secondary alcohol (8S)-2.114  
(2.6 mg, 20 % un-optimized yield) as yellow oil.  
 
Rf = 0.25 (3:1 CH2Cl2/Acetone) ;  
FTIR (thin film): 3406, 2981, 2935, 1615, 1263, 1224, 1161, 1072, 1031, 983, 921, 883, 
771 cm-1;  
1
H NMR (500 MHz, CDCl3) ! (ppm) 6.01–5.93 (m, 1H), 5.75 (ddd, J = 17.1, 10.7, 5.5 
Hz, 1H), 5.53 (ddd, J = 11.9, 6.7, 2.9 Hz, 1H), 5.36 (dd, J = 17.3, 1.2 Hz, 1H), 5.25 (ddd, 
J = 10.5, 5.5, 1.2 Hz 1H), 5.24 (dt, J = 10.5, 1.4 Hz, 1H), 4.98 (ddt, J = 14.3, 5.6, 2.7 Hz, 
1H), 4.50 (ddt, J = 12.1, 3.5, 1.6 Hz, 1H), 4.38–4.26 (m, 2H) 2.36–2.27 (m, 1H), 1.67 
(dd, J = 11.8,10.8 Hz, 1H), 1.2 (s, 1H); 
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13
C NMR (125 MHz, CDCl3) ! (ppm) 134.2, 129.9, 127.9, 118.3, 78.8 (d, JCP = 6.8 Hz), 
77.2 (d, JCP = 11.3 Hz), 73.6 (d, JCP = 10.1 Hz), 73.6 (d, JCP = 10.1 Hz), 28.7 (d, JCP = 5.7 
Hz); 
31
P NMR (162 MHz, CDCl3) ! (ppm) -3.26 (t, JPH = 23.3 Hz); 
HRMS  cald for C9H13NaO5P (M+Na)
+ 255.0398; found 255.0403 (TOF MS ES+). 
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(4R,6R,7R,Z)-7-methylnona-2,8-diene-1,4,6,7-tetraol (2.142)  
 
To the phosphate (8S)-2.104 (66 mg, 0.268 mmol) was added 4.0 mL of THF  
(0. 02 M) under argon atmosphere and cooled to 0 ºC.  Then LiAlH4 was slowly added 
(31 mg, 0.0.815 mmol, 3 equiv.) to the reaction mixture and the reaction was stirred at 0 
ºC for 1 h until all starting materials were consumed (monitored by TLC 1:1 EtOAc: 
acetone) and allowed to continue for 15 more minutes at 0 ºC. (total reaction time 
typically about 1 h). The reaction was quenched by slow, dropwise addition of 31 µL of 
H2O, followed by slow, dropwise addition of 30 µL of 15 % NaOH (aq), and finishing 
with an addition of 93 µL of H2O. At this point, the mixture is allowed to reach room 
temperature until all salts appear to become a white color.  SiO2 was then added and the 
solvent removed, and was placed on a short silica gel plug and eluted with a 1:1 EtOAc: 
acetone mixture, producing 35 mg (64% yield) of tetraol 2.142. 
 
Rf = 0.3 (1:1 EtOAc/Acetone); 
Optical Rotation: [!]D = +46 (c = 0.05, acetone); 
FTIR (thin film): 3339, 2951, 2910, 2877, 1458, 1410, 1238, 1099 cm-1; 
1
H NMR (500 MHz, acetone-d6) " (ppm) 5.96 (dd, J = 17.4, 10.9 Hz, 1H), 5.50 (m, 2H), 
5.28 (dd, J = 17.4, 2.1 Hz, 1H), 5.02 (dd, J = 10.8, 2.0 Hz, 1H), 4.68 (dddd, J = 6.6, 4.6, 
2.6, 2.3 Hz, 1H), 4.19 (ddd, J = 12.4, 5.4, 1.7 Hz, 1H), 4.10 (ddd, J = 12.6, 4.2, 3.8 Hz, 
OH
OH OH
H3C
OH
O
P
O O
O
OHH3C
     64%
 LiAlH4,THF, 0 ºC
(8S)-2.104 2.142
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1H), 3.91 (d, J = 4.8 Hz, 1H), 3.70 (m, 3H), 3.54 (s, 1H), 1.67 (ddd, J = 15.0, 9.3, 1.9 Hz, 
1H), 1.44 (ddd, J = 15.0, 7.8, 2.6 Hz, 1H), 1.22 (s, 3H); 
13
C NMR (126 MHz, acetone-d6) ! ppm 144.2, 135.9, 130.4, 112.7, 75.6, 74.6, 65.4, 
58.7, 40.3, 24.6; 
HRMS  cald for C10H18NaO4 (M+Na)
+ 225.1103; found 225.1105 (TOF MS ES+). 
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(3S,4R,6R,Z)-6,9-bis(( tert-butyldimethylsilyl)oxy)-3-methylnona-1,7-
diene-3,4-diol (2.143) 
 
To the solution of tetraol 2.142 (17 mg, 0.08 mmol) in 1 mL of CH2Cl2 (0.1M) 
was added 2,6-lutidine (41 µL, 0.36 mmol, 4.5 equiv.).  The solution was then cooled to  
-78 ºC and TBSOTf (40 µL, 0.17 mmol, 2.2 equiv.) was added dropwise to the solution 
with stirring.  The reaction was stirred at -78 ºC for 2 h, until all the starting materials 
were consumed, monitored by TLC (4:1 Hexane/EtOAc).  The reaction was diluted with 
2 mL of CH2Cl2 and quenched with 1 mL of saturated aqueous NH4Cl, and layers were 
separated, and the aqueous layer was extracted 3 more times with CH2Cl2.  The combined 
organic layers were then washed with brine, dried with MgSO4.  Purification by flash 
chromatography (hexane: ethyl acetate) provided bis-TBS protected diol 2.143 (25 mg, 
75 % yield) as a yellow oil. 
Rf = 0.3 (4:1 Hexane/EtOAc) 
Optical Rotation: [!]D = +18 (c = 0.25, CH2Cl2); 
FTIR (thin film): 3459, 3010, 2954, 2879, 2858, 1079, 1009, 923 cm-1; 
1
H NMR (500 MHz, CDCl3) " (ppm) 5.82 (dd, J = 17.4, 10.9 Hz, 1H), 5.63–5.49 (m, 
2H), 5.29 (dd, J = 17.4, 1.6 Hz, 1H), 5.12 (dd, J = 10.9, 1.6 Hz, 1H), 4.83 (dt, J = 8.3, 
4.3, Hz, 1H), 4.21 (ddd, J = 12.9, 6.5, 1.3 Hz, 1H), 4.13 (ddd, J = 13.4, 5.2, 1.7 Hz, 1H), 
CH2Cl2, -78 ºC
OH
OH OH OTBSOH OTBS
H3C
OH
H3C
OH
TBSOTf, 2,6-lut.
2.142 2.143
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3.78 (m, 1H), 3.71 (d, J = 2.9 Hz, 1H), 2.49(s, 1H), 1.64 (t, J = 4.3 Hz, 2H), 1.27(s, 3H), 
0.9 (s, 18H), 0.5 (s, 12H); 
13
C NMR (126 MHz, CDCl3) ! ppm 140.8, 133.5, 128.8, 113.7, 74.9, 74.3, 68.1, 59.4, 
38.5, 25.9 (2C), 25.8 (2C), 25.7 (2C), 24.6, 18.3, 18.0, -4.5, -5.2, -5.3(2); 
HRMS  cald for C22H46NaO4Si2 (M+Na)
+ 453.2832; found 453.2811 (TOF MS ES+). 
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(2R,6R)-6-isopropoxy-2-vinyl-3,6-dihydro-2H-pyran (2.97) 
 
 
To a 100 mL round bottom flask was added alkyne 2.1282 (1.10 g, 6.53 mmol) freshly 
distilled quinoline (42 mg, 0.327 mmol, 0.05 equiv.), and degassed EtOAc (65 mL, 
0.1M) and was placed under a H2 atmosphere. To this stirring mixture was added 5% Pd-
CaCO3 (139 mg, 0.065 mmol Pd, 0.01 equiv.). The reaction was allowed to proceed for 2 
h (monitored by GC and TLC 20:1 Hexane/Et2O) and the mixture was filtered through 
Celite® and the solvent removed gently.  The crude product was passed through a short 
SiO2 plug (20:1 petroleum ether/ Et2O) to provide desired alkene 2.97  (877 mg 80% 
yield) as clear oil.  
Rf = 0.35 (20:1 Hexane/Ether) 
Optical Rotation: [!]D  = +59 (c = 0.37, CH2Cl2) 
FTIR: (neat) 3080, 3045, 2970, 2924, 2894, 1647, 1458, 14231182, 1126, 1101, 1034, 
1009, 860, 719, 783 cm-1; 
 1
H NMR (500 MHz, CDCl3) " (ppm) 6.04–5.99 (m, 1H), 5.91 (ddd, J = 17.3, 10.6, 5.6 
Hz, 1H), 5.73 (ddd, J = 10.0, 2.8, 1.5 Hz, 1H), 5.30 (dt, J = 17.3, 1.6 Hz, 1H), 5.16 (dt, J 
= 10.6, 1.6 Hz, 1H), 5.12 (d, J = 1.2 Hz, 1H), 4.43 (ddt, J = 10.0, 4.8, 0.6 Hz, 1H), 4.01 
(q, J = 6.3 Hz, 1H), 2.15–2.01 (m, 2H), 1.23 (d, J = 6.2 Hz, 3H), 1.18 (d, J = 6.2 Hz, 3H); 
O
O 0.01 equiv. 5% Pd-CaCO3
0.05 equiv. quinoline
H2, EtOAc, RT, 2 h
80%
O
O
2.128 2.97
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13
C NMR (125 MHz, CDCl3) ! (ppm) 138.2, 128.4, 126.1, 115.4, 93.2, 69.6, 66.7, 30.2, 
23.8, 22.1; 
HRMS  cald. for C10H16NaO2 (M+Na)
+ 191.1048; found 191.1052 (TOF MS ES+).  
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(R)-6-vinyl-5, 6-dihydro-2H-pyran-2-one (2.98) 
 
A solution of lactol 2.97 (1.01 g, 5.99 mmol) in CH2Cl2 (120 mL, 0.05M) was 
treated with PCC (6.5 g, 29.95 mmol), 4 Å molecular sieves (1.14 g, 190 mg/mmol of 
2.97) and AcOH (3.6 g, 59.9 mmol).  After stirring at RT for 5 h, water (30 mL) was 
added and the reaction mixture was extracted with CH2Cl2 (2 x 100 mL) and the solvent 
was removed gently.  The crude product was passed through a short SiO2 plug, eluting 
with 5:1 Hexane/EtOAc to provide desired lactone 2.98 (596 mg 82% yield) as yellow 
oil. 
Rf = 0.18 (5:1 Hexane/EtOAc); 
Optical Rotation: [!]D = +168 (c = 0.525, CHCl3); 
FTIR: (neat) 3080, 3045, 2970, 2924, 2894, 1722, 1647, 1423, 1381, 1246, 1126, 1101, 
860, 719, 783 cm-1; 
1
H NMR (500 MHz, CDCl3) " (ppm) 6.89 (ddd, J = 9.8, 5.4, 3.1 Hz, 1H), 6.06 (ddd, J = 
9.8, 2.4, 1.3 Hz, 1H), 5.96 (ddd, J = 17.2, 10.6, 5.7 Hz, 1H), 5.39–5.43 (ddd, J = 17.2, 
1.3, 1.0 Hz, 1H), 5.31–5.29 (ddd, J = 10.6, 1.1, 1.1 Hz, 1H)), 4.96–4.91 (m, 1H), 2.53–
2.40 (m, 2H); 
13
C NMR (125 MHz, CDCl3) " (ppm) 163.8, 144.4, 134.8, 121.6, 117.9, 77.8, 29.4; 
PCC/AcOH CH2Cl2
  rt
O
i-PrO
O
O
2.98
O
O
2.129
2.97
4 Å M. S., 5h
2.98: 2.19 = 20:1
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HRMS  cald. for C7H8NaO2 (M+Na)
+ 124.0524; found  124.0519 (TOF MS ES+). 
 
 
(R)-2-vinyl-2H-pyran-4(3H)-one (2.129) . 
Rf = 0.21 (5:1 Hexane/EtOAc); 
1
H NMR (500 MHz, CDCl3) ! (ppm) 7.37 (d, J = 6.0 Hz, 1H), 5.96 (ddt, J = 13.4, 10.7, 
6.7 Hz, 1H), 5.45–5.37 (m, 2H), 5.32 (d, J = 5.8, 4.8 Hz, 1H)), 4.94–4.87 (m, 1H), 2.66–
2.51 (m, 2H); 
13
C NMR (125 MHz, CDCl3) ! (ppm) 191.8, 162.7, 134.3, 118.3, 107.2, 79.4, 41.4; 
HRMS  cald. for C7H8NaO2 (M+Na)
+ 124.0524; found  124.0526 (TOF MS ES+). 
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(1R,2S,5R)-5-((tert-butyldimethylsilyl)oxy)-2-methylcyclohex-3-ene-1,2-
diol (2.146) 
 
To a 25 mL pressure tube under argon was added diol 2.143  (10 mg, 0.023 
mmol), iPr protected lacto1 2.97 (12 mg, 0.07 mmol) and degassed CH2Cl2 (0.23 µL, 0.1 
M).  To this reaction mixture was added HG–II catalyst (1 mg, 0.0013 mmol, 6 mol %) 
and refluxed for 3 h.  The reaction was cooled to rt, and solvent was removed under 
reduced pressure.  Purification by flash chromatography (4:1 Hexane:EtOAc) was 
afforded the both 2.146  (3.3 mg, 68% yield) and 2.145 (1.8 mg 12% yield) as yellow 
color oil. 
Rf = 0.2 (4:1 Hexane/EtOAc) for 2.146 and Rf  = 0.3 (4:1 Hexane/EtOAc) for 2.145 ; 
FTIR (thin film): 3400, 3010, 2954, 2925, 2854, 2488, 1610, 1461, 1361, 1060 cm-1; 
1
H NMR (500 MHz, CDCl3) ! (ppm) 5.73 (dd, J = 10.0, 3.4 Hz, 1H), 5.61–5.57 (m, 1H), 
4.43 (dd, J = 8.4, 4.8 Hz, 1H), 3.89 (ddd, J = 8.0, 5.4, 2.6 Hz, 1H), 2.26 (d, J = 5.6 Hz, 
1H), 2.08 (ddd, J = 13.2, 8.0, 4.9 Hz, 1H), 2.03 (s, 1H), 1.81 (ddd, J = 13.4, 5.9, 2.8 Hz, 
1H), 1.36 (s, 3H), 0.90 (d, J = 2.9 Hz, 9H), 0.09 (d, J = 2.0 Hz, 6H). 
13
C NMR (126 MHz, CDCl3) ! ppm; 132.4, 131.7, 71.8, 69.6, 65.0, 36.9, 26.6, 25.8(3C), 
18.2, -4.6, -4.7; 
HRMS  cald for C13H26NaO3Si (M+Na)
+ 281.1549; found 281.1541 (TOF MS ES+). 
OTBSOH
OTBS
6 mol %  HG–II 
40 ºC, 3 h
OTBSOH
OTBS
O
i-PrO
O
i-PrO
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(1S,6R,8R)-8-((S,E)-4-((2R,6R)-6-isopropoxy-3,6-dihydro-2H-pyran-2-yl)-
2-((triethylsilyl)oxy)but-3-en-2-yl)-2,9,10-trioxa-1-
phosphabicyclo[4.3.1]dec-4-ene 1-oxide (2.154) 
 
To a 25 ml pressure tube under argon was added phosphate (8S)-2.104  (29 mg, 
0.12 mmol, 1 equiv.), iPr protected lacto1 2.97  (60 mg, 0.35 mmol) and degassed 
CH2Cl2 (0.5 mL, 0.25M).  To this reaction mixture was added Grubbs–II catalyst (7 mg, 
0.008 mmol, 10 mol %) and dried CuI (3.4 mg, 0.02 mmol, 15 mol %) and refluxed for  
6h–10h until almost all the starting materials were consumed. (Monitored by TLC 
analysis 6:1 CHCl3/MeOH).  The reaction was cooled to rt, and the solvent was removed 
under reduced pressure.  The crude reaction mixture was subjected to TES protection 
with out further purification. [Note: Separation of the cross-metathesis product 2.95  and 
the unreacted phosphate (8S)-2.104  was very difficult and could be easily obtained after 
TES protection of the crude product].  
To the crude product mixture in CH2Cl2 was added freshly distilled 2,6 lutidine 
(19 µL, 0.13 mmol) and reaction was cooled to 0 ºC. To the stirring reaction mixture was 
added TESOTf (29 µL, 0.13 mmol ) and reaction was stirred for 2 h at 0 ºC until all the 
starting materials were consumed. (TLC 8:1 CH2Cl2/EtOAc). Reaction was quenched 
with NH4Cl and layers were separated. Aqueous layer was extracted CH2Cl2 (3 x 2 mL) 
and combined organic layers were dried with MgSO4 and concentrated under reduced 
O
P
O O
O
CuI, CH2Cl2 O
P
O O
O
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O
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H3C OH
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pressure.  Purification by flash chromatography (8:1 CH2Cl2/EtOAc) provided the TES 
protected product 2.154 (22 mg) in 40% overall yield .  
Rf = 0.2 (8:1 CH2Cl2/EtOAc) for TES protected product 2.154 ;  
= 0.3 (8:1 CH2Cl2/EtOAc) for TES protected starting material 2.153 ;  
FTIR (thin film): 3383, 3038, 2955, 2935, 2876, 1610, 1375, 1299, 1180, 1088, 997, 
981 cm-1; 
Optical Rotation: [!]D  = -7.4 (c = 0.54, CHCl3); 
1
H NMR (500 MHz, CDCl3) " (ppm) 6.04–5.98 (m, 2H), 5.8 (dd, J = 15.7, 6.1 Hz, 1H), 
5.7 (dtd, J = 11.5, 2.8, 1.5 Hz, 1H), 5.7 (dd, J = 15.9, 0.9 Hz, 1H), 5.5 (ddd, J = 11.8, 3.9, 
2.5 Hz, 1H), 5.2 (bd, J = 26.4 Hz, 1H), 5.1 (dd, J = 1.3 Hz, 1H), 5.0 (dtd, J = 14.6, 5.6, 
2.7 Hz, 1H), 4.4 (ddd, J = 10.2, 5.9, 3.8 Hz, 1H), 4.4 (ddd, J = 27.7, 14.7, 6.7 Hz, 1H), 4.2 
(dt, J = 11.9, 1.6 Hz, 1H), 4.0 (q, J = 6.2 Hz, 1H), 2.3 (ddd, J = 14.7, 12.0, 6.3 Hz, 1H), 
2.1–2.0 (m, 2H), 1.8 (ddd, J = 15.2, 3.4, 2.1 Hz, 1H), 1.4 (s, 3H), 1.2 (d, J = 6.2 Hz, 3H), 
1.2 (d, J = 6.2 Hz, 3H), 1.0 (dd, J = 8.0 Hz, 9H), 0.6 (dq, J = 8.2, 2.3 Hz, 6H); 
13
C NMR (125 MHz, CDCl3) " (ppm) 134.8, 131.2, 130.0, 128.4, 127.8, 126.1, 93.4, 
81.3(d, JCP = 7.4 Hz), 77.2 (d, JCP = 7.0 Hz), 75.5 (d, JCP = 10.2 Hz), 70.0, 66.4, 63.0 (d, 
JCP = 6.3 Hz), 30.7, 29.0 (d, JCP = 5.3 Hz), 23.8, 22.5, 22.3, 7.1(3C), 6.6 (3C); 
31
P NMR (162 MHz, CDCl3) " (ppm) -2.88 (t, JPH = 23.4 Hz); 
HRMS  cald for C24H41O7PSiNa (M+Na)+ 523.2257; found 523.2253 (TOF MS ES+). 
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(R)-6-((S,E)-3-hydroxy-3-((1S,6R,8R)-1-oxido-2,9,10-trioxa-1-
phosphabicyclo[4.3.1]dec-4-en-8-yl)but-1-en-1-yl)-5,6-dihydro-2H-pyran-
2-one (2.157) 
 
To a 25 mL flask under argon was added phosphate (8S)-2.104   (191 mg, 0.775 
mmol, 1 equiv.), lactone 2.98  (48 mg, 0.388 mmol, 0.5 eq) and degassed CH2Cl2 (3.2 
mL, 0.25M with respect to phosphate (8S)-2.104).  To this reaction mixture was added 
HG–II catalyst (14.5 mg, 0.023 mmol, 4 mol %) and dried CuI (11 mg, 0.058, 15 mol %) 
and refluxed for 3 h.  Another 0.3 eq of lactone (28 mg, 0.232 mmol) in 0.5 mL of 
CH2Cl2 and HG–II (3.6 mg, 0.0058 mmol, 2.5 mol%) was added and refluxing was 
continued for 2 h.  Similarly, lactone (28 mg. 0.232 mmol, 0.3 eq) and HG–II (3.6 mg, 
0.0058 mmol, 2.5 mol%) was added to the reaction mixture after 2 h of refluxing once 
more and reaction was refluxed at the same temperature for another 3 h [total reaction 
time was 10 h].  (Portionwise addition of lactone prevent the homo-dimerization of 
lactone)  The reaction was cooled to RT, and the solvent was removed under reduced 
pressure.  Purification by flash chromatography (1:6 Hexane:EtOAc to 100 % EtOAc) 
provided 2.157  (155 mg, 58 % isolated yield and 88 % BRSM) color less oil. 
Rf = 0.2 (10:1 EtOAc/Acetone);  
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FTIR (thin film): 3411, 3380, 3101, 2955, 2922, 2853, 2359, 2341, 1717, 1383, 1292, 
1258, 1072, 1036, 993 cm-1; 
Optical Rotation: [!]D = -18.0(c = 0.165, CHCl3); 
1
H NMR (500 MHz, CDCl3) " (ppm) 6.91 (ddd, J = 9.5, 5.3, 3.1 Hz, 1H), 6.08 (dd, J = 
2.4, 1.0 Hz, 1H), 6.04(dd, J = 1.1, 2.5 Hz, 1H), 6.01 (dd, J = 15.5, 5.6 Hz, 1H), 5.80 (dd, J 
= 15.5, 1.3 Hz, 1H), 5.60 (ddd, J = 11.9, 3.8, 2.5 Hz, 1H), 5.23 (d, J = 24.9 Hz, 1H), 
5.06–4.93 (m, 2H), 4.45–4.34 (m, 2H), 2.55–2.31 (m, 2H), 1.75 (d, J = 14.9 1H), 1.65  
(br s, 1H) 1.44–1.35 (m, 3H), 1.30–1.21 (m, 1H); 
13
C NMR (125 MHz, CDCl3) " (ppm) 163.8, 144.8, 134.3, 129.9, 127.9, 127.5, 121.5, 
80.9 (d, JCP = 7.2 Hz), 77.1 (d, JCP = 19.4 Hz), 77.2 (d, JCP = 6.6 Hz), 73.5 (d, JCP = 9.3 
Hz), 63.2 (d, JCP = 6.3 Hz), 29.8, 29.2 (d, JCP = 5.5 Hz), 24.9; 
31
P NMR (162 MHz, CDCl3) " (ppm) -2.92 (t, JPH = 26.7 Hz); 
HRMS  cald for C15H19NaO7P (M+Na)+ 365.0776; found 365.0771 (TOF MS ES+). 
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(R)-6-((S,E)-3-((1S,6R,8R)-1-oxido-2,9,10-trioxa-1-
phosphabicyclo[4.3.1]dec-4-en-8-yl)-3-((triethylsilyl)oxy)but-1-en-1-yl)-
5,6-dihydro-2H-pyran-2-one (TES-2.157). 
 
 
To the solution of phosphate 2.157 (52 mg, 0.152 mmol) in 1.5 mL of CH2Cl2 
(0.1M) was added 2,6-lutidine (70.6µL, mmol, 4.0 equiv.).  The solution was then cooled 
to 0 ºC and TESOTf (69.0 µL, mmol, 2.0 equiv.) was added dropwise to the solution with 
stirring.  The solution was stirred at 0 ºC for 3h, until all the starting materials were 
consumed, monitored by TLC (100 % EtOAc).  The reaction was diluted with 2 mL of 
CH2Cl2 and quenched with 1 mL of saturated aqueous NH4Cl, and layers were separated, 
and the aqueous layer was extracted 3 more times with CH2Cl2.  The combined organic 
layers were then washed with brine and dried with MgSO4.  Purification by flash 
chromatography (1:3 hexane: ethyl acetate) provided 54.6 mg of the silyl protected 
phosphate TES-2.157  as a yellow oil in 80 % yield. 
Rf = 0.5 (100 % EtOAc);  
FTIR (thin film): 3033, 2953, 2912, 2876, 2359, 2332, 1724, 1618, 1458, 1380, 1302, 
1244, 1090, 1060, 980 cm-1; 
Optical Rotation: [!]D  = -2.9(c = 2.25, CHCl3); 
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1
H NMR (500 MHz, CDCl3) ! (ppm) 6.90 (ddd, J = 9.5, 5.3, 3.1 Hz, 1H), 6.07 (d, J = 
9.8 Hz, 1H), 6.04–5.99 (m, 1H), 5.92–5.77 (m, 2H), 5.58 (ddd, J = 11.8, 3.5, 2.7 Hz, 1H), 
5.22 (d, J = 24.5 Hz, 1H), 5.03–4.92 (m, 2H), 4.35 (ddd, J = 27.8, 14.8, 6.7 Hz, 1H), 4.25 
(td, J = 11.9, 1.7 Hz, 1H), 2.51–2.36 (m, 2H), 2.29 (ddd, J = 14.7, 12.1, 6.3 Hz, 1H), 1.80 
(d, J = 14.7 Hz, 1H), 1.42 (s, 3H), 0.95 (t, J = 7.9 Hz, 9H), 0.62 (qd, J = 8.2, 2.0 Hz, 6H); 
13
C NMR (125 MHz, CDCl3) ! (ppm) 156.8, 137.6, 130.5, 123.0, 120.8 (2C), 114.6, 
73.8 (d, JCP = 7.3 Hz), 70.1, 70.2, 68.6 (d, JCP = 10.2 Hz), 56.0 (d, JCP = 6.4 Hz), 22.9, 
21.9 (d, JCP = 5.3 Hz), 15.5, 0.1 (3C), -0.4 (3C); 
31
P NMR (162 MHz, CDCl3) ! (ppm) -3.03 (t, JPH = 23.9 Hz) 
HRMS  cald for C21H33NaO7PSi (M+Na)+ 479.1631; found 479.1604 (TOF MS ES+). 
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(1S,6R,8R)-8-((S,E)-4-((2R,6R)-6-isopropoxy-3,6-dihydro-2H-pyran-2-yl)-
2-((triethylsilyl)oxy)but-3-en-2-yl)-2,9,10-trioxa-1-
phosphabicyclo[4.3.1]dec-4-ene1-oxide (2.154) 
 
A solution of TES-2-157  (48 mg, 0.105 mmol) in 1.3 mL of CH2Cl2 was treated 
with 0.16 mL of DIBAL–H (1.0 M in toluene) at –78 ºC.  Reaction was removed from – 
78 ºC and kept at -30 ºC temperature for 10 min and slowly warmed to 0 ºC. After 1 h, 
total consumption of starting material by TLC (1:1 CH2Cl2/EtOAc) was observed and 1 
mL of saturated aqueous NaHCO3 was added and the organic layer was separated. The 
aqueous layer was extracted with CH2Cl2 (2 x 2 mL) and dried with Na2SO4, and 
concentrated and oily product obtained was directly used in the next step without further 
purification.  The product was dissolved in 0.5 mL of anhydrous benzene and 0.26 mL of 
i-PrOH and catalytic amount of pyridinium p-toluenesulfonate (PPTS)(1.3 mg, 5 mol %) 
was added.  The reaction mixture was stirred at 25 ºC for 2 h and quenched by addition of 
1 mL of saturated aqueous NaHCO3.  The layers were separated and the aqueous layer 
was extracted twice with CH2Cl2.  The organic layers were combined, dried with Na2SO4.  
Purification with flash chromatography (1:4 Hexane/EtOAc) afforded 2.154  as a 
colorless oil in 85 % overall yield for two steps.  
Rf = 0.5 (1:4 Hexane/EtOAc); [Note: Spectral data are provided in page X] 
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(2Z,4R,6R,7R,8E)-9-((2R,6R)-6-isopropoxy-3,6-dihydro-2H-pyran-2-yl)-7-
methyl-7-((triethylsilyl)oxy)nona-2,8-diene-1,4,6-triol (2.158) 
 
To the phosphate 2.154 (49.3 mg, 0.099 mmol) was added 3.52 mL of Et2O 
(0.028 M) under argon atmosphere and subsequently cooled to 0 ºC.  Then LiAlH4 was 
slowly added (7.5 mg, 0.463 mmol, 2 equiv.) to the reaction mixture and the reaction was 
stirred at 0 ºC for 1 h until all starting materials were consumed which was monitored by 
TLC 100 % EtOAc) and allowed to continue for 15 more minutes at 0 ºC. (total reaction 
time typically about 1 h). The reaction was quenched by slow, dropwise addition of 8 mg 
of H2O, followed by slow, dropwise addition of 8 mg of 15 % NaOH (aq), and finishing 
with an addition of 24 mg of H2O.  At this point, the mixture is allowed to reach room 
temperature until all salts appear to become a white color.  SiO2 was then added and the 
solvent removed, and was placed on a short silica gel plug and eluted with a 100 % 
EtOAc: acetone mixture, producing 20.2 mg (77% yield) of triol 2.158. 
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(1S,6R,8R)-8-((R)-2-((triethylsilyl)oxy)but-3-en-2-yl)-2,9,10-trioxa-1-
phosphabicyclo[4.3.1]dec-4-ene 1-oxide (2.153) 
 
  To the solution of phosphate 2.141 (100 mg, 0.406 mmol) in 4 mL of CH2Cl2 
(0.1M) was added 2,6-lutidine (95 µL, 0.923 mmol, 2.0 equiv.).  The solution was then 
cooled to 0 ºC and TESOTf (140 µL, 0.609 mmol, 1.5 equiv.) was added dropwise to the 
solution. The solution was stirred at 0 ºC until completion (about 1 hour).  The reaction 
was quenched with 3 mL of saturated aqueous NH4Cl, layers were separated, and the 
aqueous layer was extracted with CH2Cl2 (3 x 5 ml).  The combined organic layers were 
then washed with brine, dried with MgSO4.  Purification by flash chromatography  (1:2 
hexane/ethyl acetate) provided 101 mg (90 % yield) of the silyl protected phosphate 
2.153  as a white crystalline solid. 
Rf = 0.25 (1:2 hexane/ethyl acetate);  
M.P: 112–116 ºC;  
FTIR (thin film): 2955, 2914, 2876, 1630, 1294, 1263, 1236, 1220, 1134, 1074, 1061, 
978 cm-1; 
Optical Rotation: [!]D  = -36.4 (c = 1.05, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) " (ppm) 6.00 (dddd, J = 11.9, 6.7, 3.6, 2.4 Hz, 1H), 5.80 
(dd, J = 17.3, 10.7 Hz, 1H), 5.56 (ddd, 11.9, 3.9, 2.6 Hz, 1H), 5.30 (dd, J = 17.3, 1.1 Hz, 
O
P
O O
O
OHCH3
1. TESOTf, 2,6-lut.
     CH2Cl2, 0 ºC9
11
(8S)-2.104 2.153
90 % O
P
O O
O
OTESCH3
9
11
 189 
1H), 5.21 (dddd, J = 25.0, 2.5, 1.9, 1.7 Hz, 1H), 5.17 (dd, J = 10.7, 1.1 Hz, 1H), 4.99 
(dddd, J = 14.7, 5.6, 5.5, 2.7 Hz, 1H), 4.34 (ddd, J = 27.7, 14.2, 6.8 Hz, 1H), 4.24 (ddd, J 
= 11.9, 1.8, 1.7 Hz, 1H), 2.31 (ddd, J = 14.7, 11.9, 6.4 Hz, 1H), 1.79 (ddd, J = 13.1, 2.4, 
1.8 Hz, 1H), 1.40 (s, 3H), 0.95 (t, J = 8.0 Hz, 9H), 0.61 (qd, J =7.2, 1.6 Hz, 6H); 
13
C NMR (125 MHz, CDCl3) ! (ppm) 142.0, 130.3, 128.0, 115.7, 81.5 (d, JCP = 7.6 Hz), 
77.4 (d, JCP = 6.6 Hz), 76.4 (d, JCP = 10.0 Hz), 63.2 (d, JCP = 6.4 Hz), 29.0 (d, JCP = 5.4 
Hz), 22.7, 7.3 (3C), 6.9 (3C); 
31
P NMR (162 MHz, CDCl3) ! (ppm) -2.89 (t, JPH = 27.0 Hz); 
HRMS  cald for C16H29NaO5PSi (M+Na)+ 383.1420; found 383.1423 (TOF MS ES+). 
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(4R,6R,7R,Z)-7-methyl-7-((triethylsilyl)oxy)nona-2,8-diene-1,4,6-triol 
(2.141). 
 
To the phosphate 2.153 (40.0 mg, 0.111 mmol) was added 3.9 mL of THF (0.028 
M) under argon atmosphere and subsequently cooled to 0 ºC.  To this solution LiAlH4 
(12 mg, 0.333 mmol, 3 equiv.) was slowly added and allowed to continue stirring at 0 ºC 
until all the starting material consumed (monitored by TLC 1:2 Hexane/EtOAc). The 
reaction was quenched by slow, dropwise addition of 13 µL of H2O, followed by slow, 
dropwise addition of 13 µL of 15 % NaOH (aq), and finishing with an addition of 39 µL 
of H2O. At this point, the mixture is allowed to reach room temperature until all salts 
appear to have become a white color. SiO2 was then added and the solvent removed, and 
was placed on a short silica gel plug and eluted with a 1:4 Hexane/EtOAc mixture, 
producing 150 mg (68% yield) of mono-protected tetraol 2.141. 
Rf = 0.2 (1:3 hexane/ethyl acetate);  
FTIR (thin film): 3342, 2955, 2912, 2877, 1630, 1458, 1413, 1049, 1010, 977 cm-1; 
Optical Rotation: [!]D = +17.4 (c = 2.20, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) " (ppm) 5.93 (dd, J = 17.4, 10.9 Hz, 1H), 5.69 (dddd, J = 
6.3, 5.0, 1.2, 1.1 Hz, 1H), 5.57 (ddt, J = 11.2, 7.8, 1.3 Hz, 1H), 5.31 (dd, J = 17.4, 1.4 Hz, 
1H), 5.13 (dd, J = 10.9, 1.4 Hz, 1H), 4.67 (dd, J = 8.4, 8.3 Hz, 1H), 4.28 (ddd, J = 7.0, 
6.7, 6.1 Hz, 1H), 4.18 (ddd, J = 8.6, 7.1, 5.9 Hz, 1H), 3.82 (dd, J = 7.1, 3.9 Hz, 1H), 3.77 
2. LiAlH4, Et2O
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(br s, 1H), 3.63 (m, 1H), 1.80 (ddd, J = 14.8, 6.7, 3.8 Hz, 1H), 1.58 (br s, 1H), 1.54 (ddd, 
J = 14.8, 7.0, 2.7 Hz, 1H), 1.27 (s, 3H), 0.99 (t, J = 8.0 Hz, 9H), 0.69 (q, J = 8.0 Hz, 6H); 
13
C NMR (125 MHz, CDCl3) ! (ppm) 142.0, 135.7, 130.0, 113.5, 76.2, 75.7, 65.3, 59.0, 
40.6, 25.0, 7.2 (3C), 5.4 (3C); 
HRMS  cald for C16H32NaO4Si (M+Na)+ 339.1968; found 339.1970 (TOF MS ES+). 
 192 
(5S,6R,8R,Z)-8-((tert-butyldimethylsilyl)oxy)-3,3-diethyl-5,13,13,14,14-
pentamethyl-5-vinyl-4,12-dioxa-3,13-disilapentadec-9-en-6-ol (2.160) 
 
To the solution of triol 2.160 (15 mg, 0.05 mmol) in 0.5 mL of CH2Cl2 (0.1M) 
was added 2,6-lutidine (25 µL, 0.21 mmol, 4.5 equiv.).  The solution was then cooled to  
-78 ºC and TBSOTf (24 µL, 0.10 mmol, 2.2 equiv.) was added dropwise to the solution 
with stirring.  The solution was stirred at -78 ºC for 2h, until all the starting materials 
were consumed, monitored by TLC (4:1 Hexane/EtOAc).  The reaction was diluted with 
1 mL of CH2Cl2 and quenched with 0.5 mL of saturated aqueous NH4Cl, and layers were 
separated, and the aqueous layer was extracted 3 more times with CH2Cl2.  The combined 
organic layers were then washed with brine, dried with MgSO4.  Purification by flash 
chromatography (hexane: ethyl acetate) provided bis-TBS protected monoalcohol 2.160 
(25 mg, 84% yield) as a yellow oil. 
Rf = 0.3 (4:1 hexane/ethyl acetate);  
FTIR (thin film): 3464, 3016, 2954, 2929, 2879, 2858, 1620, 1471, 1362, 1254, 1080 
cm-1; 
Optical Rotation: [!]D = +4.4 (c = 3.34, CH2Cl2); 
1
H NMR (500 MHz, CDCl3) " (ppm) 5.93 (dd, J = 17.4, 10.8 Hz, 1H), 5.48 (ddd, J = 
10.8, 5.1, 5.0 Hz, 1H), 5.37 (ddd, J = 11.2, 6.2, 1.6 Hz, 1H), 5.28 (dd, J = 17.4, 1.6 Hz, 
1H), 5.10 (dd, J = 10.8, 1.6 Hz, 1H), 4.48 (ddd, J = 9.4, 3.8, 3.6 Hz, 1H), 4.29 (ddd, J = 
OH
OH OH
CH3 OTES
TBSOTf, 2,6-lut.
OTBS
OH OTBS
CH3 OTES
CH2Cl2, -78 ºC
84%
2.141 2.160
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13.1, 7.0, 1.6 Hz, 1H), 4.13 (ddd, J = 13.1, 5.3, 1.7 Hz, 1H), 3.68 (dd, J = 5.8, 3.8 Hz, 
1H), 2.59 (s, 1H), 1.90 (ddd, J = 14.5, 9.7, 3.8 Hz, 1H), 1.31 (dddd, J = 9.8, 5.8, 4.9, 3.9 
Hz, 1H), 1.21 (s, 3H), 0.98 (t, J = 8.0 Hz, 9H), 0.90 (s, 9H), 0.88 (s, 9H), 0.66 (qd, J = 
8.0,1.9 Hz, 6H), 0.07 (s, 9H), 0.05 (s, 3H); 
13
C NMR (125 MHz, CDCl3) ! (ppm) 142.3, 134.0, 129.7, 113.3, 75.9, 75.5, 66.8, 59.6, 
43.0, 25.8(7C), 23.8, 18.5, 18.3, 7.0(3), 5.7(3), -3.4, -4.5, 5.2; 
HRMS  cald for C28H60NaO4Si3 (M+Na)+ 567.3697; found 567.3688 (TOF MS ES+). 
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(5R,6R,8R,Z)-8-((tert-butyldimethylsilyl)oxy)-3,3-diethyl-5,13,13,14,14-
pentamethyl-5-vinyl-4,12-dioxa-3,13-disilapentadec-9-en-6-yl-bis(2-
(trimethylsilyl)ethyl) phosphate (2.161) 
 
A solution of the alcohol 2.160 (5.9 mg, 0.018 mmol) in pyridine (0.6 mL) was cooled 
to 0 ºC, and a freshly prepared solution of PCl3 (2 M in CH2Cl2, 2 µL, 0.02 mmol) was 
added to the stirred solution in one portion via syringe. After 10 min at 0 ºC, freshly 
distilled 2-trimethylsilylethanol (15.5 µL) and a catalytic amount of DMAP (~0.1 mg) 
were added and mixture was warmed to RT over 1 h.  Reaction was diluted with CH2Cl2 
(0.6 mL) and 30% aqueous hydrogen peroxide (43 µL) were added, and stirring was 
continued for 2 h at 23 ºC. The mixture was poured into 0.5N HCl ( 0.5 mL) and 
extracted with CH2Cl2 (3 x 2 mL) Combined organic layers were dried over Na2SO4 and 
concentrated under reduced pressure. Purification by flash chromatography afforded 
2.161 (6.6 mg, 74 % yield) as yellow oil. 
 
Rf = 0.2 (10:1 Hexane/EtOAc);  
1
H NMR (500 MHz, CDCl3) ! (ppm) 6.04 (dd, J = 10.9, 17.6 Hz 1H), 5.47–5.43 (m, 
1H), 5.37 (d, J = 9.4 Hz, 1H), 5.31 (dd, J = 11.8, 1.8 Hz, 1H), 5.28 (d, J = 5.9 Hz, 1H), 
4.47 (t, J = 8.8 Hz, 1H), 4.32 (dd, J = 13.2, 6.8 Hz, 2H), 4.08 (m, 4H), 3.87 (d, J = 7.7 Hz, 
OTBS
O OTBS
P
O
RO
RO
H3C
OTES
R= -CH2CH2TMS
OTBS
OH OTBS
H3C
OTES
 PCl3, TMSCH2CH2OH
then H2O2
2.160 2.161
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1H), 1.78–1.68 (m, 1H), 1.58 (s, 3H), 1.26 (s, 4H), 1.23 (m, 1H) 1.09 (m, 18H), 0.98 (m, 
12H), 0.90 (m, 18H), 0.72 – 0.63 (m, 6H), 0.05 (t, J = 4.0 Hz, 9H); 
31
P NMR (162 MHz, CDCl3) ! (ppm) -0.55 and -4.29; 
HRMS  cald for C38H86O7PSi5 (M+H)+ 825.4958; found 825.4905 (TOF MS ES+) 
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(5R,6R,8R,Z)-8-((tert-butyldimethylsilyl)oxy)-3,3-diethyl-5-((E)-2-
((2R,6R)-6-isopropoxy-3,6-dihydro-2H-pyran-2-yl)vinyl)-5,13,13,14,14-
pentamethyl-4,12-dioxa-3,13-disilapentadec-9-en-6-ol (TBS-2.158) 
 
To the solution of triol 2.158 (32 mg, mmol) in 1.0 mL of CH2Cl2 (0.1M) was 
added 2,6-lutidine (52 µL, 4.4 mmol, 4.5 equiv.).  The solution was then cooled to -78 ºC 
and TBSOTf (50 µL, 0.22 mmol, 2.2 equiv.) was added dropwise to the solution with 
stirring.  The solution was stirred at -78 ºC for 2 h, until all the starting materials were 
consumed, monitored by TLC (8:1 Hexane/EtOAc).  The reaction was diluted with 2 mL 
of CH2Cl2 and quenched with 1 mL of saturated aqueous NH4Cl, and warmed to rt.  The 
layers were separated, and aqueous layer was extracted 3 more times with CH2Cl2.  The 
combined organic layers were then washed with brine, dried with MgSO4.  Purification 
by flash chromatography (8:1 Hexane:EtOAc) provided 53 mg of the bis TBS protected 
product TBS-2.158 as a yellow oil in 80 % yield. 
Rf = 0.5 ( 8:1 Hexane/EtOAc);  
FTIR (thin film): 3340, 3417, 2955, 2858, 2707, 1650, 1080, 837 cm-1; 
Optical Rotation: [!]D  = +29 (c = 0.2, CHCl3); 
1
H NMR (500 MHz, CDCl3) " (ppm) 6.01 (dd, J = 9.9, 5.2 Hz, 1H), 5.87–5.77 (m, 2H), 
5.73 (dtd, J = 10.0, 2.8, 1.3 Hz, 1H), 5.48 (ddd, J = 11.5, 6.3, 5.4 Hz, 1H), 5.36 (ddd, J = 
OH
OH OHO
OTBS
OH OTBSO
H3C
OTES H3C
OTES
 TBSOTf, -78 ºC
80 %
i-PrO i-PrO
2.158 TBS-2.158
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10.8, 3.1, 1.5 Hz, 1H), 5.11 (s, 1H), 4.51 (dd, J = 9.5, 3.1 Hz, 1H), 4.48–4.42 (m, 1H), 
4.31 (ddd, J = 13.2, 7.1, 1.5 Hz, 1H), 4.15 (ddd, J = 13.2, 5.2, 1.7 Hz, 1H), 4.00 (dt, J = 
12.4, 6.2 Hz, 1H), 3.73 (dd, J = 6.1, 3.4 Hz, 1H), 2.64 (s, 1H), 2.14–1.97 (m, 2H), 1.89 
(ddd, J = 14.5, 10.1, 3.4 Hz, 1H), 1.56 (s, 1H), 1.30 (ddd, J = 14.6, 6.1, 3.4 Hz, 2H), 
1.24–1.22 (m, 6H), 1.18 (d, J = 6.2 Hz, 3H), 0.99 (t, J = 8.0 Hz, 9H), 0.93–0.87 (m, 20H), 
0.67 (ddd, J = 11.0, 7.9, 2.6 Hz, 6H), 0.08 (s, 8H); 
13
C NMR (125 MHz, CDCl3) ! (ppm) 135.0, 133.7, 129.5, 128.7, 128.6, 126.1, 93.2, 
75.8, 74.7, 69.5, 66.6, 66.2, 59.3, 42.7, 30.6, 25.9 (6C), 23.9 (2C), 22.1, 18.3, 18.1, 7.0 
(3C), 5.5 (3C), -3.3, -4.5, -5.2 (2C); 
HRMS  cald for C36H72O6PSi3Na (M+Na)+ 707.4534; found 707.4530 (TOF MS ES+). 
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(S)-6-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-5,6-dihydro-1,2-oxathiine 2,2-
dioxide (2.165).  
 
To a stirring solution of diene 2.164 (2.01 g, 7.703 mmol) in freshly distilled, CH2Cl2 
(700 mL, 0.011 M) was added Grubbs–II catalyst (196 mg, 0.231 mmol) and the reaction 
was refluxed for 1 h until all the starting materials were consumed (monitored by TLC 
2:1 Hexane/EtOAc).  Reaction was cooled to RT and concentrated under reduced 
pressure.  Purification by flash chromatography afforded the RCM product 2.165  (1.5 g, 
78% yield) as a white crystalline solid.  
Rf = 0.2 ( 2:1 Hexane/EtOAc); 
M.P: 1105–107 ºC;  
 FTIR (thin film): 3066, 2987, 2937, 2894, 1625, 1419, 1352, 1182, 1066, 894, cm-1; 
Optical Rotation: [!]D  = –0.9 (c = 2.27, CHCl3); 
1
H NMR (500 MHz, CDCl3) " (ppm); 6.57 (s, 2H), 4.80 (ddd, J = 9.7, 7.6, 4.9 Hz, 1H), 
4.24–4.19 (m, 2H), 4.04 (dd, J = 8.9, 4.0 Hz, 1H), 2.57 (ddd, J = 8.0, 4.2, 2.5 Hz, 2H), 
1.44 (s, 3H), 1.37 (s, 3H); 
13
C NMR (125 MHz, CDCl3) " (ppm) 136.7, 126.2, 110.6, 81.1, 75.9, 66.5, 27.2, 26.7, 
24.9; 
HRMS  cald for C9H14O5PSNa (M+Na)+ 257.0460; found 257.0420 (TOF MS ES+). 
Grubbs-II
CH2Cl2
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1-((1S,  6R,  8R)-1-oxo-2,9,10-trioxa-1-phosphabicyclo[4.3.1]dec-4-en-8-
yl)ethanone(2.103)   
 
 
O
P
O O
O
O
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 (R)-2-((1S,6R,8R)-1-oxo-2,9,10-trioxa-1-phosphabicyclo[4.3.1]dec-4-en-
8-yl)but-3-en-2-ol(2.104)  
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(1S,6R,8R)-8-(1-hydroxyallyl)-2,9,10-trioxa-1-phosphabicyclo[4.3.1]dec-
4-ene 1-oxide (2.114)
 
  
O
OO
P
O
OH
 203 
 204 
(4R,6R,7R,Z)-7-methylnona-2,8-diene-1,4,6,7-tetraol (2.142)  
  
 
OH
OH OH
H3C
OH
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(3S,4R,6R,Z)-6,9-bis(( tert-butyldimethylsilyl)oxy)-3-methylnona-1,7-
diene-3,4-diol (2.143) 
 
OTBS
OH OTBS
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(1R,2S,5R)-5-((tert-butyldimethylsilyl)oxy)-2-methylcyclohex-3-ene-1,2-
diol (2.146) 
 
 
OHH3C
OTBS
OH
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(2R,6R)-6-isopropoxy-2-vinyl-3,6-dihydro-2H-pyran (2.97)
 
O
O
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(R)-6-vinyl-5, 6-dihydro-2H-pyran-2-one (2.98)  
 
 
O
O
O
O
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(R)-2-vinyl-2H-pyran-4(3H)-one (2.129) . 
 
 
O
O
O
O
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(1S,6R,8R)-8-((S,E)-4-((2R,6R)-6-isopropoxy-3,6-dihydro-2H-pyran-2-yl)-
2-((triethylsilyl)oxy)but-3-en-2-yl)-2,9,10-trioxa-1-
phosphabicyclo[4.3.1]dec-4-ene 1-oxide (2.154) 
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(R)-6-((S,E)-3-hydroxy-3-((1S,6R,8R)-1-oxido-2,9,10-trioxa-1-
phosphabicyclo[4.3.1]dec-4-en-8-yl)but-1-en-1-yl)-5,6-dihydro-2H-pyran-
2-one (2.157)  
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(R)-6-((S,E)-3-((1S,6R,8R)-1-oxido-2,9,10-trioxa-1-
phosphabicyclo[4.3.1]dec-4-en-8-yl)-3-((triethylsilyl)oxy)but-1-en-1-yl)-
5,6-dihydro-2H-pyran-2-one(TES-2.157). 
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(1S,6R,8R)-8-((R)-2-((triethylsilyl)oxy)but-3-en-2-yl)-2,9,10-trioxa-1-
phosphabicyclo[4.3.1]dec-4-ene1-oxide(2.153) 
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 218 
(4R,6R,7R,Z)-7-methyl-7-((triethylsilyl)oxy)nona-2,8-diene-1,4,6-triol 
(1.41). 
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OH OH
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(5S,6R,8R,Z)-8-((tert-butyldimethylsilyl)oxy)-3,3-diethyl-5,13,13,14,14-
pentamethyl-5-vinyl-4,12-dioxa-3,13-disilapentadec-9-en-6-ol (2.160)  
 
OTBS
OH OTBS
CH3 OTES
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(5R,6R,8R,Z)-8-((tert-butyldimethylsilyl)oxy)-3,3-diethyl-5,13,13,14,14-
pentamethyl-5-vinyl-4,12-dioxa-3,13-disilapentadec-9-en-6-yl-bis(2-
(trimethylsilyl)ethyl) phosphate (2.161)  
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(S)-6-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-5,6-dihydro-1,2-oxathiine 2,2-
dioxide (2.165).   
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(5R,6R,8R,Z)-8-((tert-butyldimethylsilyl)oxy)-3,3-diethyl-5-((E)-2-
((2R,6R)-6-isopropoxy-3,6-dihydro-2H-pyran-2-yl)vinyl)-5,13,13,14,14-
pentamethyl-4,12-dioxa-3,13-disilapentadec-9-en-6-ol (TBS-2.158)   
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General Experimental Methods 
 All reactions were carried out in an oven- or flame-dried glassware under argon 
atmosphere using standard gas-tight syringes, cannulae, and septa.  Stirring was achieved 
with oven-dried magnetic stir bars. Et2O, THF and CH2Cl2 were purified by passage 
through a purification system (Solv-Tek) employing activated Al2O3  (Grubbs, R. H.; 
Rosen. R. K.; Timmers, F. J. Organometallics 1996, 15, 1518–1520).  Et3N was purified 
by passage over basic alumina and stored over KOH.  Butyllithium was purchased from 
Aldrich and titrated prior to use.  All olefin metathesis catalysts were acquired from 
Materia and used without further purification.  Flash column chromatography was 
performed with Sorbent Technologies (30930M-25, Silica Gel 60A, 40-63 um) and thin 
layer chromatography was performed on silica gel 60F254 plates (EM-5717, Merck).  
Deuterated solvents were purchased from Cambridge Isotope laboratories. 1H and 13C 
NMR spectra were recorded in CDCl3 (unless otherwise mentioned) on a Bruker DRX-
500 spectrometer operating at 500 MHz, and 125 MHz, respectively and calibrated to the 
solvent peak. 31P NMR spectra was recorded on Bruker DRX-400 spectrometer operating 
at 162 MHz. High-resolution mass spectrometry (HRMS) was recorded on a LCT 
Premier Spectrometer (Micromass UK Limited) operating on ESI (MeOH).  Observed 
rotations at 589 nm, were measured using AUTOPOL IV Model automatic polarimeter.  
IR was recorded on Shimadzu FTIR-8400S instrument. 
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(1R,6R,8S)-8-phenethyl-2,9,10-trioxa-1-phosphabicyclo[4.3.1]dec-4-ene-
1-oxide (3.94) 
 
 To a stirring solution of triene (R,R)-3.951 (125 mg, 0.543 mmol) in freshly 
distilled, freeze-degas-thawed CH2Cl2 (78 mL, 0.007 M) was added Hoveyda-Grubbs 2
nd 
Gen.(HG–II) catalyst (13.6 mg, 0.022 mmol) and the reaction was refluxed for 45 min. 
After completion of RCM, cis–stilbene [2 equiv with respect to the triene (R,R)-3.95 
was dissolved in freshly distilled, freeze-degas-thawed 1,2-dichloroethane (11 mL, 0.05 
M) and added to the crude reaction mixture, followed by addition of HG–II (20 mg, 0.033 
mmol).  The reaction was continued at 70 ºC with simultaneous evaporation of the excess 
CH2Cl2 from the previous reaction to reach optimal concentration for CM reaction (11 
mL, 0.05 M).  The reaction was continued (at 70 ºC) for an additional 6 h until all the 
starting materials were consumed by TLC analysis.  The reaction mixture was cooled to 
room temperature and o-nitrobenzenesulfonyl hydrazine (o-NBSH) (1.4 g, 5.43 mmol) 
and Et3N (2.6 mL, at 2 mL/g of o-NBSH) were added, upon which the reaction was 
stirred at RT for 10 h. (Note : The reaction flask was wrapped with aluminum foil to 
avoid decomposition of o-NBSH due to light).  Excess o-NBSH (676 mg, 2.7mmol) and 
Et3N (1.3  mL, at 2 mL/g of o-NBSH) were added and the reaction was stirred for an 
additional 5 h.  The reaction mixture was diluted with EtOAc (20 mL) and extracted with 
sat. NaHCO3 (15 mL).  The aqueous layer was washed with EtOAc (2x10) and the 
O O
O
P
O
O O
O
P
O
Ph
i. HG-II (3 mol %)
CH2Cl2, reflux, 0.5 h
ii. HG-II (6 mol %)
cis–Stilbene
    DCE, reflux, 6 h
iii. then o-NBSH, Et3N
CH2Cl2 rt, 24 h(R,R)-3.95 3.94
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combined organic layers were dried (Na2SO4), concentrated under reduced pressure. 
Purification by flash column chromatography (1:1 hexanes/EtOAc) afforded 81 mg of 
desired product 3.94  (52% overall yield) as a colorless solid.  
Rf = 0.25 (1:3 Hexanes/EtOAc);  
M.P:110–112 ºC;  
FTIR (thin film): 3026, 2852, 2923, 1454, 1296 cm-1;  
Optical Rotation: [!]D  = -89.6 (c = 0.895, CHCl3);  
1
H NMR (500 MHz, CDCl3) " (ppm) 7.32–7.26 (m, 2H), 7.23–7.17 (m, 3H), 6.04–5.97 
(m, 1H), 5.58 (ddd, J = 11.8, 3.8, 2.3 Hz, 1H), 5.19 (br.d, JPH = 24.6 Hz, 1H), 5.01 (dddd, 
J = 11.8, 7.5, 5.4, 2.8 Hz, 1H), 4.60 (dd, J = 14.9, 5.7 Hz, 1H), 4.36 (ddd, J = 27.7, 14.8, 
6.7 Hz, 1H), 2.91–2.82 (m, 1H), 2.77–2.68 (m, 1H), 2.27–2.17 (m, 1H), 2.07 (ddd, J = 
14.1, 9.1, 4.6 Hz, 1H), 1.91–1.79 (m, 1H), 1.72–1.63 (m, 1H); 
13
C NMR (125 MHz, CDCl3) " (ppm) 140.8, 129.8, 129.0 (2C), 128.0 (2C), 127.9, 
126.1, 77.2 (d, JCP = 6.7 Hz), 75.8 (d, JCP = 6.7 Hz), 63.0 (d, JCP = 6.4 Hz), 37.5 (d, JCP = 
9.3 Hz), 34.8 (d, JCP = 5.9 Hz), 30.7 ;  
31
P NMR (162 MHz, CDCl3) " (ppm) -2.98; 
HRMS  cald for C14H17O4PNa (M+Na)
+  303.0762; found 303.0764 (TOF MS ES+). 
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(3S,5S)-1-phenyloct-7-ene-3,5-diol (3.92) 
 
To a stirring solution of phosphate 3.94 (30 mg, 0.105 mmol) in 0.4 mL of DCE 
were added Et3N (0.07 mL, 4.9 mmol) and HCOOH (0.0095 mL, 2.48 mmol).  The 
solution of 5 mol % Pd(OAc)2 (1.5 mg, 0.007 mmol) and H(Bu3P)BF4 (1.8 mg, 0. 007 
mmol) in 0.2 mL of DCE was quickly cannulated into the reaction mixture containing 
phosphate.  The reaction was heated to 60 ºC and stirred at this temperature until the 
color of the reaction turned black (~1 h) as well as disappearance of starting material by 
TLC analysis.  The reaction was cooled to room temperature, diluted with 2 mL CH2Cl2 
and 1 mL of 10% aqueous HCl was added.  The layers were separated and the aqueous 
layer was re-extracted (2 x 3 mL ) with CH2Cl2.  The organic layer was then concentrated 
to ~1 mL under reduced pressure MeOH (0.2 mL) followed by TMSCHN2 (0.3 mL, 2.0M 
in diethyl ether) were added to the stirring solution that caused the reaction to bubble 
vigorously. The reaction was allowed to stir for 5 min. and was monitored for 
disappearance of the phosphate acid.  Upon completion of the reaction, a drop of glacial 
acetic acid was added and the mixture was extracted with CH2Cl2 and a saturated 
NaHCO3 (aq) solution.  The aqueous layer was re-extracted (2 x 3mL) with CH2Cl2, dried 
(Na2SO4), filtered, and concentrated under reduced pressure and the crude mixture was 
subjected to the next reaction with out purification.  
6. LiAlH4, Et2O, 0 ºC
Ph O O
5. i. Pd(OAc)2, HCO2H
    H(Bu3P)BF4, Et3N
DCE, 60 ºC
Ph OH OH
P
OMeO
42 % 
over two steps
OO
O
P
O
Ph
3.94 3.108
3.92
ii. TMSCH2N2, MeOH
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The 1:1 diastereomeric phosphate 3.108  in Et2O (3.7mL) was cooled to 0 ºC and 
LiAlH4 (7.9 mg, 0.21 mmol) was added slowly.  Upon completion of the addition, the 
reaction was stirred at 0 ºC for 1 h, and quenched via slow sequential addition of H2O (8 
µL), 10% NaOH (8 µL),and H2O (24 µL), and the reaction was removed from the ice 
bath.  After stirring for 1 h, white salts formed, and the salts were filtered through a pad 
of Celite® and washed with Et2O and filtrate was concentrated under reduced pressure.  
The resulting clear oil was passed through a short silica plug (2:1 Hexane/EtOAc) 
afforded 10 mg of 3.92 in 42% overall yield as a colorless oil.  
 
Rf = 0.25 (2:1 Hexanes/EtOAc); 
FTIR (neat) 3018, 2927, 2956, 2854, 1274, 1215, 742 cm-1;  
Optical Rotation: [!]D  = +4.2 (c = 0.95, CHCl3); 
1
H NMR (500 MHz, CDCl3) " (ppm) 7.31–7.27 (m, 2H), 7.23–7.18 (m, 3H), 5.86–5.76 
(m, 1H), 5.17 (s, 1H), 5.15–5.13 (m, 1H), 4.04–3.96 (m, 2H), 2.81 (ddd, J = 13.8, 10.0, 
5.7 Hz, 1H), 2.68 (ddd, J = 13.8, 9.8, 6.5 Hz, 1H), 2.55 (s, OH), 2.37 (s, OH), 2.30–2.5 
(m, 2H), 1.92–1.84 (m, 1H), 1.83–1.74 (m, 1H), 1.70–1.66 (m, 2H); 
13
C NMR (125 MHz, CDCl3) " (ppm) 142.0, 134.5, 128.4 (3C), 125.9 (2C), 118.4, 68.8, 
68.2, 42.0, 42.0, 39.1, 32.2; 
HRMS  cald. for C14H20O2Na (M+Na)
+  243.1361; found 243.1359 (TOF MS ES+)  
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(R)-6-((4S,6S,E)-4,6-dihydroxy-8-phenyloct-1-en-1-yl)-5,6-dihydro-2H-
pyran-2-one– (+)-Strictifolione (3.1).  
 
 
To a stirring solution of olefin 3.92  (8.4 mg, 0.038 mmol, 2 equiv.) in degassed CH2Cl2 
(0.7 mL, 0.05M) was added lactone 3.93  (2.5 mg, 0.02 mmol) and HG–II catalyst (1.2 
mg, 0.002 mmol, 5 mol %) and the reaction was refluxed at 40 ºC for 1.5 h until all 
starting material were consumed.  The reaction was cooled to room temperature, and the 
solvent was removed under reduced pressure. Purification by flash column 
chromatography (2:1 Hexane/EtOAC) afforded 3.1  (4.8 mg, 77% yield) as a white 
crystalline solid.  
 
Rf = 0.3 (2:1 Hexanes/EtOAc); 
M.P: 111–113 ºC;  
FTIR (neat)  3415, 3026, 2921, 2850, 2356, 1712, 771 cm-1;  
Optical Rotation: [!]D  = +78.8 (c = 0.085, CHCl3); 
1
H NMR (500 MHz, CDCl3) " (ppm)  7.32–7.27 (m, 2H), 7.23–7.19 (m, 3H), 6.90 (ddd, 
J = 9.7, 5.1, 3.6 Hz, 1H), 6.05 (ddd, J = 9.8, 2.1, 1.8 Hz, 1H), 5.87 (ddd, J = 14.68, 7.6, 
7.05 Hz, 1H), 5.70 (dd, J = 15.6, 6.4 Hz, 1H), 4.95–4.86 (m, 1H), 3.99–4.03 (m, 2H), 
Ph
OH OH
O
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2.87–2.62 (m, 2H), 2.44 (m, 2H), 2.30 (t, J = 6.6 Hz, 2H), 1.93–1.74 (m, 2H), 1.67 (t, J = 
5.6 Hz, 2H), 1.57 (s, 2H); 
13
C NMR (125 MHz, CDCl3) ! (ppm) 163.9, 144.6, 141.8, 131.0 , 130.1, 128.5 (2 C), 
128.4 (2C), 125.9, 121.6, 77.7, 68.9, 68.3, 42.1, 40.4, 39.0, 32.2, 29.7; 
HRMS  cald. for C19H24O4Na (M+Na)
+  339.1572; found 339.1584 (TOF MS ES+)  
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(1S,6S,8R)-8-(4-phenylbutyl)-2,9,10-trioxa-1phosphabicyclo[4.3.1]dec-4-
ene 1-oxide (3.98) 
 
 
 To a stirring solution of triene (S,S)-3.951 (50 mg, 0.217 mmol) in freshly 
distilled, freeze-degas-thawed CH2Cl2 (31 mL, 0.007 M) was added HG–II (5.4 mg, 
0.0087mmol) and the reaction was refluxed for 45 min. After completion of RCM, but-3-
en-1-ylbenzene [0.065 mL, 0.434 mmol] was dissolved in freshly distilled, freeze-degas-
thawed 1,2-dichloroethane (4.3 mL, 0.05 M) and added to the crude reaction mixture, 
followed by addition of HG–II catalyst (8.1 mg, 0.013 mmol).  The reaction was 
continued at 70 ºC with simultaneous evaporation of the excess CH2Cl2 from the previous 
reaction to reach optimal concentration for CM reaction (4.3 mL, 0.05 M).  The reaction 
was continued (at 70 ºC) for an additional 6 h until all the starting materials were 
consumed by TLC analysis.  The reaction mixture was cooled to room temperature and o-
nitrobenzenesulfonyl hydrazine (o-NBSH) (540.3 mg, 2.17 mmol) and Et3N (1.1 mL, at 2 
mL/g of o-NBSH) were added, upon which the reaction was stirred at RT 10 h. (Note : 
The reaction flask was wrapped with aluminum foil to avoid decomposition of o-NBSH 
due to light).  Excess o-NBSH (174.3 mg, 0.7mmol) and Et3N (0.55  mL, at 2 mL/g of o-
NBSH) were added and the reaction was stirred for an additional 5 h.  The reaction 
O O
O
P
O
ii. HG-II (6 mol %)
    DCE, reflux, 6 h
iii. then o-NBSH, Et3N
CH2Cl2 rt, 24 h
S S
O O
O
P
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mixture was diluted with EtOAc (10 mL) and extracted with sat. NaHCO3 (5 mL).  The 
aqueous layer was washed with EtOAc (2 x 5 mL) and the combined organic layers were 
dried (Na2SO4), concentrated under reduced pressure. Purification by flash column 
chromatography (1:1 hexanes/EtOAc) afforded 36 mg of desired product 3.98  (54 % 
overall yield) as a white solid.  
Rf = 0.26 (1:2 Hexanes/EtOAc);  
M.P: 90–92 ºC;  
FTIR (thin film): 3024, 2929, 2856, 1452, 1298, 1068,972 cm-1;  
Optical Rotation: [!]D  = +65.45 (c = 0.165, CHCl3);  
1
H NMR (500 MHz, CDCl3) " (ppm) 7.31–7.27 (m, 3H), 7.23–7.15 (m, 2H), 6.03 (dddd, 
J =11.9, 6.7, 3.0, 2.2 Hz, 1H), 5.58 (ddd, J = 11.8, 3.8, 2.3 Hz, 1H), 5.19 (br.d, JPH = 24.6 
Hz, 1H), 5.01 (dddd J = 17.4, 12.1, 6.1, 2.8 Hz, 1H), 4.60 (m, 1H), 4.36 (ddd, J = 27.7, 
14.8, 6.7 Hz, 1H), 2.6 (t, J = 7.6 Hz, 2H), 2.17 (ddd, J =14.6, 11.9, 6.2 Hz  1H), 1.80 
(ddd, J = 18.7, 8.4, 5.4 Hz, 1H), 1.72–1.51 (m, 4H), 1.46–1.38 (m, 1H) 1.26 (s, 1H); 
13
C NMR (125 MHz, CDCl3) " (ppm) 142.2, 129.7, 128.4 (2C), 128.3 (2C), 128.0, 
125.8, 77.1, 76.6 (d, JCP = 6.8 Hz), 62.9 (d, JCP = 6.3 Hz), 35.7, 37.6 (d, JCP = 9.3 Hz), 
34.8 (d, JCP = 5.9 Hz), 31.0, 24.2; 
31
P NMR (162 MHz, CDCl3) " (ppm) -3.06;  
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HRMS  cald for C16H21O4PNa (M+Na)
+  331.1075; found 331.1074 (TOF MS ES+). 
(4R,6R)-10-phenyldec-1-ene-4,6-diol (3.97) 
 
To a stirring solution of phosphate 3.98 (145 mg, 0.473 mmol) in 1.9 mL of DCE 
were added Et3N (0.3 mL, 2.1 mmol) and HCOOH or formic acid (0.041 mL, 1.06 
mmol). The solution of 5 mol % Pd(OAc)2 (6.4 mg, 0.028 mmol) and H(Bu3P)BF4 (8.09 
mg, 0.028 mmol) in 0.9  mL of DCE was quickly cannulated in to the reaction mixture 
containing phosphate. The reaction was heated to 60 ºC and stirred at this temperature 
until the color of the reaction turned black (~1 h) as well as disappearance of starting 
material by TLC analysis.   
The reaction was cooled to room temperature, diluted with 2 mL CH2Cl2 and 1.5 
mL of 10% aqueous HCl was added. The layers were separated and the aqueous layer 
was re-extracted (2x 5 mL) with CH2Cl2. The organic layer was then concentrated to  
~1 mL under reduced pressure. MeOH (0.3 mL) followed by TMSCHN2 (0.3 mL, 2.0M 
in diethyl ether) were added to the stirring solution that caused the reaction to bubble 
vigorously. The reaction was allowed to stir for 5 min. and was monitored for 
disappearance of the phosphate acid.  Upon completion of the reaction a drop of glacial 
acetic acid was added and the mixture was extracted with CH2Cl2 and a saturated solution 
of NaHCO3. The aqueous layer was re-extracted (2x 5 mL) with CH2Cl2, dried (Na2SO4), 
6. LiAlH4
OH OH
Ph
3
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filtered, and concentrated under reduced pressure. Flash chromatography  
(2:1 Hexane/EtOAC) provided 100 mg of 3.110 (~1:1 diastereomeric mixture at 
phosphate) in 70% yield as a clear oil.  
The 1:1 diastereomeric phosphate mixture (100 mg, 0.328 mmol) in Et2O (11 mL) 
was cooled to 0 ºC and LiAlH4 (24.8 mg, 0.656 mmol) was slowly added. Upon 
completion of the addition, the reaction was stirred at 0 ºC for 1 h, and quenched via slow 
sequential addition of H2O (25 µL), 10% NaOH (25 µL), and H2O (75 µL), and warmed 
to RT. After stirring at RT for 1 h, white salts formed, the salts were filtered through a 
pad of Celite® and washed with Et2O and was concentrated under reduced pressure. The 
resulting clear oil was passed through a short silica plug (1:2 Hexane/EtOAc) to afford 53 
mg of 3.97 in 65% yield as a colorless oil.  
Rf = 0.2 (1:3 Hexanes/EtOAc); 
FTIR (neat) 3361, 3076, 3026,  2931,  2856, 1641, 1452, 1064, 698 cm-1;  
Optical Rotation: [!]D  = -5.37 (c = 0.67, CHCl3); 
1
H NMR (500 MHz, CDCl3) " (ppm) 7.31–7.26 (m, 2H), 7.16–7.21 (m, 3H), 5.86–5.77 
(m, 1H), 5.17 (m, 1H), 5.14 (m, 1H), 4.03–3.92 (m, 2H), 2.63 (t, J = 7.7 Hz, 2H), 2.38 (s, 
2 OH), 2.30–2.25 (m, 2H), 1.69–1.25 (m, 8H); 
13
C NMR (125 MHz, CDCl3) " (ppm) 142.5, 134.6, 128.3 (2C), 128.3 (2C), 125.7, 
118.3, 69.2, 68.2, 42.0, 41.8, 37.3, 35.9, 31.4, 25.4; 
HRMS  cald. for C16H24O2Na (M+Na)
+  271.1674; found 271.1672 (TOF MS ES+)  
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 (R)-6-((4R,6R,E)-4,6-dihydroxy-10-phenyldec-1-en-1-yl)-5,6-dihydro-2H-
pyran-2-one (3.2).  
 
 
To stirring solution of olefin 3.97  (14 mg, 0.056 mmol, 2 equiv.) in degassed 
CH2Cl2 (1.1 mL, 0.05M was added lactone 3.93  (3.49 mg, 0.02 mmol) and HG–II 
catalyst (1.8 mg, 0.002 mmol, 5 mol %) and refluxed for 1.5 h.  The reaction was cooled 
to RT, and solvent was removed under reduced pressure. Purification by flash 
chromatography (2:1 Hexane/EtOAC) provided 3.2  (6.8 mg, 70% yield) as a colorless 
liquid. 
Rf = 0.3 (1:4 Hexanes/EtOAc); 
FTIR (neat)  3415, 3026, 2921, 2854, 2356, 1708, 1248 cm-1;  
Optical Rotation: [!]D  = +62 (c = 0.190, CHCl3); 
1
H NMR (500 MHz, CDCl3) " (ppm) 7.32–7.27 (m, 2H), 7.23–7.19 (m, 3H), 6.90 (ddd, 
J = 8.6, 4.6, 3.9 Hz, 1H), 6.05 (dt, J = 9.7, 1.6 Hz, 1H), 5.87 (ddd, J = 14.68, 7.9, 6.72 Hz, 
1H), 5.70 (dd, J = 15.6, 6.4 Hz, 1H), 4.91 (dd, J = 14.6, 6.5 Hz, 1H), 4.04–3.99 (m, 1H), 
3.94 (td, J = 7.6, 3.9 Hz, 1H), 2.63 (t, 2H), 2.46–2.43 (m, 2H), 2.30 (t, J = 6.7 Hz, 2H), 
1.71–1.55 (m, 6H), 1.53–1.44 (m, 2H), 1.36 (ddd, J = 12.2, 7.1, 4.4 Hz, 1H), 1.26 (s, 1H); 
OH OH
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13
C NMR (125 MHz, CDCl3) ! (ppm) 164.0, 144.7, 142.5, 131.2, 130.0, 128.4 (2C), 
128.3 (2C), 125.7, 121.6, 77.8, 69.2, 68.2, 41.9, 40.3, 37.3, 35.8, 31.4, 29.7, 25.4; 
HRMS  cald. for C21H28O4Na (M+Na)
+  367.1885; found 367.1876 (TOF MS ES+)  
 237 
(1R,6R,8S)-8-phenethyl-2,9,10-trioxa-1-phosphabicyclo[4.3.1]dec-4-ene-
1-oxide (3.94)  
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(3S,5S)-1-phenyloct-7-ene-3,5-diol (3.92) 
 
 
 
Ph
OH OH
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(R)-6-((4S,6S,E)-4,6-dihydroxy-8-phenyloct-1-en-1-yl)-5,6-dihydro-2H-
pyran-2-one– (+)-Strictifolione (3.1).  
 
 
 
Ph
OH OH O
O
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(1S,6S,8R)-8-(4-phenylbutyl)-2,9,10-trioxa-1phosphabicyclo[4.3.1]dec-4-
ene 1-oxide (3.98).  
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(4R,6R)-10-phenyldec-1-ene-4,6-diol (3.97) 
 
 
 
OH OH
Ph
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(R)-6-((4R,6R,E)-4,6-dihydroxy-10-phenyldec-1-en-1-yl)-5,6-dihydro-2H-
pyran-2-one (3.2).  
 
 
 
OH OH O
O
Ph
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Table 1.  Crystal data and structure refinement for C10H15O5P. 
Identification code  q16c 
Empirical formula  C10 H15 O5 P 
Formula weight  246.19 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 7.5476(3) Å != 90°. 
 b = 11.7948(4) Å "= 90°. 
 c = 12.7172(5) Å # = 90°. 
Volume 1132.12(7) Å3 
Z 4 
Density (calculated) 1.444 Mg/m3 
Absorption coefficient 2.229 mm-1 
F(000) 520 
Crystal size 0.32 x 0.08 x 0.06 mm3 
Theta range for data collection 5.11 to 69.31°. 
Index ranges -7<=h<=8, -13<=k<=12, -15<=l<=14 
Reflections collected 9802 
Independent reflections 1997 [R(int) = 0.0246] 
Completeness to theta = 66.00° 98.9 %  
Absorption correction Multi-scan 
Max. and min. transmission 1.000 and 0.752 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1997 / 0 / 206 
Goodness-of-fit on F2 1.092 
Final R indices [I>2sigma(I)] R1 = 0.0224, wR2 = 0.0601 
R indices (all data) R1 = 0.0225, wR2 = 0.0602 
Absolute structure parameter 0.081(17) 
Extinction coefficient 0.0009(4) 
Largest diff. peak and hole 0.239 and -0.178 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for C10H15O5P.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
P 2780(1) 4469(1) 2025(1) 17(1) 
O(1) 4339(1) 4360(1) 2831(1) 19(1) 
O(2) 2268(1) 3237(1) 1666(1) 19(1) 
O(3) 3686(2) 5046(1) 1050(1) 21(1) 
O(4) 1271(1) 5080(1) 2463(1) 22(1) 
O(5) 7931(2) 4854(1) 3352(1) 24(1) 
C(1) 6633(3) 4258(2) 5290(1) 35(1) 
C(2) 6402(2) 3567(1) 4482(1) 28(1) 
C(3) 7220(2) 3733(1) 3412(1) 23(1) 
C(4) 5824(2) 3618(1) 2532(1) 19(1) 
C(5) 5092(2) 2441(1) 2302(1) 22(1) 
C(6) 3707(2) 2439(1) 1418(1) 21(1) 
C(7) 4429(2) 2660(1) 335(1) 21(1) 
C(8) 4230(2) 3562(1) -275(1) 22(1) 
C(9) 3340(2) 4667(1) -22(1) 22(1) 
C(10) 8683(2) 2851(1) 3244(1) 25(1) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for C10H15O5P. 
_____________________________________________________ 
P-O(4)  1.4589(11) 
P-O(1)  1.5656(11) 
P-O(3)  1.5707(11) 
P-O(2)  1.5718(10) 
O(1)-C(4)  1.4720(17) 
O(2)-C(6)  1.4715(17) 
O(3)-C(9)  1.4587(17) 
O(5)-C(3)  1.4292(18) 
O(5)-H(5O)  0.89(3) 
C(1)-C(2)  1.323(3) 
C(1)-H(1A)  0.98(2) 
C(1)-H(1B)  1.01(2) 
C(2)-C(3)  1.507(2) 
C(2)-H(2)  1.109(16) 
C(3)-C(10)  1.532(2) 
C(3)-C(4)  1.542(2) 
C(4)-C(5)  1.522(2) 
C(4)-H(4)  0.953(18) 
C(5)-C(6)  1.536(2) 
C(5)-H(5A)  0.96(2) 
C(5)-H(5B)  1.02(2) 
C(6)-C(7)  1.504(2) 
C(6)-H(6)  0.938(19) 
C(7)-C(8)  1.325(2) 
C(7)-H(7)  0.93(2) 
C(8)-C(9)  1.501(2) 
C(8)-H(8)  0.94(2) 
C(9)-H(9A)  1.01(2) 
C(9)-H(9B)  0.989(19) 
C(10)-H(10A)  0.98(2) 
C(10)-H(10B)  0.95(2) 
C(10)-H(10C)  0.97(2) 
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O(4)-P-O(1) 112.14(6) 
O(4)-P-O(3) 115.32(6) 
O(1)-P-O(3) 103.03(6) 
O(4)-P-O(2) 112.06(6) 
O(1)-P-O(2) 107.36(6) 
O(3)-P-O(2) 106.21(5) 
C(4)-O(1)-P 116.88(9) 
C(6)-O(2)-P 118.19(9) 
C(9)-O(3)-P 121.75(9) 
C(3)-O(5)-H(5O) 110.3(14) 
C(2)-C(1)-H(1A) 123.2(12) 
C(2)-C(1)-H(1B) 123.2(13) 
H(1A)-C(1)-H(1B) 113.6(18) 
C(1)-C(2)-C(3) 124.56(16) 
C(1)-C(2)-H(2) 131.3(8) 
C(3)-C(2)-H(2) 103.4(8) 
O(5)-C(3)-C(2) 108.77(12) 
O(5)-C(3)-C(10) 110.47(13) 
C(2)-C(3)-C(10) 109.48(13) 
O(5)-C(3)-C(4) 107.45(12) 
C(2)-C(3)-C(4) 111.31(13) 
C(10)-C(3)-C(4) 109.34(12) 
O(1)-C(4)-C(5) 108.38(12) 
O(1)-C(4)-C(3) 106.30(11) 
C(5)-C(4)-C(3) 117.89(13) 
O(1)-C(4)-H(4) 106.8(11) 
C(5)-C(4)-H(4) 109.0(10) 
C(3)-C(4)-H(4) 108.0(11) 
C(4)-C(5)-C(6) 112.93(12) 
C(4)-C(5)-H(5A) 110.3(11) 
C(6)-C(5)-H(5A) 104.2(12) 
C(4)-C(5)-H(5B) 108.8(11) 
C(6)-C(5)-H(5B) 108.9(11) 
H(5A)-C(5)-H(5B) 111.7(15) 
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O(2)-C(6)-C(7) 110.69(12) 
O(2)-C(6)-C(5) 110.08(11) 
C(7)-C(6)-C(5) 115.10(13) 
O(2)-C(6)-H(6) 103.5(11) 
C(7)-C(6)-H(6) 109.1(11) 
C(5)-C(6)-H(6) 107.7(11) 
C(8)-C(7)-C(6) 129.37(14) 
C(8)-C(7)-H(7) 120.7(13) 
C(6)-C(7)-H(7) 110.0(13) 
C(7)-C(8)-C(9) 128.49(14) 
C(7)-C(8)-H(8) 120.1(13) 
C(9)-C(8)-H(8) 111.4(13) 
O(3)-C(9)-C(8) 112.73(13) 
O(3)-C(9)-H(9A) 109.9(11) 
C(8)-C(9)-H(9A) 110.7(11) 
O(3)-C(9)-H(9B) 102.3(11) 
C(8)-C(9)-H(9B) 113.7(11) 
H(9A)-C(9)-H(9B) 107.1(15) 
C(3)-C(10)-H(10A) 114.1(13) 
C(3)-C(10)-H(10B) 109.1(13) 
H(10A)-C(10)-H(10B) 107.3(18) 
C(3)-C(10)-H(10C) 106.0(12) 
H(10A)-C(10)-H(10C) 109.9(18) 
H(10B)-C(10)-H(10C) 110.5(18) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å2x 103)for C10H15O5P.  The anisotropic 
displacement factor exponent takes the form: -2!2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
P 17(1)  17(1) 17(1)  0(1) 2(1)  0(1) 
O(1) 19(1)  20(1) 19(1)  -4(1) 0(1)  3(1) 
O(2) 18(1)  18(1) 22(1)  -1(1) 2(1)  -2(1) 
O(3) 25(1)  19(1) 19(1)  -1(1) 3(1)  -4(1) 
O(4) 21(1)  23(1) 23(1)  -1(1) 2(1)  3(1) 
O(5) 21(1)  19(1) 31(1)  -4(1) 3(1)  -2(1) 
C(1) 33(1)  45(1) 28(1)  -6(1) 2(1)  -4(1) 
C(2) 26(1)  32(1) 25(1)  2(1) -2(1)  -3(1) 
C(3) 23(1)  21(1) 24(1)  -3(1) -2(1)  -1(1) 
C(4) 19(1)  20(1) 20(1)  -2(1) 3(1)  3(1) 
C(5) 24(1)  19(1) 22(1)  1(1) 1(1)  2(1) 
C(6) 22(1)  14(1) 26(1)  -2(1) 1(1)  -1(1) 
C(7) 20(1)  21(1) 22(1)  -7(1) 2(1)  0(1) 
C(8) 21(1)  26(1) 19(1)  -4(1) 3(1)  -2(1) 
C(9) 26(1)  24(1) 17(1)  0(1) 1(1)  0(1) 
C(10) 22(1)  20(1) 34(1)  -2(1) -4(1)  2(1) 
______________________________________________________________________________
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Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for C10H15O5P. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(5O) 8940(30) 4854(19) 2980(18) 38(6) 
H(1A) 7290(30) 4972(19) 5241(16) 36(5) 
H(1B) 6100(30) 4117(19) 6009(17) 41(6) 
H(2) 5820(20) 2705(14) 4434(12) 10(4) 
H(4) 6320(20) 3923(14) 1904(14) 15(4) 
H(5A) 6010(30) 1954(16) 2047(15) 23(4) 
H(5B) 4520(30) 2127(17) 2972(16) 23(4) 
H(6) 3140(20) 1730(15) 1424(14) 18(4) 
H(7) 5100(30) 2049(17) 114(16) 30(5) 
H(8) 4650(30) 3550(18) -967(17) 28(5) 
H(9A) 2020(30) 4613(16) -144(14) 26(5) 
H(9B) 3780(30) 5312(16) -445(14) 20(4) 
H(10A) 8310(30) 2070(20) 3375(17) 37(5) 
H(10B) 9080(30) 2890(18) 2536(18) 32(5) 
H(10C) 9630(30) 3055(17) 3721(16) 25(5) 
________________________________________________________________________________
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Table 6.  Torsion angles [°] for C10H15O5P. 
________________________________________________________________ 
O(4)-P-O(1)-C(4) 171.25(10) 
O(3)-P-O(1)-C(4) -64.12(11) 
O(2)-P-O(1)-C(4) 47.75(11) 
O(4)-P-O(2)-C(6) -167.35(9) 
O(1)-P-O(2)-C(6) -43.80(10) 
O(3)-P-O(2)-C(6) 65.89(11) 
O(4)-P-O(3)-C(9) -100.78(12) 
O(1)-P-O(3)-C(9) 136.71(11) 
O(2)-P-O(3)-C(9) 23.99(13) 
C(1)-C(2)-C(3)-O(5) -12.6(2) 
C(1)-C(2)-C(3)-C(10) 108.2(2) 
C(1)-C(2)-C(3)-C(4) -130.81(18) 
P-O(1)-C(4)-C(5) -56.60(14) 
P-O(1)-C(4)-C(3) 175.76(9) 
O(5)-C(3)-C(4)-O(1) -68.57(15) 
C(2)-C(3)-C(4)-O(1) 50.42(16) 
C(10)-C(3)-C(4)-O(1) 171.50(12) 
O(5)-C(3)-C(4)-C(5) 169.66(13) 
C(2)-C(3)-C(4)-C(5) -71.34(17) 
C(10)-C(3)-C(4)-C(5) 49.74(18) 
O(1)-C(4)-C(5)-C(6) 58.94(16) 
C(3)-C(4)-C(5)-C(6) 179.64(12) 
P-O(2)-C(6)-C(7) -79.44(13) 
P-O(2)-C(6)-C(5) 48.94(14) 
C(4)-C(5)-C(6)-O(2) -55.47(16) 
C(4)-C(5)-C(6)-C(7) 70.45(17) 
O(2)-C(6)-C(7)-C(8) 16.0(2) 
C(5)-C(6)-C(7)-C(8) -109.64(19) 
C(6)-C(7)-C(8)-C(9) 5.4(3) 
P-O(3)-C(9)-C(8) -74.05(15) 
C(7)-C(8)-C(9)-O(3) 39.0(2) 
Symmetry transformations used to generate equivalent atoms:  
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Table 7.  Hydrogen bonds for C10H15O5P [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 O(5)-H(5O)...O(4)#1 0.89(3) 1.90(2) 2.7754(15) 166(2) 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z   
